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ABSTRACT
In this thesis, some of the causes and mechanisms of platelet 
aggregation have been discussed. Platelet/granulocyte aggregates 
occur in stored blood and have been implicated in the development of 
respiratory distress syndrome following massive blood transfusions.
Seme of the factors that may be responsible for platelet aggregation 
in CPD anticoagulated blood have been examined.
Catecholamine concentrations were measured in blood plasma.
During blood collection, the concentration of plasma noradrenaline 
increased, but there seemed to be no relationship between the final 
noradrenaline concentration and the onset or extent of platelet 
aggregation.
It was found that platelet aggregation measured by the screen 
filtration pressure technique, occurred very rapidly in blood stored 
at 1°C, more gradually at 4°C, and not at all at ambient room 
temperature.
The measurement of plasma catecholamines, 5-hydroxytryptamine 
and adenosine di-phosphate concentrations during blood storage did 
not demonstrate that any one of these factors was responsible for the 
onset of platelet aggregation. However, it is suggested that these, 
and other factors, might act individually or synergistically to extend 
platelet aggregation during blood storage. It was found that adenosine 
di-phosphate released from erythrocytes might accelerate platelet 
aggregation in blood stored at 1°C.
It has been shown that potential platelet aggregating agents 
are released from platelets in blood stored at room temperature. It 
is suggested that the apparent lack of platelet aggregation at this
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temperature was due to a rapidly reduced pH, and the rapid degradation 
of adenosine nucleotides to aggregate inhibitory products.
The evidence suggests that platelet aggregation in stored blood 
is triggered by the cold, and that it may involve an energy dependent 
mechanism, possibly independent of the platelet release reaction.
It is suggested that blood storage at roan temperature would reduce 
or prevent platelet aggregation.
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FACTORS INVOLVED IN THE INDUCTION OF PLATELET
AGGREGATION DURING THE COLLECTION AND STORAGE OF HUMAN BLOOD
CHAPTER CNE 
INTRODUCTION
1.1 A BRIEF HISTORY OF BLOOD TRANSFUSION
The concept of blood transfusion is very old, though it was not 
until 1667 that the first recorded blood transfusion into man took 
place. The problem of finding a volunteer was overcome when a 
French mathematician, Denis, assisted by a surgeon, 'seized' a 
'madman' outside Paris and transfused 8 ounzes of fresh calf's blood
into his veins. Remarkably, the recipient not only recovered but
\
his madness was apparently cured. Denis became a celebrity, though 
short lived because during a second transfusion, the recipient died. 
As a consequence of this and several similar incidents, blood trans­
fusion fell into disrepute and was made criminal (in France) in 1668 
(Lewes, 1859).
It was only in 1818 that blood transfusion was revived when it 
was suggested that, when transfusing blood into humans, human blood 
must be employed (Blundell, 1818). However, only at the turn of the 
20th Century did the development of suitable anticoagulants and 
recognition of antigenic differences within a species, make blood 
transfusion relatively safe. The resultant upsurge in the demand for 
blood for transfusion paved the way for a blood banking system, which 
involved the storage of blood.
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Blood platelets were first described by Donne in 1842 (cited - 
Nour-Eldin, 1967) but it was only in 1938 that platelet aggregation 
during blood storage was documented (Fantus, 1938), Although 
improvements, such as filtration and better storage conditions have 
partly alleviated the problems associated with transfusing cellular 
aggregates, the underlying cause of aggregation during blood storage 
has yet to be resolved.
The work described in this thesis is concerned with examinations 
of certain chemical and physical parameters that may relate human blood 
collection and storage to platelet aggregation.
1.2 THE BLOOD PLATELET
The following is a brief review of platelet research with 
particular reference to aggregation.
1.2.1 PLATELET PRODUCTION
Platelets develop in the bone marrow from megakaryocytes by 
a process of compartmentation of the cytoplasm. The platelets are 
'pinched off', mainly into the marrow sinuses, and enter the circulat­
ory system where they survive for 8 - 1 0  days. Mature megakaryocytes 
also reach the lung, where up to 17% of the platelet population may 
be released (Vane, 1969). Platelet half life has been suggested as 
an index of platelet survival as opposed to platelet turnover (about 
5 x 10” platelets per day in man) (Jamieson, 1977), which is a better 
measure of platelet economy. This is because platelets are destroyed 
not just as a result of age, but also indiscriminately as a con­
sequence of the effects of certain factors which may influence 
platelet membranes, and subsequently survival (Mustard et al. 1966).
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The absolute number of platelets in the circulation is controlled 
by a negative feedback system involving a humoral factor, thrombo- 
poietic stimulating factor (TSF) which is capable of stimulating 
megakaryocyte production. A reduction in the number of platelets 
results in raised TSF levels and hence a rise in platelet production. 
(Sanderson and Golds tone, 1977). Because megakaryocytes take sane 
time to mature, platelet production may be regulated to the negative 
feedback containing a time delay and therefore may be oscillatory 
rather than constant, that is, a platelet cycle may occur (Morley,
1969). The normal platelet count is 150 - 400 x 10^L“ .^
1.2.2 PLATELET STRUCTURE (Figure 1)
Platelets are non-nucleated cells, and in the blood circulation, 
they are disc-shaped and 2 - 3 p in diameter (Mustard and Packham, 1970). 
The platelet has been divided into three regions: the peripheral 
zone, the sol-gel zone and the organelle zone (Sanderson and Gold- 
stone, 1977).
1.2.2.1 THE PERIPHERAL ZONE
This includes the exterior coat, or the glycocalyx, which is rich in 
glycoproteins and is a layer unique to the platelet. Mucopolysaccharides 
are often associated with the glycocalyx though it is now thought 
that they are not actual ccmponents (Jamieson, 1977). The glycocalyx 
is important in platelet function and in normal conditions, is 
surrounded by a nimbus of proteins called the plasmatic atmosphere.
It is not clear if the glycocalyx is an integral part of the plasma 
membrane, which makes up the remainder of the peripheral zone.
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Figure 1 NORMAL PLATELET STRUCTURE
(Platelet from a sample of citrated platelet rich plasma fixed at
37°C in glutaraldehyde and osmic acid. The discoid cell has been
sectioned in the equatorial plane, x 33,200)
Key:
DTS- (Dense tubular structures) and MT - microtubules in the sol-gel 
zone. The circumferential microtubules are involved in main­
taining the platelet discoid form.
OCS-Open canicular system. This extends from the peripheral zone 
into the organelle zone.
G - Lysosomal granules in the organelle zone.
[©-Dense bodies ("bulls-eye" granules) in the organelle zone.
GLY-Glycogen particles in the organelle zone.
M - Mitochondria in the organelle zone.
(after White, 1974)
Figure 1 NORMAL PLATELET STRUCTURE
This membrane is of the usual trilaminar structure and is rich in 
phospholipids. It has deep invaginations into the platelet 
interior, the canalicular system, which may assist in the transport 
of various platelet factors. Platelets also provide an active lipo­
protein surface which interacts with plasma coagulation factors.
The term platelet factor 3 (PF3) has been used to describe this 
lipoprotein, though it is not an identifiable biochemical substance. 
(Jamieson, 1977). The location of platelet membrane phospholipid 
has been probed with 2,4,6, trinitrobenzenesulphonate, and it has 
been shown that exposure of phosphatidylethanolamine may have a 
critical role in platelet haemostatic function, that phospholipid 
asymmetry exists, and that this may have physiological significance 
(Schick et al., 1976). A number of blood clotting factors I, V,
VIII and XIII are present in platelet preparations and most of the 
other factors, with the possible exception of factor XIII, are 
reported to be associated with platelets (Bennet and Ratnoff, 1972).
The platelet plasma membrane is 71 carbohydrate, 36% protein 
and 52% lipid. Enzymes associated with the plasma membrane include 
adenosine triphosphatase, adenal cyclase, phosphodiesterase, 
cholinesterase, acid phosphatase and several glycosyltransferases. 
Sialic acid residues, mainly contained within the glycoprotein, 
glyccphorin, are very dense on platelet membrane surfaces and partly 
contribute to the platelet charge or zeta potential (Nurden and Caen, 
1976). Platelets normally have a very high negative charge with an 
isoelectric point at 3.6 (Jamieson, 1977). The nature of the cell 
surface reflects the environment in which the cell is found and the 
molecular composition of the plasma membrane reflects any specialised 
function placed on it. Isolation of glycoproteins on the platelet
membrane surface have revealed several polypeptides, though it is 
generally agreed that 3 major glycoproteins, I, II and III, exist 
(Phillips, 1973; Steiner, 1974; Nurden and Caen, 1976; Jamieson, 
1977). These contain heterosaccharide units significantly different 
from those in red blood cell membranes (Steiner, 1974). The platelet 
membrane is asymmetrical with the carbohydrate moieties of the glyco­
proteins, most of which span the membrane, in a prominent position 
on the external surface. The molecular weights of the 3 glycoproteins 
seem to vary depending upon the investigator and the separation method, 
though glycoproteins I and II, with approximate molecular weights of
150,000 and 118,000 daltons respectively, contribute mainly to 
platelet adhesion and aggregation. The third surface glycoprotein 
is associated with pore formation and transport (Nurden and Caen, 1976). 
Sialic acid is found particularly in glycoprotein I which is 70% 
carbohydrate, having galactose as its sole neutral sugar and equimolar 
amounts of galactosamine and glucosamine as N-acetyl derivatives 
(Jamieson, 1977).
1.2.2.2 THE SOL-GEL ZONE
This consists principally of microtubules and microfilaments 
composed of a contractile protein, thrombosthenin, which is similar 
in character to actin and myosin. These structures play an important 
role in providing a cytoskeleton active in platelet shape changes 
and in clot retraction (Jamieson, 1977) A marginal bundle of fine 
tubules can be seen lying along the membrane in the equatorial 
plane of platelets (Mustard and Packham, 1970).
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1.2.2.3 THE ORGANELLE ZONE
This is the remainder of the cytoplasmic area in which are found 
a few primitive mitochondria, glycogen granules, vacuoles, possibly 
ribosomes, lysosomal granules and so-called dense (osmophilic) or 
'bulls eye' granules (Mustard and Packham, 1970). Platelet 
fractionation and subsequent enzyme assay have shown that acid phos­
phatase has the highest specific activity of all the acid hydrolases 
found in platelets, and that it is mostly firmly bound in the lysosomal 
granules (Polasek, 1968; Zucher and Borrelli, 1959).
Human platelets are very rich in most lysosomal enzymes, including 
acid phosphatase,/S-glucuronidase,^3-galactosidase, the cathepsins 
(Day et al., 1969) and collagénase (Chesney et al., 1972). Lysosomal 
granules have also been associated with fibrinogen and platelet 
factor 4 (PF4) (Holmsen et al., 1969a). However, better separation 
procedures have demonstrated that fibrinogen is contained within 
the dense granules (Broekman et al., 1975), associated with 5-hydroxy- 
hyptamine (5HT), adenosine diphosphate (ADP), adenosine triphosphate 
(ATP), catecholamines, calcium and potassium (Born, 1956; Holmsen et 
al., 1969a; Jamieson, 1977). More recently, evidence has been 
produced that another storage granule exists, separate from the 
dense granules and lysosomes, in which it is suggested are stored 
PF4, fibrinogen and a platelet specific protein,(S-thrcmboglobulin 
(Fukami and Salganicoff, 1977; Dawes et al., 1978).
The results of 32p radiolabelling of platelets suggest that 
three pools of adenine nucleotides exist, two being metabolic and 
the third (the largest, containing about 60% of the total platelet 
ATP content) contained in the dense granules. One of the metabolic 
pools is described as a release energy pool, which provides energy
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for the platelet release reaction (described later) and the other, 
which is retained, is probably involved in platelet energy requirements 
distinct from the release reaction. The concentration of ATP in 
the dense granules is large in comparison with that of 5HT, the ratio 
being about 5:1 in human platelets. The ratio of ATP to ADP has been 
estimated to be 0.6:1.1 (Holmsen et al., 1969b).
1.2.3 PLATELET METABOLISM
Platelets require energy to carry out all their functions but the 
study of platelet metabolic requirements during their resting state is 
difficult due to stimulation of the release reaction during platelet 
isolation. It is possible that anaerobic glycolysis is the main 
pathway for energy production (Maynert and Isaac, 1968) though there 
may be more complete glucose oxidation via oxidative phosphorylation 
depending upon mitochondrial efficiency. Platelets can metabolise a 
variety of hexoses including glucose, glycogen, fructose and galactose. 
A large proportion of platelet ATP provides energy for the release 
reaction and probably, takes no part in platelet metabolism. Like 
other cells, platelets are sensitive to changes in adenine nucleotide 
levels so that reduced ATP concentration result in increased phospho- 
rylase activity and hence glycogenolysis. (Mustard and Packham, 19701.
1.2.4 PLATELET RJNCTION
Platelets have four main functions, storage and transport; 
defence; haemostasis; and blood coagulation (Mustard et al., 1966).
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1.2.4.1 STORAGE AND TRANSPORT
Platelets contain most of the blood 5HT, estimated to be between
g
200 and 1300 ng/10 platelets (Franzen and Eysell, 1969); and a 
large proportion of histamine and catecholamines. It is not clear 
how far this acts as a transport mechanism; perhaps as a means of pro­
viding vaso-active compounds at a local point of injury (Mustard et al.,
1966). However, it is widely recognised that platelets are able to 
take up both 5HT (Maynert and Isaac, 1968; Pletscher, 1968;
Baumgartner, 1970) and catecholamines (Barthel and Markwardt, 1974;
Born et al., 1967a). The platelet surface has specific binding sites 
for both 5HT and catecholamines.
1.2.4.2 DEFENCE
Platelets are capable of phagocytosis and therefore may contribute 
to a defence mechanism (Mustard et al., 1966). Indeed, it has been 
suggested that the primary role of platelets is defence against 
foreign organisms (Copley and Witte, 1976). Many observations have 
been made of platelet clunping and adherence to bacteria, and it has 
been demonstrated that the body's first reaction to bacterial invasion 
is platelet agglutination and adherence of platelets to bacteria, 
jointly termed conglutination. This may act together with platelet 
phagocytosis ability in general body surveillance against bacteria, 
viruses and even tumor cells (though ingested viruses in platelets 
may effectively be 'harboured'), resulting in elimination perhaps 
by local monocytic phagocytosing systems engulfing the entire 
platelet clump. Aggregated platelets are capable of neutrophil 
chemotaxis possibly via release of a lipo-oxygenase, 12, hydroxy,5,8,
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10,14 eicosatetraenoic acid (HETE) (Turner et al., 1975). HETE may 
' be the main chemotactic material for monocytes, since evidence 
suggests that the complement fraction C5a, which is widely held to 
possess powerful chemotactic properties, is not chemotactic for 
monocytes (Turner et al., 1975). However, other evidence suggests 
that a 'platelet protein fraction' released during aggregation, and 
itself lacking chemotactic activity, generates such activity by 
acting directly on C5 (Weksler, 1974; Niewlarowski, 1977). The 
two activities may be the same, but since one is reported to be 
lipid and the other protein, there are possibly two separate mech­
anisms.
1.2.4.3 BLOOD COAGULATION
Platelets are important in blood coagulation for three 
reasons. Firstly, many blood coagulation factors and PF3 are 
associated with platelets. Secondly, platelets are responsible for 
clot retraction (Bennet and Ratnoff, 1972). Finally, stimulated 
platelets may be able to promote in-vivo blood clotting (Mustard 
et al., 1966; Ehrman et al., 1978) via activation of factor XII in 
the intrinsic coagulation pathway (Walsh, 1973).
There is evidence for multiple different functions of platelets 
in intrinsic coagulation including 'contact product forming activity' 
where platelet surface properties may be altered by aggregating agents 
to activate factor XII (Walsh, 1973; Ardlie and Han, 1974). Another 
function is 'factor xa forming activity', which is the capacity of 
platelets to enhance the reactions of factors XIa, VIII, IX and X to 
form Xa. (Walsh, 1973). Also, platelets are rich in fibrinogen,
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which is released during the release reaction (see later).
PF3, often erroneously used synonymously with platelet pro- 
coagulant activity (Ehrman et al., 1978) is important in intrinsic 
blood coagulation. The mechanism of its conversion to an active form 
is unknown, though activity seems to depend on the presence of at 
least one phospholipid dependent protein (Wu and McCoy, 1977). PF3 
is almost certainly the 'platelet like activity of serum' described by 
O'Brien (1955) and Alagille and Soulier (1957) and also the 'platelet 
dust' described by Wolf (1967).
PF3 activity, which catalyses particularly the reactions of 
factor Xa and V to activate prothrombin in the presence of calcium 
ions (Walsh, 1973), has been postulated as being the initiator of the 
intrinsic coagulation pathway (Mammen et al, 1960 - cited Wu and 
McCoy, 1977).
Clot retraction is associated with certain changes in platelets 
and may be linked to the aggregating activity of thrombin. (See later). 
The aggregates become linked by pseudopodia, contraction of which 
(dependent on thrambosthenin) produces the contraction of the clot 
(Bennet and Ratnoff, 1972).
Platelet shape change, the first visible event in aggregation, 
is itself associated with the development of platelet procoagulant 
activity. This is the binding of soluble activated coagulant prot­
eins to the platelet surface prior to coagulation, and it is possibly 
due to exposure of phospholipid on the platelet membrane (Ehrman 
et al., 1978).
1.2.4.4 HAEMOSTASIS
Possibly the most widely documented activity of platelets is
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their ability to aggregate under the influence of a variety of aggreg­
ation inducers. The role of platelets in blood haemostasis is to adhere 
to exposed collagen to form a platelet plug when the vascular integrity 
is lost. (Mustard et al., 1966; Jamieson, 1974; Wang et al., 1975). 
The plug formation is a consequence both of platelet aggregation and 
of the release reaction which facilitates the interaction of coagulation 
factors leading to fibrin formation and clot retraction (Ardlie and 
Han, 1974). It is widely believed that in the haemostatic process, 
the early stages of platelet aggregation occur prior to, and independent 
of coagulation reactions. However, in-vitro studies have suggested 
that small amounts of thrombin present, or formed prior to clotting, 
may serve as the initial stimulus to platelet changes in haemostasis, 
and that platelet aggregation and blood coagulation are interdependent 
and can be regarded as one phenomenon (Ardlie and Han, 1974, Akbar 
and Ardlie, 1978).
There is evidence that platelets nay also affect the fibrino­
lytic, plasminogen-plasmin system thought to be an important haema- 
static regulatory mechanism to prevent inappropriate extension of the 
plug, which, if uncontrolled, may lead to total vessel occlusion 
(Joist, 1977).
Although platelet counts vary from one person to another, they 
have been estimated to be about four times greater than necessary 
for haemostasis. This leads to the alternate hypothesis, either 
that platelet function is homogeneous, large numbers being required 
to meet all demands, or that platelet function is heterogeneous with 
a subpopulation of platelets being responsible for normal haemostasis. 
Evidence favours the latter hypothesis and suggests that a sufcpopulation 
of megathrcmbocytes (large platelets) are the more important functioning
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platelets in haemostasis (Karpatkin, 1978).
1.2.4.5 PLATELETS AND THROMBOSIS, AND THE USE OF ANTI -PLATELET DRUGS
In addition to playing a vital role in preventing blood loss fron 
vessels damaged by injury, platelets are involved in the occlusion 
of arteries damaged by atherosclerotic disease, a condition known as 
arterial thrombosis. Platelets are also thought to play a role in 
venous thromboembolism though veins do not become atherosclerotic 
(Lancet, 1977). Venous thrombi originate as "white heads" composed 
of platelets, leucocytes and fibrin (Walsh, 1977) and usually begin 
in valve pockets where rheological conditions favour the formation 
of relatively stagnant pools of blood (Weiss, 1976).
Considerable attention has been paid towards drugs and agents 
that might prevent thrombus formation. Heparin is used successfully 
in protecting against deep vein thrombosis and pulmonary embolisms, 
perhaps because of the importance of blood coagulation in venous 
thrombosis. Platelet aggregation may be a more important event in the 
initiation of an arterial thrombus, and a growing body of clinical 
evidence supports the use of antiplatelet drugs as the approach to pre­
vention of arterial thrombosis. The roles of ADP, prostaglandins and 
cyclic adenosine monophosphate (cAMP) in platelet aggregation have 
been important in evaluating the potential effectiveness of various 
drugs. However, though many compounds have been shown to inhibit 
platelet function in-vitro (Mustard and Packham, 1970), only a 
few have been tested for their antithrombotic effects in man (Hirsch,
1977). These include acetyl salicylic acid (aspirin) vfaich inhibits 
the platelet release reaction by inhibiting the synthesis of prost­
aglandin cyclic peroxide intermediates. Sulphinpyrazone, a
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uricosuric agent closely related to phenylbutazone, inhibits platelet 
function in an unknown manner (Weiss, 1976). Dipyridamiole is one of 
a number of pyrimido-pyrimidine compounds which inhibit platelet func­
tion, probably by increasing cAMP levels by inhibiting phosphodiester­
ase activity. Hydroxychloroquine, often used as an anti-inflammatory 
agent, weakly inhibits ADP induced platelet aggregation. Finally, 
clofibrate is a hypolipidemic agent which appears to reduce platelet 
adhesiveness, though like hydroxychloroquine, no convincing evidence 
exists that it is an effective antithrombotic drug. (Hirsch, 1977). 
Recent evidence for a role of prostaglandins and prostaglandin 
intermediates in the control of thrombosis (see prostaglandins) has 
lead to new approaches in the search for antithrombotic agents.
Lipid peroxidation has been implicated in atherosclerosis, and one 
possibility is that inhibition of prostacyclin synthesis by lipid 
peroxides could be a reason for the increased tendency to thrombotic 
complications in atherosclerosis. Antioxidants, by protecting prost­
acyclin synthetase would therefore form a basis for antithrombotic 
therapy (Lancet, 1977a).
1.2.5. PLATELET AGGREGATION - THE EVENTS
The chain of events that occurs on platelet stimulation follows 
a well defined pattern, involving shape change, primary aggregation, 
release and secondary aggregation. It is not clear if these 
stages are separate and distinct, but the extent of the reaction is 
related to the type and strength of the stimulus. Under certain 
conditions, platelet aggregation is completely reversible and does not 
iirpair platelet survival, or their involvement in further platelet 
functions. Reversible aggregation is probably better defined as
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incomplete aggregation, the cells not having had a strong enough 
stimulus to completely aggregate (Holmsen, 1974).
A wide variety of biological agents are known to be capable of 
inducing platelet aggregation, including ADP, adrenaline, noradren­
aline, 5HT, long chain fatty acids, collagen and thrombin (Mustard 
and Packham, 1970), calcium (Born, 1962) and vasopressin (Haslam 
and Rosson, 1971).
1.2.5.1 ENERGY REQUIREMENTS FOR AGGREGATION
The majority of platelet functions studied depend upon a cont­
inuous cellular production of ATP. Those that do not, include plate­
let agglutination by, for example, polylysine, though these activities 
are often distinguished from aggregation because of the lack of ATP 
dependence (Solum, 1968 - cited Holmsen, 1977a). ATP is the source 
of energy during the whole aggregation chain and is associated with 
increased glycolysis, oxidative phosphorylation and glycogenolysis 
(Deisseroth et al., 1970; Schneider, 1974). Interpretation of some 
results should be treated with caution, however, as several studies 
relating platelet function and metabolism have used washed, 
resuspended platelets in EDTA containing media. Such platelets 
have altered morphology with pseudopodia and large vacuoles, in 
contrast to resting platelets in whole blood, or citrated platelet 
rich plasma (PRP)(Holmsen, 1977a). However, glycogen is an import­
ant source for increased ATP production during platelet activation 
probably arising from direct mobilisation of glycogen. The process, 
glycogenolysis, normally depends upon cyclic adenosine monophosphate 
(cAMP) activating a cAMP dependent protein kinase. This, in turn, 
begins a series of enzyme activations resulting in the breaking of
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the -1,4- linkages of glycogen to yield glucose 1-phosphate. This 
type of mechanism allows amplification of the original signal at 
each activation step, and hence a small change in cAMP can cause a 
large change in the activity of the final enzyme, phosphophosphorylase. 
The process probably explains how increased platelet aggregation is 
associated with a decrease in cAMP (Schneider, 1974), though other 
evidence suggests that control of platelet phosphorylase activity may 
be modulated by non-cyclic adenine nucleotides (Deisseroth et al.,
1970).
Protein kinase catalysed phosphorylation reactions are involved 
in contractile protein functions as well as membrane permeability 
control. High levels of membrane phosphorylation appear to maintain 
the platelet in a non-aggregating state and it has been preposed 
that the rapid dephosphorylation of the platelet surface is the common 
reaction that leads to membrane changes and subsequent platelet 
aggregation (Booyse et al., 1973).
1.2.5.2 MEASUREMENT OF PLATELET AGGREGATION
The stages of aggregation have been widely assayed using the 
aggregometer (Born, 1962), in which light transmission changes as 
a consequence of shape change and aggregation in stirred PRP or 
resuspended platelets are recorded. Characteristic patterns of 
aggregation have been observed. It is thought that adrenaline does 
not induce a shape change (Holmsen, 1974; MacFarlane and Mills, 1975), 
though this is controversial (Mustard and Packham, 1970), and the 
primary aggregation phase is not distinguishable from secondary agg­
regation induced by collagen (Weiss, 1976) (Figure 2).
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Platelet aggregation responses (using PRP in an aggregometer)
A - Normal patterns
B - Response on exposure to drugs that inhibit the release 
reaction (e.g. aspirin and indanethacin).
(Fran Weiss, 1976)
1.2.5.3 PLATELET SHAPE CHANGE AND FIRST STAGE AGGREGATION
Platelet shape change, the discocyte - echinocyte transformation 
(Ehrman, 1978), is the earliest manifestation of platelet stimulation 
(Luscher, 1977), when platelets swell from their normal disc shape 
to a sphere (Holmsen, 1974) sometimes with pseudopodia (Hovig, 1974). 
Unlike the other events in aggregation, the shape change process is 
thought to be independent of extracellular divalent cations (Massini, 
1977). It is characterised by the disappearance of the peripheral 
ring of microtubules, and by the morphologically discernable contract­
ile activity involving thrcmbosthenin. These are both dependent 
upon intracellular calcium in the same way as actin and myosin in 
muscle contraction (Luscher, 1977). The shape change results in 
'sticky' platelets which adhere to form loose reversible aggregates 
(Barrer and Ellison, 1977). This primary aggregation depends upon 
the presence of certain extracellular factors (discussed in aggreg­
ation mechanisms).
1.2.5.4 THE PLATELET RELEASE REACTION
If the aggregating stimulus is above a specific threshold level, 
a second phase of aggregation is observed, and this is associated 
with the release reaction. This reaction is characterised by the 
discharge of various substances. The process is very rapid and is 
morphologically associated with centralisation of the dense granules 
(observed in vitro). Centralisation has been termed, the "contractile 
wave", and probably involves polymerized cytoplasmic thrcmbosthenin 
rather than any organised microtubule system (Hovig, 1974). This is 
followed by fusion of many of these granules with the membranes of
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the platelet canalicular system, and discharge of the contents of the 
granules into the system. The substances released include non- 
metabolic ADP and ATP, 5-HT, adrenaline, noradrenaline, platelet factor 
4, fibrinogen, potassium and calcium ions, PF3, ¡5-glucuronidase, and 
(i -thrcmboglobulin (Holmsen, 1969a; Detwiler and Feinman, 1973;
Barrer and Ellison, 1977; Niewiarowski, 1977). The amounts released 
seem to depend upon the type of aggregating agent and the concentration 
of viable platelets. For example/ 0.5 adrenaline will induce the 
release of up to 55% of the total intracellular ADP from the platelets 
in citrated human PRP (Mills et al., 1968). This corresponds to approx­
imately 2.5 )]M per 10" platelets (D'Souza and Glueck, 1977). 1 - 2 UM
ADP will induce a similar release of intracellular ADP. Adrenaline, 
thrombin, collagen and ADP are each capable of inducing the release 
of 30% to 40% of platelet ATP (Mills et al., 1968; D'Souza and Glueck, 
1977). It has been estimated that collagen is capable of inducing 
the release of up to 80% of the 5-HT, 60% of the ADP, 40% of the ATP 
and 50% of the potassium ion content of platelets (Holmsen et al., 1969a). 
Thrombin is thought to be the most powerful release reaction stimulating 
agent, followed equally by collagen, and ADP, and then by adrenaline 
(D'Souza and Glueck, 1977).
Most of the released substances are associated with the "bulls 
eye" granules, or like PF3, with the plasma membrane (Barrer and 
Ellison, 1977). However, some aggregating agents may provoke other 
changes including lysosomal activation. For example, thrombin and 
collagen cause a significantly greater release of /3-glucuronidase 
(Mills et al., 1968). This type of activation is sometimes referred 
to as release II. Thrombin and collagen induce both release I and
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release II/ and includes lysosomal acid hydrolases such as -glucuron­
idase, ^ f-galactosidase, and the cathepsins. Only release I occurs 
with aggregation induced by adrenaline and ADP, causing the release 
of the contents of the dense granules (Holmsen et al., 1969a).
The release process may be divided into three steps (Holmsen 
et al./ 1969a):
a) Induction, an interaction between the aggregating agent and the 
plasma membrane, during which a "release inpulse" is created. 
Primary aggregation takes place during this step.
b) Intracellular transmission, the transmission of the "inpulse" 
from the plasma membrane to the ^ ¿-granules. Calcium ions have 
been suggested as this intracellular transmitter (Holmsen, 1974).
c) Extrusion, the process triggered by the "inpulse" which leads to 
the specific emptying of the granular content extracellularly.
Many of the extruded substances are of biological importance and 
platelets may be regarded as being immediate homeostatic secretory 
cells.
Acid phosphatase is not released during the release reaction, 
and the detection of traces of acid phosphatase in the plasma 
following the induction of platelet aggregation is probably due to 
cellular damage (Mills et al., 1968).
Extracellular calcium ions may be important for the release 
reaction, though both collagen and thrombin are able to induce 
release in their absence. (Mueller-Eckhardt and Luscher, 1968 - 
cited Massini, 1977).
1.2.5.5 SECOND STAGE PLATELET AGGREGATION
This stage of aggregation is associated particularly with the
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release of 5HT, ADP, calcium ions, and catecholamines during the 
release reaction, and it can be regarded as release linked aggregation. 
It is widely considered that this stage is irreversible (Born, 1962; 
Mustard and Packham, 1970; White et al., 1973; Ardlie and Han, 1974; 
Barrer and Ellison, 1977), though it is also thought that platelets 
can go through the entire cycle of activation and still be capable 
of returning to their resting state, in spite of having shed the 
contents of their storage granules (Luscher, 1977). The latter may 
occur under controlled in-vitro conditions, but it seems unlikely 
that it occurs during normal ir^vivo haemostasis and coagulation.
1.2.5.6 VISCOUS METAMORPHOSIS .
Viscous metamorphosis is the term reserved for the fusion of 
a large number of platelets into an irreversible amorphous mass. 
During this stage, platelet lysis occurs and acid phosphatase and 
lactic dehydrogenase are released. Acid phosphatase release has 
been used as a marker of platelet destruction (Brown et al., 1975). 
Viscous metamorphosis is observed with thrombus formation, blood 
coagulation (Zucker and Borrelli. 1959; Sharp, 1958) and blood 
storage (Polasek, 1968). These metamorphosed aggregates are often 
associated with fibrin strands, which are thought to stabilise the 
aggregate (Mustard et al., 1966). The release of acid phosphatase 
during platelet lysis is sometimes referred to as the second phase 
release reaction (Mustard and Packham, 1970), but this term can be 
confused with the term release II. Release II is probably strictly 
an in-vitro term to distinguish between the effects of collagen and 
thrcmbin and other aggregating agents. Second phase release is a 
continuation of release II associated with platelet lysis. However,
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in-vitro release I could also result in second phase release, depend­
ing upon the strength of the stimulus and the state of the platelets.
1.2.6 THE MECHANISMS OF PLATELET AGGREGATION
The mechanisms by which platelets adhere to thrombogenic surfaces, 
change shape, aggregate, and release their granular contents are not 
fully understood, though evidence is available for the involvement 
of many factors including surface charge, glycosyltransferases, 
prostaglandins, calcium ions, ADP and fibrinogen.
1.2.6.1 ENDOGENOUS ADP
Endogenous ADP is thought to play a central role as the mediating 
agent between the aggregation agent and the platelet response 
(Haslam, 1964; Benner and Brunner, 1973; Jamieson, 1977). This 
role is based upon ADP clearing studies using for example, phos- 
phoenolpyruvate/pyruvate kinase (Haslam, 1964) and creatine phosphate/ 
creatine phosphokinase (Izrael et al., 1974) in which platelet aggre­
gation was very much reduced. However, there is evidence against a 
role for released ADP in primary aggregation, since the release of 
ADP has not been detected during first phase aggregation by adrenaline, 
thrombin, 5HT or vasopressin (MacFarlane and Mills, 1975) and 
studies, again with creatine phosphate/creatine phosphokinase, have 
shown that platelet adhesion to collagen fibrils is not mediated via 
endogenous ADP (Tschopp and Baumgartner, 1976).
Therefore, it is probable that endogenous ADP is not involved in 
adhesion, shape change or primary aggregation, but that these 
result as direct responses to the aggregating agent. It seems that
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ADP is involved only in the second stage of aggregation as a conse­
quence of its release in the release reaction; its possible mechanism 
being discussed later.
1.2.6.2 THE POLE OF CALCIUM IONS IN PLATELET AGGREGATION
Platelets contain large amounts of calcium, most of which is 
thought to be in the dense granules and released during the platelet 
release reaction, along with ATP, ADP and 5HT (Massini, 1977).
However, a recent comparison of the release of ATP and calcium ions 
showed that the release of calcium preceded the release of ATP and 
by a kinetically distinct reaction (Detwiler and Feinman, 1973). 
Vesicles similar to the sarcoplasmic reticulum of muscle cells are 
another calcium ion storage compartment, as are the cytoplasm, the 
mitochondria and even the platelet surface. Platelet activation is 
triggered by a rise in cytoplasmic calcium resulting in increased 
contractile activity. Shape change requires the breakdown of the 
peripheral ring of microtubules which hold platelets in their 
discoid shape. This is most probably due to intracellular calcium 
ions, which are known to depolvmerise microtubules. Platelet 
aggregation and release require calcium ions involved in the contractile 
system (Massini, 1977), though thrcmbosthenin contraction may also 
be controlled by ADP, indicating the existence of two independent 
systems that control aggregation and release in intact platelets 
(Aledort et al., 1973). It has been preposed that the role of calcium 
ions in the mechanism of the release reaction is in altering the 
membranes of the storage organelles and cytoplasmic membranes in such 
a way that fusion is induced resulting in the extrusion of the contents
- 21 -
of the organelles (Lucy, 1970; Massini, 1977).
Holmsen (1974) suggested an alternative scheme for platelet 
aggregation in which, instead of regarding the stages as separate 
(Jamieson, 1974), the functions are manifestations of one basic 
cellular reaction. The aggregating agent interacts with the 
platelet membrane resulting in the release of an intracellular 
transmitter which activates ATP requiring systems. He postulates 
that this transmitter is intracellular calcium and that the basic 
reaction is cellular contraction. The stage reached in the sequence 
depends upon the type and strength of the stimulus and the respons­
iveness of the platelets.
Extracellular calcium ions have been demonstrated to be necessary 
for platelet aggregation by, ADP, 5HT, adrenaline, thrombin and 
vasopressin (Massini, 1977), although agents such as thrombin, 
collagen and antibody/antigen complexes are thought to be able to 
induce release in the absence of extracellular calcium.
This requirement for calcium or other divalent cations raises 
the question of how aggregation can take place in citrated PRP or 
whole blood. It has been found that ADP at even 5 x 10”^M can induce 
aggregation in citrated human PRP (Born and Cross, 1963), even 
though it was found that, working with unwashed resuspended pig 
platelets, the optimal calcium ion concentration was about the normal 
physiological one (Born and Cross, 1964).
More recently, however, it has been found that the optimum 
calcium ion concentration for aggregation is below the physiological 
level (Heptinstall, 1976), and that the addition of citrate could 
favour, at least, secondary aggregation, by reducing the 
calcium concentration (Akbar and Ardlie, 1978). Anticoagulation
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with citrate containing anticoagulants is designed to prevent blood 
coagulation, but the fact that sufficient calcium ions remain free 
to allow platelet aggregation is suggested by the action of EDTA, 
which chelates all divalent cations and effectively inhibits ADP 
induced aggregation (Born and Cross, 1963). Magnesium ions are 
complexed to a lesser extent than calcium ions by citrate and may 
act as an alternative to calcium ions in platelet aggregation in 
anticoagulated plasma or blood. However, magnesium ions have 
been shown to be less effective than calcium ions in platelet 
aggregation (Born and Cross, 1964) and perhaps it is a combination 
of available divalent cations that functions in platelet aggreg­
ation in citrated blood.
1.2.6.3 THE ROLE OF PROSTAGLANDINS IN PLATELET AGGREGATION .
The second phase of platelet aggregation is inhibited by, for 
exairple, acetyl salicylic acid (aspirin) and indomethacin. These 
drugs also inhibit prostaglandin synthesis, and this suggests a 
role for prostaglandins, or their intermediates, in platelet 
aggregation (Smith et al., 1974a). This is supported by the obser­
vation that platelets produce prostaglandins when stimulated by 
aggregation inducers (Smith and Willis, 1970; Smith et al., 1973). 
Although primary platelet aggregation can be induced by exogenous 
arachidonic acid, a prostaglandin precursor (Smith et al., 1974a), 
and certain exogenous prostaglandins themselves (Smith et al., 1977), 
the formation of endogenous prostaglandins does not take place until 
the onset of the release reaction (Smith et al., 1973). Hence 
primary aggregation probably only involves the direct effect of 
the aggregated agent with calcium ions and fibrinogen as cofactors
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(Holmsen, 1977b). Activation of prostaglandin synthesis is 
probably responsible for the platelet release reaction (Gerrard 
et al., 1975; Weiss et al., 1976), and the release reaction may 
be regarded as the link between prostaglandin synthesis and platelet 
aggregation (Smith et al., 1974b).
One prostaglandin precursor is arachidonic acid, and its 
liberation frcm membrane phospholipid is the crucial step. This 
may occur by hydrolytic cleavage of the ester bond by phospho­
lipase A2, a membrane bound enzyme, that requires calcium ions for 
activity. Hence its stimulation within the intact platelet may 
require mobilisation of calcium from an intracellular store 
(Weiss et al., 1976; Holmsai, 1977b). Whether calcium mobilisation 
is the primary mechanism by which aggregating agents initiate 
prostaglandin synthesis or not, is not known. The next step in 
prostaglandin synthesis is oxidative cyclization of the precursor 
for which a coenzyme is required to provide the necessary reducing 
equivalents. It has been suggested that catecholamines and 5HT may 
be the natural coenzymes in regulating the in-vivo biosynthesis of 
prostaglandins (Sun et al., 1970); and platelets store both.
Recent evidence suggests that the interaction of an aggregating 
agent with the platelet membrane activates a unique precursor 
serine protease on the platelet outer membrane surface. This 
activated protease then activates phospholipase A2 (Aoki et al., 1978) 
presumably by hydrolytic cleavage in the presence of calcium ions. 
However, inhibition of this protease with, for example, aprotinin, 
inhibited only the second phase of aggregation, thus providing 
further evidence for the role of prostaglandin synthesis in release 
linked aggregation only.
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It is known that both prostaglandins E 2  and (PGE2  and 
PGF2iC) are formed during platelet aggregation (Smith et al., 1974b) 
and PGE2 is thought to be a potential aggregation inducer. However, 
it has been demonstrated that endoperoxide intermediates formed 
during prostaglandin synthesis are more powerful aggregating 
agents. These endoperoxide intermediates, PGH2  and PGG2  are formed 
by cyclic oxidation of arachidonic acid and have jointly been 
termed "labile aggregating stimulating substance (LASS)"
(Willis, 1974; Gerrardet al., 1975). More recent work has further 
elucidated the prostaglandin biosynthetic pathway and has shown 
that a further intermediate, formed from PGH2 , is produced, 
thromboxane A2, which is a very powerful aggregating agent (Sun et 
al., 1977). (Figure 3)
Arachidonic Acid
cyclooxygenaseI
prostacyclin
, synthetase Prostacyclin 4 '
I
6-keto PGF1dC Thromboxane A,
I
Thromboxane B,
Figure 3. SUMMARY OF PROSTAGLANDIN SYNTHESIS FROM ARACHIDONIC ACID
The mechanism of prostaglandin induced aggregation is unknown, 
though synthesis is associated with reduced cAMP levels (similar to
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platelet aggregation). However, it may be that prostaglandin and 
cAMP levels are in a cause and effect relationship (Salzman et al., 
1973). ADP, prostaglandin endoperoxides and thromboxane A 2  initiate 
a similar sequence of internal transformations in platelets that 
lead to release and aggregation, though the changes triggered by ADP 
are less pronounced than those triggered by endoperoxides and throm­
boxane A 2 . ADP also places a greater dependence on external factors 
such as fibrinogen and calcium ions. The mechanism of changes induced 
by ADP and prostaglandins are independent of each other. During 
collagen induced aggregation, both endogenous prostaglandins and 
released ADP become available simultaneously and platelet aggreg­
ation is probably induced by both (Kinlough-Rathbone et al., 1977).
The response is probably greater than would be produced by either 
ADP or prostaglandins alone (Smith et al., 1977).
An important role for prostaglandins has been proposed in 
the regulation of thrombus formation, whereby a powerful anti­
aggregating agent is present to help control thrombus formation 
as a result of thromboxane A2 release during haemostasis. This 
agent, prostaglandin I2  (PG^) (also called prostaglandin X, or 
prostacyclin), is formed in another pathway from PGI^ (Figure 3) 
and is found in endethelial cell walls. It is thought that a balance 
exists between the levels of thromboxane A 2  formed in platelets, 
and PGI2  in the vessel walls and that this balance prevents thrombus 
formation on undamaged vessel walls (Lancet, 1976). Recent evidence 
suggests that P G ^  may actually be a circulating hormone, generated 
in the lungs and functioning as an active control of platelet 
aggregation in-vivo (Moncada et al., 1978). It is interesting that 
hyperventilation may increase the output of PG^, whereas tobacco
- 26 -
smoke may diminish it (Gryglewski et al., 1978).
1.2.6.4 THE CONTPDVERSIAL ROLE OF CYCLIC GUANOSINE MDNOPHOSPHATE 
(CGMP ) IN PLATELET AGGREGATION
Many compounds that inhibit platelet aggregation and release, 
for exanple adenine, act by increasing cAMP concentrations in 
platelets. It is known that a rise in cAMP in many systems is 
associated with a reduction in cGMP. Collagen, thrombin and adren­
aline have been found to increase cGMP concentrations in platelets 
and this rise is slightly in advance of aggregation, proceeding 
rapidly as aggregation commences. This evidence suggests that 
the initiation of the release reaction requires an increase in 
cGMP (Haslam and McClenoghan, 1974; White et al., 1973). However, 
another study found that though induced release is associated 
with raised cGMP, it was unclear whether cGMP was necessary to medi­
ate the reaction (Haslam et al., 1975). Recent evidence, using 
artificially increased cGMP levels has shown that cGMP does not mod­
ulate the release reaction (Weiss et al., 1978). Since a reduced 
cAMP level is associated with aggregation, it seems probable that 
the increased cGMP concentration is a consequence of this reduction 
but that it is not a mediator of platelet release.
1.2.6.5 THE MECHANISM OF PLATELET AGGREGATION IN HAEMOSTASIS .
Particular interest has been shown in the mechanism of collagen 
induced platelet aggregation because of the role of collagen and 
platelets in thrombus formation during haemostasis. Collagen 
constitutes a substantial part of the subendothelial basement
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membrane of blood vessels# and it is its exposure# as a consequence 
of vascular damage, that provides the stimulus for platelet adhes­
ion and aggregation resulting in a haemostatic plug. Collagen 
structure is important, a quaternary structure with a specific 
charge being essential for aggregation (Miyata et al.# 1976; Wang 
et al.# 1975). Platelet charge is also important. During aggreg­
ation# the normal surface negative charge decreases (Seaman, 1976) 
probably due to an orientation change in the platelet surface 
exposing more negatively charged groups, including the carboxyl 
groups of terminal sialic acid residues. When the vascular intima 
is damaged, the initial haemostatic reaction is the adherence of 
platelets to the exposed collagen and to each other. This latter 
phenomenon is known as platelet agglutination. It is not an 
energy requiring process and involves a plasma protein, "factor 
VIII related protein", binding to platelet surfaces (Solum et al., 
1977). The mechanism of platelet agglutination is unknown but it is 
important in haemostasis, causing circulating platelets to clump to- 
gether at an injury site. The mechanism for platelet collagen adhe­
sion may involve an enzyme/acceptor complex between collagen 
glycosyl transferase, and collagen galactosyl transferase on the 
platelet surface, and incomplete heterosaccharide chains on the 
collagen fibrils. Galactose and glucose frcm the appropriate 
sugar nucleotides, for example uridine diphosphate glucose (UDP 
glucose) in platelet membranes, are transferred to the appropriate 
acceptors on collagen. The essential step in the theory is the 
interaction of the platelet enzyme and the collagen acceptor 
(Roseman, 1970). ADP released frcm erythrocytes has been shown 
to induce adhesiveness in platelets (Harrison and Mitchell, 1966)
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and to be important in haemostasis (Gaarder et al., 1961). However, 
using creatine phosphate/creatine phosphokinase to rapidly remove 
any released ADP, Tschopp and Baumgartner (1976) showed that ADP 
played no part in platelet adhesion to subendothelium or fibrillar 
collagen. Perhaps the role for ADP may be, that together with 
uridine diphosphate (UDP), it increases the affinity of the enzyme 
for its acceptor (Jamieson, 1977).
Although collagen does not produce the primary aggregation 
phase (Weiss, 1976) seen in the aggregameter, during platelet 
aggregation by most other aggregating agents, the adhesion between 
collagen and platelets can be likened to a primary aggregation 
process. Since collagen is known to induce the release reaction 
with release of adenine nucleotides (Kobayashi and Didisheim,
1973), platelet aggregation induced by collagen probably involves 
ADP release and prostaglandin synthesis similar to other aggreg­
ating agents in secondary aggregation.
Collagen induced release is associated with the liberation of 
collagenase from lysoscmalocgranules, associated with fi-glucuron­
idase (Mills et al., 1968). This collagenase may function in a 
negative feedback mechanism limiting thrombus formation (Chesney 
et al., 1972).
m d d e o f action o f some ot h e r aggregation inducers
The information detailed so far on platelet function and 
aggregation mechanisms serves to demonstrate the diversity of 
platelet activity and the different mechanisms involved. The 
majority of work on platelets has involved separation techniques to 
produce either platelet rich plasma or platelet suspensions.
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Though both are essential for examining platelets per se, they 
are "artificial" media for platelets, and it is conjectural whether 
platelets behave in the same manner in whole blood. However, before 
examining platelet aggregation in exsanguinated blood, it is worth 
considering the mode of action of several other aggregation inducers 
that may play a role in aggregation in stored blood.
1.2.6.6 EXOGENOUS ADP
ADP is a powerful aggregating agent, and if added to platelet 
rich plasma (PRP) in concentrations as low as 1 x 10 M, it will 
cause irreversible aggregation (Born, 1962; Seaman, 1976).
ADP activity requires the presence of calcium ions (Born, 1962; 
Haslam, 1964) and fibrinogen (Mustard and Packham, 1970), the 
latter possibly being the "unknown plasma factor" (Haslam, 1964) or 
the "heat labile plasma protein" (Born and Cross, 1964) required for 
ADP induced aggregation. If calcium is absent then only the shape 
change occurs. Fibrinogen has been shown to become associated with 
platelet membranes immediately after the addition of ADP (Mustard 
et al., 1978). ADP receptor sites, possibly involving sialic acid, 
exist on platelets (Born and Cross, 1963) and there have been 
calculated to be as many as 2 x 10 receptors per platelet (Born, 
1965). It has been suggested that ADP induced aggregation involves 
a stoichiometric interation between platelets and ADP (Born, 1962). 
Although it is not possible to demonstrate firm binding of ADP to 
platelets, there may be transient binding because a small degree 
of conversion of ADP to ATP has been observed (Mustard and Packham,
1970). This is possibly due to the presence of a membrane site
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for phosphoryl groups that enables conversion of exogenous ADP to 
ATP (Feinberg et al., 1973).
Perhaps a complex of ADP, calcium ions and plasma fibrinogen 
forms bridges that interconnect the platelets. Another hypo­
thesis is that bombardment by ADP molecules produce a configurat­
ional change in a protein on the platelet surface resulting in 
the formation of disulphide bonds between the platelets and 
plasma fibrinogen. Inhibition of platelet aggregation by substances 
which prevent sulphydryl groups from reacting, such as dithiothreitol, 
favour this hypothesis (Born, 1967). Recent evidence suggests that 
fibrinogen may contribute to the cross links, and that calcium ions 
may be involved in maintaining the optimal conformation of the 
fibrinogen molecule (Mustard et al., 1978). The configurational 
change in surface proteins may be due to the involvement of thrcmb- 
osthenin (Izrael et al., 1974), which is directly affected by ADP 
(Puszkin et al., 1973).
Below a certain concentration, ADP induced aggregation is 
spontaneously reversible in-vitro (Born, 1962). ADP is rapidly 
broken down in plasma (Haslam and Mills, 1967) and the cause of the 
reversal of aggregation may be due to the action of seme of the 
breakdown products of ADP (Born, 1962; Born and Cross, 1963;
Born, 1967). It is not known if any one enzyme is specifically 
responsible for ADP breakdown in plasma, though an ADPase has 
been shown to be involved (Mills, 1966) but not adenylate kinase 
(Haslam and Mills, 1967). The products of ADP degradation may 
include adenosine and AMP, both of which interfere with platelet 
aggregation. AMP probably competes with ADP for aggregating sites 
on platelets (Born, 1962) and adenosine, at low concentrations,
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activates adenylate cyclase, thus increasing the concentration of 
cAMP which mediates the inhibition of platelet aggregation 
(Haslam and Lynham, 1973).
1.2.6.7 THROMBIN
Thrombin in concentrations of 1 to 4 National Institute of Health 
_1
(NIH) units ml / has been shown to induce second stage aggregation 
in washed resuspended platelets. Released ADP is the mediator 
of this action (Haslam, 1964). In PRP, only 0.25 NIH units ml  ^ is 
required to cause the release of up to 50% of the platelets' ADP 
content, and this demonstrates that thrombin is a more powerful 
releasing agent than collagen, exogenous ADP, or adrenaline 
(D 'Souza and Glueck. 1977).
The mechanism by which thrcmbin induces platelet shape change 
and primary aggregation has been shown to involve a 120,000 dalton 
glycoprotein, hydrolysis of which, results in a change in organisation 
of membrane proteins so that additional proteins are exposed to the 
membrane surface (Phillips, 1973). The platelet surface substrate 
m y  be fibrinogen, and there is a requirement for calcium ions 
(Mustard and Packham, 1970).
The interaction of platelets with ADP leads to the activation 
of coagulation factor XII and PF3 (Walsh, 1973) which may initiate 
thrombin generation (Ardlie and Han, 1974). It was noticed during 
ADP induced aggregation in PRP, that the extent of platelet aggreg­
ation was related to the ADP concentration, and that the increase 
in aggregation was related to increased PF3 availability. As a 
result, it was suggested that second stage platelet aggregation may
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be induced by thrcmbin generated through the intrinsic coagulation 
pathway on the platelet membrane, and that the extent of the 
platelet response to ADP may depend upon the extent of activation 
of the intrinsic pathway (Ardlie and Han, 1974). Evidence to support 
this hypothesis included the observation that an intact intrinsic 
pathway is required for ADP induced second stage aggregation, and 
that extending the activation of the pathway using Russell's viper ven­
om (to activate factor X) resulted in an increased response of plate­
lets to low ADP concentrations. It was suggested that thrombin 
generated on the platelet membrane was responsible. Fibrinogen was 
found to be necessary, and it was considered that an enzyme - substrate 
complex between thrcmbin and fibrinogen may have been responsible 
for the primary aggregation induced by ADP. The role of thrcmbin may 
not be confined to release induced by ADP but may be extended to 
explain, for example, collagen and adrenaline induced release. The 
significance of the relationship is that coagulation and aggregation 
nay be interdependent and therefore, that they may be regarded as one 
phenomenon (Ardlie and Han, 1974). An argument against this 
hypothesis is the observed aggregation induced by exogenous ADP 
when heparin is present (Born and Cross, 1963). However, this is 
considered to be aggregation mediated by prostaglandin intermediates 
which do not require ADP for their action and which are, therefore, 
independent of the products of the release reaction (Akbar and 
Ardlie, 1978). Thrcmbin is also capable of inducing aggregation 
without ADP and prostaglandins, suggesting a third aggregating mech­
anism (Kinlough-Rathbone et al., 1977), which may be the activity 
described above. Perhaps all three mechanisms play a role in thrcmbin 
induced platelet aggregation in-vivo.
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1.2.6.8 5-HiDRDXmYPTAMINE
5HT induces the aggregation of human platelets in PRP, though
the extent of aggregation is small and the process reverses rapidly
without reaching the second phase (Baumgartner, 1970). However,
the platelets of most other animals are very responsive to 5HT
(Swank and Fellman, 1967). In human whole blood, the exposure of
-1
platelets to 5HT concentrations as high as 1 pg.ml rarely induces 
aggregation (Swank et al, 1963). In contrast, 5HT very markedly 
potentiates the ADP induced aggregation of human and other animals 
platelets, both in blood (Swank and Fellman, 1967) and in PRP 
(Mustard and Packham, 1970). This potentiation will be discussed 
further in the section on synergism.
O
Human platelets contain large quantities of 5HT, about 50ng.10 
platelets. The 5HT is stored mainly in the bulls eye granules 
(Baumgartner, 1970) where it is protected iron degradation by 
monoamine oxidase, to 5-hydroxyindole 3-acetic acid and 5 hydroxy- 
tryptophol (Pletscher, 1968). The 5HT concentration may be increased 
by up to 50% if exposed to raised plasma levels of 5HT (Baumgartner, 
1969). Platelets may be able to synthesise small amounts of 5HT 
intracellularly (Lovenberg et al, 1968), though this is controversial 
(Maynert and Isaac, 1968), but most of the platelets'content of 5HT 
is taken up during blood circulation (Pletscher, 1968). The uptake 
process is both passive and active, the latter being able to occur 
against a considerable concentration gradient (Baumgartner, 1970). 
Specific receptor sites exist for 5HT on the platelet membrane 
(Baumgartner and Born, 1969; Drummond and Gordon, 1975). Active 
5HT uptake, which commences with the binding of 5HT, probably 
involves an energy dependent carrier system (Pletscher, 1968), and
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it has been proposed that aggregation of platelets induced by 5HT 
is mediated by ADP released fran platelets incident to ATP utilis­
ation in active 5HT uptake (Baumgartner, 1970). The presence of 
receptor sites helps to explain the concentration dependency of 
5HT induced aggregation, since above certain concentrations, aggreg­
ation ceases, probably due to 5HT saturation of the receptor sites 
(Baumgartner and Born, 1969; Barthel and Markwardt, 1974).
Presumably, this explains the limited aggregability of platelets by 
5HT, since perhaps insufficient ADP is available to extend aggreg­
ation beyond the first phase. In rats, evidence has been obtained 
to suggest that more than one type of receptor site exists for 5HT 
on platelets; a specific site existing for 5HT uptake and another 
for 5HT induced shape change (Drummond and Gordon, 1975). If this 
is so, it suggests that two separate activities occur. In the 
first, the binding of 5HT to a specific site invokes a physiological 
response, namely shape change, and in the second, the binding of 
5HT to another specific uptake site results in ADP production and in 
extremes, mild platelet aggregation.
Despite the weak aggregating ability of 5HT, a central role for 
5HT in secondary platelet aggregation has been proposed. It was 
observed that adrenaline and noradrenaline induced aggregation in 
whole blood was inhibited in the presence of a 5HT inhibitor, UML 
491 (a lysergic acid derivative). This lead to the suggestion that 
the catecholamines may act through 5HT, probably by releasing 5HT in 
the release reaction, which together with ADP produces secondary 
platelet aggregation (Swank and Fellman, 1967). No further evidence 
is available, though it is possible that UML 491 in fact inhibits the 
release reaction, perhaps by the inhibition of prostaglandin synthesis.
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This seems likely, as another specific 5HT antagonist, methysergide, 
has been shown to have no effect on second phase aggregation (Thcmas,
1967).
1.2.6.9 CATECHOLAMINES
Both adrenaline and noradrenaline have been shown to cause 
platelet aggregation in hunan PEP (O'Brien, 1964a), though 
noradrenaline is 50% (Born et al., 1967a) to 90% (O'Brien, 1964b) 
less effective than adrenaline. Dopamine probably does not induce 
platelet aggregation (Alexander et al., 1978). All three catechol­
amines are able to potentiate platelet aggregation induced by low 
concentrations of ADP, thranbin, collagen and, to a small extent, 
5HT, though noradrenaline is only about 20% to 50%, and dopamine 
only 1% as active as adrenaline (Mills and Roberts, 1967). Con­
siderable individual variation in susceptibility of human platelets 
to adrenaline and noradrenaline has been observed, which is not 
related to age, gender, time, exercise or any common variable 
(O'Brien, 1964a). Catechol-o-methyl transferase activity has been 
demonstrated in hunan platelets. This enzyme may convert the cate­
cholamines to their methylated derivatives, which lack aggregating 
ability. Perhaps the variation in platelet responsiveness to 
adrenaline and noradrenaline could be explained by variations in 
platelet transferase activity (Stramentinoli, 1978).
Catecholamine induced aggregation is blocked by «C-adrenergic 
antagonists such as phentolamine, and it has been suggested that the 
mechanism of catecholamine induced aggregation is via&C-adrenergic 
receptors (Mills and Roberts, 1967; Thomas, 1967; Robison et al.,
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1969; Barthel and Markwardt, 1974; Alexander et al., 1978). 
Catecholamines compete for these receptors, estimated to be about 
100 per platelet, in a stereospecific manner, with the potency 
series of (-) adrenaline greater than (-) noradrenaline. This 
may explain the more potent aggregating ability of adrenaline 
(Alexander et al., 1978). There are probably nofl -adrenergic 
receptors on platelets (Robison et al, 1969). An increase in cAMP 
activity in platelets is associated with aggregation inhibition 
(Haslam and Lynham, 1973; Michel et al., 1976). Catecholamines 
act upon the oc-adrenergic receptors to produce a decrease in the 
intracellular level of cAMP in platelets (Robison et al., 1969; 
Moskowitz et al., 1971) probably due to their known inhibitory 
effects on adenylate cyclase (Born et al., 1967a). The nature 
of the supposed interaction between «-adrenergic receptors and 
adenylate cyclase is not clear, though bound catecholamines nay 
inhibit adenyl cyclase activity via a direct link between the 
ot-receptor and the catalytic subunit of adenylate cyclase 
(Alexander et al., 1978).
It has been reported that both the first and second phases of 
aggregation involve ADP, since apparently, even the first phase is 
much reduced by including an adenosine diphosphatase prepared from 
viper venom (Haslam, 1967 - cited Mustard and Packham, 1970). How­
ever, this is controversial as adrenaline, without the mediation of 
ADP, has been reported to induce primary aggregation in human 
platelets (Mills and Roberts, 1967).
Blood platelets are carriers of catecholamines (Weil-Malherbe 
and Bone, 1954) associated with 5HT, ADP and ATP in the bulls eye 
granules. There is more noradrenaline than adrenaline (Weil-Malherbe
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and Bone, 1954), and though the relative levels are disputed, the
O
catecholamines have been calculated to total approximately 800pg.10 
platelets (Thomas, 1957). The catecholamines are taken up into plate­
lets frcm plasma and it is possible that, rather like 5HT, uptake 
may be related to platelet aggregation (Born et al., 1967a; Barthel 
and Markwardt, 1974). Fibrinogen is thought to be necessary as a 
cofactor in catecholamine induced platelet aggregation-(Mustard and 
Packham, 1970).
1.2.6.10 SYNERGISM BETWEEN PLATELET AGGREGATION INDUCERS
Studies in-vitro have shown that ADP, thrombin and collagen 
can act synergistically in platelet aggregation and the release 
reaction. Low concentrations of ADP, insufficient to induce 
aggregation, combined with low concentrations of thrombin or 
collagen will cause extensive aggregation and release (Kinlough- 
Rathbone et al., 1977). Synergism has also been shown to occur 
between low concentrations of adrenaline and ADP; adrenaline and 
collagen; adrenaline and thrombin, 5HT and ADP, adrenaline and 
5HT; ADP and 5HT; noradrenaline and ADP; and, noradrenaline and 
5HT. (Swank and Fellman, 1967; Mills and Roberts, 1967: Thomas, 
1967; Baumgartner and Born, 1969; Barthel and Markwardt, 1974; 
Takano, 1975). It seems probably that synergism would also occur 
between more than two inducing agents.
The extent to which one inducer will potentiate another is not 
clear. For example, both adrenaline and 5HT have been proposed as 
particularly powerful potentiating agents (Thomas, 1967; Swank and
- 38 -
Fellman, 1967), yet 5HT is thought to be particularly active with 
noradrenaline and that no combinations of 5HT with thrcmbin, or ADP 
show mutual potentiation, at least in dog PRP (Takano, 1975),
The mechanism of synergism remains to be elucidated, but it 
was found that prostaglandin synthesis often plays an important role. 
However, this role is very much reduced when thrcmbin is involved, 
probably due to the proposed third aggregating mechanism initiated 
only by thrombin (Kinlough-Rathbone et al., 1977). The role of 
prostaglandins is probably the reason for earlier observations that 
adrenaline particularly potentiated ADP and thrombin induced 
secondary aggregation (Mills and Roberts, 1967; Thomas, 1967).
Synergism also occurs on a more general basis, since the release 
reaction can be regarded as potentiation of platelet aggregation 
by the original stimulus. As the release reaction involves both 
release of granular contents and prostaglandin synthesis, the 
platelets seem to have two means of potentiating the response to 
external stimuli via two separate positive feedback loops (Holmsen, 
1977b).
1.3 PLATELET AGGREGATION DURING BLOOD STORAGE
Platelet aggregation plays an essential role in haemostasis 
and blood coagulation and, to seme extent, in defence mechanisms.
The aggregation process depends upon an initiating stimulus. The 
mechanisms of some stimuli have been reviewed. The fact that plate­
lets aggregate during the storage of blood was first recorded 
by Fantus in 1938. Since then, numerous publications have repeated 
the observations mainly in attenpts to determine optimal blood
- 39 -
Storage conditions, to examine the chemical and physical changes 
occuring during blood storage, and to describe the physiological 
effects of transfusing blood containing cellular aggregates.
1.3.1 THE DEVELOPMENT OF PLATELET AGGREGATES DURING BLOOD STORAGE
There are two anticoagulants in common use for long term blood 
storage - acid: citrate: dextrose (ACD) and citrate: phosphate: 
dextrose (CPD). During blood storage in both ACD and CPD at 4°C. 
there is a steady reduction in the platelet count to about 50% of 
its original level after 10 days (Limbird and Silver, 1974;
Marshall et al., 1975.). The decrease in platelet count is 
inversely related to the increase in concentration of microaggreg­
ates during the storage of whole blood (Solis et al., 1974a, b). 
Simple platelet aggregates appear within 24 hours, the platelets 
becoming more densely packed and fused together after 3 days.
Platelet viability is markedly reduced after only 24 hours. 
Degenerating granulocytes start to beccme part of the fused aggregate 
after 3 to 4 days, possibly explaining why aggregates form to a 
lesser extent in PRP (Marshall et al., 1975. ). The more rapid 
aggregate formation seen in platelet concentrates is possibly due 
to the close proximity of the cells and the effects of centrifugation 
(Barrett et al., 1975). Fibrin is generally regarded as being imp­
ortant in stabilising aggregates, though there is seme controversy 
as to whether it is (Swank, 1961; Harp et al., 1974; Dawidson et
al., 1975) or is not (Dawidson, 1977) a component of blood storage
. 125aggregates. However, experiments with I labelled fibrinogen 
showed that after about 10 days, fibrin did begin to accumulate on
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pre-existing aggregates increasing the aggregate mass (Arrington 
and McNamara, 1974). Also, the use of urokinase and streptokinase 
as exogenous activators of fibrinolysis reduced the aggregate 
volume, suggesting that fibrin may be important as a cohesive 
element in formed microaggregates (Gervin et al., 1975).
Aggregates may reach up to 200 pm in diameter, although the 
majority are below 30 pm (Swank, 1971). It has been estimated 
that after 2 weeks storage, 90% of aggregates range between 10 and 
40 pm in diameter and that at 3 weeks, the average number of 
aggregates is 5 x 10^ per unit of blood (450 ml). (Solis and Gibbs, 
1972). At least 40% are thought to be stable (Solis et al., 1974b).
Similar changes occur in both ACD and CPD solutions, the con­
centration of aggregates increasing alinearly in a sigmoid pattern. 
However, the extent of aggregation is different. In CPD, platelets 
tend to aggregate ntore readily during the first few days, than in 
ACD (Wright and Sanderson, 1974) but on subsequent days, the extent 
of aggregation is more rapid in ACD so that the concentration of 
aggregates in ACD and CPD beccme similar after about one week (Solis 
et al., 1974b; Marshall et al., 1975'.). Aggregation may be related 
to factors such as age and gender. Platelets from donors older than 
35 years are reported to aggregate more readily during the first 
few days than those from younger donors. Similarly in blood 
donated by males, there is a greater tendency toward platelet aggreg­
ation during the first few days than there is in blood obtained from 
females (Harpetal., 1974).
- 41 -
1.3.2 THE PHYSIOLOGICAL EFFECTS OF TRANSFUSING PLATELET AGGREGATES
After severe injury, not involving the lungs, many patients 
die from respiratory failure, a syndrome known as post traumatic 
pulmonary insufficiency, congestive atelectasis, or respiratory 
distress syndrome. Factors which have been inplicated in the 
pathogenesis of respiratory distress syndrome include fluid 
replacement such as massive blood transfusion (Bennett et al.,
1972).
The structure of the pulmonary microvasculature is such that 
it is easily obstructed by emboli. Once an embolus has lodged 
in the microcirculation, its fate may depend on several factors.
It may break down, remain unchanged, or act as a nidus from which 
in situ thrombosis propagates (Moseley and Doty, 1970). Small 
emboli may be removed by the reticulo-endothelial system (Swank 
and Porter, 1963), though even transient obstruction by a sufficient 
number of emboli could produce significant lung parenchymal damage 
(Moore, 1974). Because large numbers of aggregates are contained in 
stored blood, which could be filtered off in the pulmonary vascular 
bed, they are thought to be implicated in the development of respir­
atory distress syndrome following massive blood transfusions (Moseley 
and Doty, 1970; McNamara et al., 1972; Reul et al., 1974;
Dawidson et al., 1975; Takaori et al., 1977; Barrett et al., 1978). 
Seme of the evidence for this implication is as follows.
The transfusion of stored blood into dogs has been shown to be 
associated with an increase in pulmonary arteriovenous shunting 
of blood and a decreased diffusion capacity of the lung for oxygen. 
The causal factor was a large number of microemboli subsequently
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found in the pulmonary microcirculation which has been found to be 
dose related to the number of cellular aggregates in the trans­
fused blood (Reul et al., 1974; Barrett et al., 1975 - cited Barrett 
et al., 1978). In another series of experiments, dogs' lungs were 
examined following the transfusion of stored autologous blood. The 
examination revealed extensive occlusion of the pulmonary micro- 
circulation with platelet aggregates (McNamara et al., 1972;
Connell and Swank, 1973). Evidence of the effects of transfused 
platelet aggregates in man were first based upon observations of 
battle casualties who received massive blood transfusions. The 
measurement of low arterial oxygen partial pressures following 
transfusion, may be considered to support the idea of a role of 
transfused cellular aggregates in respiratory distress syndrome 
(Moseley and Doty, 1970). Objective data has only recently been 
presented showing the pulmonary effects in humans of blood transfus­
ions containing microaggregates. Pulmonary function was measured 
in man before and after intraoperative blood transfusion, and 
demonstrated the development of pulmonary microembolisation after 
only two units of blood had been transfused (Takaori et al., 1977). 
This observation was more recently confirmed in patients transfused 
with over 20% of their blood volumes, where an increase in 
pulmonary arteriovenous shunting was observed in an amount directly 
proportional to the quantity of microaggregates administered 
(Barrett et al., 1978).
However, some disagreement exists as to the harm transfused 
microaggregates may cause. In a series of experiments, dogs in 
haemorrhagic shock were resuscitated by transfusion of stored auto­
logous blood into the left pulmonary artery. It was assumed that if
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microaggregates affected vascular resistance there should be a 
redistribution of pulmonary blood frctn the left to the right lung.
No distribution occured and vascular resistance rose in both lungs 
with the same magnitude. This suggested that aggregates did not 
play a major role in pulmonary changes associated with haemorrhagic 
shock. (Giordano et al., 1976). It has been observed that, although 
many blood vessels may become occluded as result of massive blood 
transfusions, the number of cellular aggregates present in stored 
blood is probably insufficient to occlude enough of the the pulmon­
ary vasculature to produce the observed respiratory symptoms 
(Gervin et al., 1974a). Experimentally, large quantities of glass 
beads have to be injected to cause in-vitro vascular occlusion in 
dogs, and pulmonry compliance in man is such that cardiac output 
can be increased from 4 to 30L.min with no change in pulmonary art­
erial pressure (Giordano et al., 1976). It has been reported that 
after in situ lung perfusion studies using stored autologous 
blood in baboons, lung biopsies revealed no traces of microemboli.
The observed, increased pulmonary vascular resistance was considered 
to have been mainly due to underlying humoral factors with mechanical 
obstruction by platelet aggregates playing an additive role.
The primary mechanism may be pulmonary vasoconstriction in response 
to high plasma concentrations of 5HT and ADP released from aggregated 
platelets (Bennett et al., 1972). This may be added to by the 
reduced pH of stored blood, increasing metabolic acidosis in the 
recipient (Davidson et al., 1975) which is itself, a major deter­
minant in influencing pulmonary pressor responses such as pulmonary 
vasoconstriction (Grand and Downing, 1970). Recipients of massive 
transfusions are in a.severe state of shock before transfusion and
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there is little doubt that shock plays a major role in the develop­
ment of respiratory distress syndrome. This is a consequence, 
not only of vasoconstriction and intravascular coagulation, but also 
stimulation of in situ platelet aggregation by 5HT, catecholamines 
and vasopressin, which may be sequestered in the lung (Swank, 1968; 
Kusajima et al., 1974; Giordano et al., 1976).
It seems, therefore, that the role of transfused platelet 
aggregates in the aetiology of respiratory distress syndrome is 
unclear. The fact that 65% of the lung microvasculature can be 
occluded before hypertension develops, could disguise the effects of 
transfusing aggregates (Hyland et al., 1963 - cited Swank and Edwards,
1968). However, in severely traumatised recipients of massive blood 
transfusions, it is difficult to determine the importance of any 
one contributory factor in the development of respiratory distress 
syndrdme. Nevertheless, a role for platelet aggregates does seem 
to have been established, even though it may be a secondary one.
1.3.2.1 SECONDARY MICROEMBOLISM AETER BLOOD TRANSEUSION
Many microemboli, particularly those below 15 /m in diameter 
nay traverse the lung capillary bed after blood transfusion. An 
electron microscope study of the effects of these microaggregates 
on other organs has been reported using dogs as the transfusion 
recipients. Where biopsies were conducted immediately after trans­
fusion, cellular aggregates were found in the liver and to a much 
lesser extent in the brain and kidneys. After a delay of 20 min. 
after the end of transfusion, few aggregates were to be found in 
these organs, but alterations in the fine structure of the kidneys,
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brain and liver were clearly evident. It would appear that once 
microemboli enter the blood stream, they circulate from organ to 
organ. Their removal may not be the first capillary bed that they 
enter. More likely their removal is a slow process of attrition 
during which time, the aggregates circulate frcm one microvascular 
bed to another, causing repeated damage to each area (Connell et al., 
1973).
During extracorporeal circulation in open heart surgery, the 
lungs are bypassed and stored blood added to the bypass apparatus 
would enter the recipient intra-arterially. In these cases, the 
capillary beds of the rest of the body can be regarded as the sites 
of primary embolization. It has been suggested that the use of blood 
containing aggregates to prime the extracorporeal circuit may cause 
embolic tissue damage (Swank and Porter, 1963; Swank, 1971).
However, a study in dogs showed no histological evidence that intra­
arterial blood transfusions containing aggregates, caused focal brain 
damage, or that there was any relationship between the occurrence 
of petechial haemorrhages and the presence of aggregates in the 
stored blood. Though it was observed that removal of the cellular 
aggregates appeared to reduce mortality in the experimental dogs, 
(Wright, 1975).
1.3.2.2 THE USE OF FILTERS TO PREVENT.EMBOLIC DAMAGE
The damage caused by infusion of large quantities of micro­
aggregates has been discussed. Numerous studies have shown that 
microfiltration of stored blood prevents the detremental changes 
described both from direct blood transfusion and via extracorporeal
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circulation (Solis and Gibbs, 1972; Reuletal., 1973; Davidson 
et al., 1975; Takaori et al., 1977; Kennedy et al., 1977). Stand­
ard blood pack filters with pore sizes of 170 jum are not suitable 
for filtering microaggregates. The better microfilters will remove 
the majority of particles greater than 15 ^ cm in diameter (Dawidson, 
1977), though the varying qualities of the available microfilters 
will not be considered here.
The effect of microfiltration of stored blood could be considered 
as evidence for a role for cellular aggregates in the mechanical 
obstruction of the pulmonary vasculature. However, microfilters 
may remove vasoactive amines such as 5HT (Davidson et al., 1975) and 
therefore do not clarify what role transfused platelet aggregates 
might play in respiratory distress syndrome.
1.3.2.3 METHODS TO REDUCE AGGREGATE FORMATION IN STORED BLOOD
Microfiltration of stored blood is an efficient method for the 
removal of platelet aggregates. There are disadvantages, however, 
including cost, their nuisance value if speed is essential, and the 
reported possible alteration of erythrocyte survival (Gervin et al., 
1975). Some of the alternatives to filtration will be briefly 
discussed.
1.3.2.3.1 PREVENTION OF AGGREGATION BY DRUGS AND AGITATION
Aspirin in concentrations of 100 to 200 ¿iM will decrease plate­
let stickiness and if added to blood before storage, has been reported 
to reduce aggregate formation by up to 50% (Gervin et al., 1975).
The addition of non-toxic concentrations of PGE, to blood stored at
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4°C was also found to reduce platelet aggregation, increase their 
life span and did not impair the platelets'haemostatic effectiveness 
(Becker et al., 1974; Valeri et al., 1972). Adenosine was also 
found to minimise platelet aggregation (Mourad, 1968) and is also 
known to improve 2,3,diphosphoglycerate preservation in erythrocytes 
(Benesch and Benesch, 1969). Continuous gentle agitation of blood 
throughout storage has been observed to reduce platelet aggregation 
(Arrington and McNamara, 1975); though the type of agitation is 
considered important (Holme et al., 1978) and may even destroy 
platelets, giving the impression of reduced platelet aggregation 
(Gervin et al., 1978).
1.3.2.3.2 THE REMOVAL OF AGGREGATES AND SEPARATION OF BLOOD COM­
PONENTS
Microaggregates can be eliminated from stored blood by removing 
the buffy coat, where the largest number of aggregates have been 
found (Gervin et al., 1974b), by differential centrifugation 
(Gervin et al., 1975). However, this reduces the haemostatic 
effectiveness of transfused blood. To control bleeding, platelet 
viability is an essential prerequisite, and erythrocytes and 
leucocytes are unneoessarv. For this ouroose. platelets mav be 
separated and stored for a short term as platelet concentrates in a 
small volume of plasma. A volume of 50ml has been considered most 
suitable for platelet viability (Murphy and Gardner, 1976; Holme 
et al., 1978). Platelet viability and reduced aggregation are thought 
to be best preserved by maintaining a pH between 6.8 and 7.2 (Murphy 
and Gardner, 1975), and by storage at 22°C which maintains
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platelet viability for up to 96 hours (Murphy and Gardner, 1969). 
Gentle agitation, as described for whole blood storage, is also 
considered important (Holme etal., 1978). The use of crycprot- 
ective agents, such as dimethylsulphoxide has been successfully used 
for freezing platelet concentrates with little loss of platelet 
function (Lundberg, 1970; Baldini et al., 1976).
1.3.2.3.3 THE USE OF AGGREGATE FREE BLOOD
Only fresh whole blood is comparatively aggregate free 
(Gervin et al., 1975) and is the ideal form of blood for transfusion. 
This category could include the use of autotransfusion, in which 
blood lost by a patient is collected and returned within a short 
time, and is especially useful during major surgery where a large 
blood loss might be expected (Wilson and Taswell, 1968). The use 
of autotransfusion in which blood is collected from a donor to be 
returned after blood storage, would be subjected to the same aggreg­
ation problems as discussed in whole blood platelet aggregation.
1.4 THE PLAN FOR THE INVESTIGATION OF POSSIBLE CAUSES OF PLATELET
AGGREGATION IN WHOLE BLOOD
Evidence has been presented for the possible mechanisms of 
platelet aggregation and for the probable role of these aggregates 
in the development of respiratory distress syndrome in severely 
traumatised patients. Although considerable attention has been paid 
to the prevention of transfusing aggregates, little information is 
available as to the cause of platelet aggregation during blood stor­
age.
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1.4.1 THE MEASUREMENT OF PLATELET AGGREGATION DURING BLOOD STORAGE
The extent of platelet/granulocyte aggregation in stored blood 
can be assessed in several ways. Direct microscopy, measurement 
of the screen filtration pressure, and cell counting with the 
Coulter counter are the most popular. Both direct microscopy and 
the Coulter counter technique require sample manipulation, 
smearing or fixing for microscopy, and dilution for the counter. 
Although the latter is thought to be the most accurate (Solis et al,, 
1974a), its availability is an essential prerequisite. Screen 
filtration pressure (SFP) allows the measurement of aggregation 
to be made on the whole blood sample (Swank, 1961), thought it is 
reported not to be able to distinguish between platelet adhesion 
and platelet aggregation (Solis et al., 1974a). Changes in blood 
viscosity may also interfere with SFP measurements. However, increa­
sed viscosity probably parallels decreased erythrocyte deformability 
(Schmid-Schonbein et al., 1969) and occurs with much less magnitude 
than platelet aggregation (McNamara et al., 1971). Therefore, 
viscosity changes have a negligible effect on SFP, particularly 
during the first few days of storage.
1.4.2 THE BACKGROUND EVIDENCE FOR THE TYPE OF INVESTIGATION
During the investigation of tissue damage following extracorp­
oreal circulation for open heart surgery, in the W. E. Dunn Unit 
of Cardiology at Keele University, several observations were made. 
Sane of these were briefly as follows. Samples of human blood 
obtained iron volunteers had normal SFP's of 12 - 21 mmHg 
inmediately after collection and SFP's of 2 8 - 1 5 2  mmHg after 
7 days storage in ACD at 4°C. Blood samples obtained at the
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end of standard blood collection by the Blood Transfusion Service 
also had normal SFPrs after collection, but after 7 days, the major­
ity had SFP's of greater than 600 mmHg. This indicated that sane 
alteration occurred in blood during standard donations, and that this 
alteration may be partly responsible for the formation of cellular 
aggregates during storage. The SFP of 8 dog arterial blood samples 
stored in ACD for 7 days at 4°C increased from a mean of about 38 
rrenHg to 50mmHg but 8 venous samples increased to a mean of 398mmHg. 
After the 7 days of storage, arterial blood samples contained cellu­
lar aggregates up to 40 jm in diameter, but 6 of the 8 venous blood 
samples contained aggregates up to 150 /m in diameter. The dif­
ference in aggregation may have been due to the slower rate of venous 
blood collection compared with arterial (Wright, 1975).
These observations suggested that the rate and extent of 
cellular aggregation in stored blood may have been dependent upon 
the rate of blood collection and the proportion of the total blood 
volume taken. The indications were that the processes of 
cellular aggregation were activated during blood collection, and 
that a biochemical mechanism was involved.
1.4.3 THE FACTORS THAT MAY BE RESPONSIBLE FOR PLATELET AGGREGATION 
DURING BLOOD COLLECTION AND STORAGE
Although many agents have been shown to be able to cause 
platelet aggregation in-vitro (Mustard and Packham, 1970), the agents 
that could be responsible for aggregation in blood during storage 
are limited to those factors that may be present during blood 
collection and storage. Blood collection may be a stressful
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procedure, both psychologically (Callingham and Barrand, 1976) 
and physically, as a result of mild haemorrhage (Fowle, 1968). Be­
cause the indications were that platelet aggregation may be activated 
during blood collection, a suitable area of study was considered 
to be an examination of the known aggregation inducers that are 
released into the blood during stress. Only the catecholamines,
5HT and vasopressin fit into this category. Vasopressin is a power­
ful inducer of platelet aggregation in-vitro (Haslam and Rosson,
1971) and acute haemorrhage is a potent stimulus for its release 
(Moore, 1965). However, the only suitable assay for measuring 
plasma concentrations of vasopressin is radioimmunoassay. The 
necessary antiserum is not obtainable commercially and the facilities 
to raise one's own were not available. Therefore, the investigation 
into the possible causes of platelet aggregation in whole blood began 
with an examination of the roles of catecholamines and 5HT.
Because of the weak aggregating nature of 5HT, particular emphasis 
was originally placed on catecholamine estimations during blood 
collection, with an investigation into the roles of catecholamines 
and 5HT during storage. Several other factors were also examined. 
ADP, because of its supposed mediatory role in platelet aggregation, 
and because of its high concentration in both platelets and erythro­
cytes making it a potential primary cause of aggregation during 
blood storage. ATP was examined because of the energy dependence 
of platelet aggregation. Cellular aggregation during storage was 
measured using the SFP technique. pH was measured during storage 
as an index of the metabolic changes resulting in a build-up of 
lactic and pyruvic acids. Plasma haemoglobin was measured to monitor 
erythrocyte integrity. Prothrombin time and partial thromboplastin
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time were measured as tests of the efficiency of the intrinsic and 
extrinsic blood coagulated pathways which may be triggered during 
blood storage and contribute to an increased SFP.
Each of these factors will be discussed in detail with evidence 
for their possible involvement in platelet aggregation during blood 
storage, as separate chapters.
- 53 -
CHAPTER TWO
CHANGES IN PLASMA CATECHOLAMINE CONCENTRATIONS 
DURING BLOOD COLLECTION AND STORAGE
2.1 CHANGES IN PLASMA CATECHOLAMINE CONCENTRATIONS DURING BLOOD
COLLECTION
Voluntary blood donation at Regional Blood Transfusion Service 
collection centres, involves the rapid donation of 450 ml of venous 
blood; about 8% of the average total blood volume.
During haemorrhage, the sympathetic nervous system is activated 
and this results in the liberation of noradrenaline from the post­
ganglionic nerve endings, and release of noradrenaline and adrenaline 
from the adrenal medulla (von Euler, 1946 - cited Chien, 1967). 
Dcpamine release is probably independent of sympathetic activity (de 
Champlain et al., 1976). Although the extent of the liberation of 
adrenaline and noradrenaline is correlated with the severity of the 
haemorrhage, this stimulation is not necessarily a consequence of 
severe blood loss, but is a response even to mild haemorrhage 
(Fowle, 1968). With the exception of aldosterone release, adrenal 
cortical secretion is probably not stimulated by mild haemorrhage 
(Moore, 1965). Aldosterone has not been reported to be able to 
stimulate platelet aggregation.
Although plasma adrenaline and noradrenaline concentrations have 
recently been reported to rise in seme anaesthetised patients during 
sodium nitreprusside induced hypotension (Rawlinson et al., 1978),
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there is no reported work on the measurement of plasma catecholamine 
concentrations during acute haemorrhage in man. However, the rapid 
withdrawal of only 10% of the blood volume in dogs, resulted in 
immediate stimulation of the adrenal medulla, and in up to a 50 fold 
increase in catecholamines in the adrenal vein (Moore, 1965). Cat­
echolamine concentrations have been measured in human fasting 
volunteers, in urine samples collected over 24 hours during which 
about 15% of their total blood volume was removed in a 15 minute per­
iod. A significant increase was observed in urine noradrenaline and 
adrenaline concentrations (Skillman et al., 1971).
Adrenal output during haemorrhage in dogs is also affected by 
emotional excitment (Chien, 1967) and fear and anxiety alone can 
stimulate adrenaline release in man (Britton et al., 1974; Carruthers, 
1975). Blood collection is a mildly stressful procedure (Callinqhaxn 
and Barrand, 1976) in which even contact with the blood sampler has 
been shown to be effective stimulus for stress induced catecholamine 
elevation (Sauebier and von Mayersbach. 1977).
Adrenaline is more powerful than noradrenaline as an aggregating 
agent by a factor of two to ten times; dopamine is thought to be
_7
ineffective (see chapter one). Adrenaline, at only 10 M can
—8induce in-vitro platelet aggregation (Born, 1967), but at 5 x 10 M 
may potentiate thrombin induced aggregation (Thomas, 1967), and at
_ o  — ]
10 M (about 1.8 ng.ml ), has been shown to potentiate ADP induced 
aggregation (Born, 1967). Mild stress has been reported to raise 
plasma catecholamine levels (Callingham, 1975), possibly to levels 
that might potentiate platelet aggregation (Born, 1967). 5HT release 
is usually associated with severe shock (Markley et al., 1975) and it 
is uncertain whether there is any significant rise in plasma 5HT
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concentration due to mild haemorrhage and associated stress. However, 
it has been shown that as little as 250 ng.ml-  ^of 5HT stimulated the 
medullae of isolated dog adrenal glands (Miller and Peskin, 1953), and 
so, if released, may potentiate catecholamine release in-vivo.
2.1.1 CATECHOLAMINE BIOCHEMISTRY AND PHYSIOLOGY
The three catecholamines found in man, noradrenaline, adrenaline 
and dopamine, are all related to 1,2 dihydroxybenzene, also known as 
catechol and hence the name catecholamines. Only the L-stereoisorter 
of catecholamines is physiologically active to any extent. They are 
mainly synthesised in the adrenal medulla and the sympathetic neurons, 
the initial step being the conversion of tyrosine to 3,4 dihydroxy- 
phenylalanine (DOPA) followed by conversion to dopamine by the non­
specific, pyridoxal phosphate dependent, amino acid decarboxylase. 
Dopamine is then taken up into vesicles, the chromaffin granules, 
which contain dopamine ^ -hydroxylase for noradrenaline synthesis 
and, particularly in the adrenal medulla, phenylethanolamine N- 
methyltransferase for adrenaline synthesis. Catecholamines are 
secreted from the chromaffin granules upon stimulation. Secreted 
catecholamines are metabolised very quickly in the target tissue, or 
the liver, though noradrenaline may be retaken up into neuronal 
vesicles, and is thought to be an inportant mechanism for quickly 
terminating neurotransmitter activity. The first step in catabolism 
of catecholamines is, either methylation or oxidation depending upon 
the circumstances. For exanple, bound noradrenaline is initially 
oxidatively deaminated by the broadly specific mitochondrial enzyme, 
monoamine oxidase. The next step is a reversal of the first, so that
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oxidation is followed by méthylation and vice versa. The main 
products for adrenaline and noradrenaline are metanephrine, 
normetanephrine and vanilmandelic acid (VMA). Biologically, the 
most important metabolic product for dopamine in noradrenaline, but 
its main urinary product is hanovanillic: acid (Figure 4). The 
concentration of catecholamines is controlled at all stages. All 
three catecholamines are allosteric inhibitors of their own synthesis 
by tyrosine hydroxylase, and for noradrenaline and adrenaline, 
hydroxylation of dopamine by dopamine ^ -hydroxylase is also a rate 
limiting step. During prolonged stress, the rates of synthesis of 
all the enzymes for catecholamine synthesis are gradually increased 
(Franzen and Eysell, 1969).
Major Pathways in the Metabolism of the Catecholamines
Figure 4
Tyrosine
Hydroxylase
Tyrosine I . ...... . Phenylalanine
| <  2%
DOPA
Amino acid 
Decarboxylase
Dopamine
hydroxylase
i
DopamineJ 2* Protocatechuic acid "Y^Methoxytyrcm ine Homovanillic 2 Acid▼ 1 —Normetanephrine,
Noradrenaline **
.Dihydroxymandelic acid* ►VMAphenylethanolamine ^ ,1 n-methyltransferase 3l
Adrenaline
Metanephrine
1 = catechol-o-methyl transferase (requires S-adenosylmethionine as
methyl donor)
2 = monoamine oxidase
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The primary function of adrenaline is as a hormone. Noradren­
aline functions as the adrenergic nerve transmitter, though it 
also functions as a hormone. Dopamine is usually found with 
noradrenaline in nerve endings, but dopamine specific nerves and 
receptors are found. The adrenal medulla contains all three cat­
echolamines, but mostly adrenaline, whereas comparatively little 
adrenaline is found in nerve endings. The response of tissues to 
catecholamine stimulation depends upon the presence of adrenergic 
receptor sites, the oc and ß  sites. Generally,oC -receptors are 
associated with smooth muscle contraction, and, with the exception 
of the intestine, /5-receptors with relaxation. Dopamine and noradr­
enaline act mainly throughoC-receptors, and adrenaline through both
\
U  and ß  . Because of this, the effect of adrenaline depends upon 
quantity and/or the sensitivity of the site. Thus, for example, 
in the pancreas, the icresponse to adrenaline predominates, inhibiting 
insulin release. However, if an«.-blocking drug, such as phentolamine, 
is given, then the fieffeet predominates, that i$ increased insulin 
release.
The physiological effects of catecholamines are many and varied, 
the following is just a brief introduction to the better understood 
effects of adrenaline and noradrenaline in man.
Noradrenaline has a vasoconstrictor effect and increases blood 
pressure. It reduces the blood supply of the kidneys, the liver, the 
skin and the muscles, but the reaction of different vascular regions 
is varied. On the other hand, it dilates the coronary vessels and 
increases the coronary blood supply. Noradrenaline increases the 
rate and force of the heart beat and increases the oxidative metabol­
ism of the heart, though its effect is substantially less than that
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of adrenaline. The same applies to other metabolic effects. 
Noradrenaline is a mild broncho-dilator and increases the frequency 
and depth of respiration in man.
Depending upon the concentration, adrenaline may cause vaso­
constriction or vasodilation. Like noradrenaline, it increases the 
rate and force of the heart beat. Adrenaline also increases the 
systolic blood pressure and causes a decrease in the peripheral res­
istance. Adrenaline increases the blood supply to skeletal muscle, 
liver and brain, but causes vasoconstriction in the skin and the 
kidneys. The net result in a state of emergency, is that blood is 
diverted from skin and viscera to the orqans which need it - such 
as skeletal muscle. Adrenaline stimulates respiration and dilates 
the bronchi. Compared with noradrenaline, adrenaline has more 
potent metabolic effects: the utilization of oxygen and the 
basal metabolic rate are increased, as is glycogenolysis.
Under conditions of stress, the adrenal medulla is stimulated 
with a resultant outout. consisting mainly of adrenaline; hence 
its descriptive title of the "emergency hormone". Higher plasma 
concentrations of adrenaline increase sensual acuity and enhance the 
the ability to think and react quickly, all effects to prepare for 
"fight or flight".
2.1.2 CATECHOLAMINE STABILITY DURING BLOOD COLLECTION AND STORAGE
Although catecholamines are rapidly removed out of circulating 
blood (Vane, 1969), evidence suggests that both adrenaline and nor­
adrenaline are quite stable in plasma removed from the blood circul­
ation, even at 37°C (Cohen et al., 1958). This may be because only
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very low levels of the main catabolising enzymes, monoamine oxidase 
and catechol-o-methyl transferase (COMT) have been found in human 
plasma. Dopamine may be catabolised due to the presence of benzyla- 
mine oxidase (Sharman, 1975). However, plasma catecholamines, may 
be reduced in exsanguinated blood quite rapidly (Carruthers et al., 
1970), partly due to uptake into platelets and erythrocytes (Sharman, 
1975). Though rapid uptake into erythrocytes has been refuted, 
particularly in the cold (Born et al., 1967b), and the rapid dis­
appearance of adrenaline in dog blood, in-vitro, has not been obser­
ved (Mangan and Mason, 1958).
However, it seems probable that in exsanguinated blood, any 
catecholamines released during blood collection may have to act 
rapidly on platelets before being taken up into blood cells. Those 
catecholamines taken up into platelets are stored in the "bulls eye" 
granules. It has recently been observed that CQMT is present in 
platelets, but it is associated with the mitochondria and is thought 
unlikely to affect the contents of the storage granules (Stra- 
mentinoli, 1978). Therefore, any catecholamines, even if in insuf­
ficient concentrations to induce platelet aggregation per se, may, 
as a consequence of stress during blood collection, be released from 
the adrenal medulla and taken up into platelets. The catechol­
amines may then be able to potentiate platelet aggregation when 
released during the release reaction, or platelet destruction.
2.2 THE MEASUREMENT OF PLASMA CATECHOLAMINES AS OPPOSED TO URINE
CATECHOLAMINES
The measurement of urinary catecholamines is a comparatively 
sinple procedure, though urine catecholamine concentrations indicate
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the sum of events that have occurred over a long period of time, and 
hence cannot measure transitory changes of sympathetic activity 
(de Champlain et al., 1976). Therefore, to measure catecholamines 
liberated in proportion to the degree of sympathetic acitvity after 
physiological stimulus, requires the more difficult measurement of 
plasma catecholamines.
2.3 THE CONDITIONS FOR BLOOD COLLECTION
Ten blood samples for catecholamine estimation were obtained 
during routine blood collection sessions at West Midlands Regional 
Blood Transfusion Service Centres. The majority of samples were, 
however, collected from University staff volunteers within our own 
laboratories. The conditions were as near as possible to those at 
the Transfusion Service Centres, though more care was exercised in 
ensurinq similar conditions frcm one donor to another. All volun­
teers were selected at random, but particular attention was payed to 
certain facts.
2.3.1 DONOR GENDER
Even though the basal plasma concentrations of circulating 
catecholamines are similar in males and females (Callingham, 1975: 
de Chaplain et al., 1976), it is possible that there might be a 
stress response difference and as it was easier to obtain male 
volunteers, it was decided to maintain one gender only.
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2.3.2 MEDICATION
Many drugs have been shown to affect platelet function. Plate­
let concentrates prepared frcm blood from volunteers who had 
previously ingested only 600 mg of aspirin have been shown to be 
haerrostatically less effective (Barrer and Ellison, 1977). Though 
this effect was not observed in another study (Aster et al., 1976^  
it was decided that to avoid any possible interference from drugs, 
all donors were free from medication for at least the 7 days 
immediately prior to blood collection.
2.3.3 TIME OF COLLECTION
All the laboratory donations were conducted between 9.00 am and 
11.00 am, so as to avoid any possible diurnal variation which has 
been observed in a minority of donors (Aronow et al., 1973). However, 
despite the reported increase in adrenaline secretion in winter 
(Callingham, 1975), collections were made all the year round.
Other variables considered could not be excluded for logistical 
reasons. These were:
2.3.4 DONOR'S AGE
Circulating catecholamines have been reported to be independent 
of age (de Champlain et al., 1976), though there is contradictory 
evidence, at least for noradrenaline, since basal levels in man have 
been reported to increase with age. This increase is thought to 
compensate for decreased adrenergic receptor sensitivity (Ziegler 
et al., 1976; Sever etal., 1977).
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2.3.5 SMOKING
Cigarette smoking has been associated with an increase in plate­
let aggregability (Strolin-Benedetti et al., 1976) which may be rel­
ated to nicotine stimulation of adrenaline release (Raab, 1962 - 
cited Franzen and Eysell, 1969).
Other factors that influence catecholamine release include 
exercise and the movement from a supine to an erect position. Even 
gentle exercise will increase the plasma noradrenaline concentration 
by about 70%, though more severe work is necessary to induce adrena­
line release (Callingham and Barrand, 1976). The effects of body 
tilting have been investigated and it was shown that tilting through 
only 30° can double the normal adrenaline and noradrenaline concent­
rations in the plasma. This was thought to be due to increased 
adrenergic nerve activity and to reflex stimulation of the adrenal 
medulla as a result of haemodynamic adjustments to an abrupt change 
in body position (Fluck and Salter, 1973). Similar effects were ob­
served when moving from a supine to an erect position (de Champlain 
et al., 1976). Because of these considerations, all volunteers were 
asked not to take any exercise and the blood collections were per­
formed with the donors in the supine position. According to Calling- 
ham (1975), the potential increase in plasma catecholamine concent­
rations due to the stress of blood collection itself, can be overcane 
by resting in a supine position for at least 30 minutes prior to 
collection. However, this period is rarely experienced by Trans­
fusion Service volunteers, and was not experienced by our own lab­
oratory volunteers. All of the latter were rested for a period 
of 10 minutes before blood collection.
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Volunteers were accepted on the same medical grounds that 
would qualify them for the Transfusion Service. The majority of 
volunteers had, in fact, previously donated blood to the Transfusion 
Service (Table 1).
2.4 ANTICOAGULATION OF BLOOD FOR STORAGE
For long term blood storage, only two anticoagulants are 
commonly used, acid: citrate: dextrose (ACD) and citrate: phosphate: 
dextrose (CPD). Heparin, though probably the safest anticoagulant, 
is only short lived and results in widespread platelet aggregation 
after only 24 hours (Swank, 1971) and may even induce aggregation 
(Eika, 1973). EDTA is very effective as a Ca chelator, but results 
in rapid platelet damage (Mollison, 1972).
Mollison (1972) has given a short history of the development of 
anticoagulants. The safety of citrate for blood preservation was 
first observed in 1914. It acts as an anticoagulant by chelating 
calcium ions, though storage of blood with trisodium citrate alone 
is unsatisfactory because erythrocytes deteriorate rapidly. In 1941, 
Maizels found that the addition of dextrose prevented this rapid 
deterioration possibly by providing energy for ATP and 2,3 diphospho- 
glycerate (2,3DPG) synthesis. Acidification was initially invest­
igated with the object of preventing caramélisation during auto­
claving, but Loutit in 1943, found it gave even better preservation 
of erythrocytes. This completed the development of ACD which was 
only improved in 1957 when Gibson described an anticoagulant that 
was less acidic than ACD.
This anticoagulant, CPD, has been compared with ACD in several
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TABLE 1.
DONOR DETAILS
a) TRANSFUSION SERVICE COLLECTIONS
EXP DONOR AGE
(yrs)
DURATION
(min)
PREVIOUS
DONOR
SMOKER
BLOOD PRESSURE
BEFORE AFTER 
(mmHg)
1 M.S. 21 6 YES NO • • • • • t
I f A.B. 23 8 YES NO • • • • •  •
2 R.B. 32 7 YES NO • • • in
I I J.D. 42 8 YES YES • • •
3 J.H. 24 17 YES YES • • • • »  •
•1 D.B. 25 6 YES NO • • • »  • •
4 M.H. 23 15 YES YES • • • •  • *
I I F.G. 55 7 YES NO • • • 1  • 1
II R.B. 23 5 YES NO •  •  • • 1  •
I I K.G. 39 6 YES NO • • • • i •
b)
ii COLLECTIONS
1 P.W. 48 18 YES YES • • • • • »
2 D.N. 22 17 YES YES • ft • • • •
3 P.C. 33 14 YES NO • • • • «  •
4 C.H. 23 14 NO YES ft ft ft » • »
5 N.C. 34 9 YES NO • • • • • •
6 S.J. 22 12 YES NO 140/80 140/82
7 A.S. 28 7 YES NO 150/90 134/90
8 N.B. 19 abandoned NO NO 130/70 110/65
9 D.B. 29 4 YES YES 130/78 130/78
EXP
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
PREVIOUS BLOOD PRESSURE
DONOR AGE
(yrs)
DURATION
(min) DONOR
SMOKER
BEFORE AFTER 
(mrtiHg)
P.W. 48 21 YES YES 126/78 120/70
N.C. 34 9 YES NO 126/70 120/80
D.N. 22 8 YES NO 110/72 110/72
G.H. 23 11 YES NO 122/80 110/76
T.D. 29 12 NO NO 140/90 126/82
R.G. 22 9 NO YES 126/60 118/64
R.O. 30 7 NO NO 126/72 127/73
G.W. 42 - YES NO •  •  • •  •  •
G.L. 23 8 YES NO 120/80 110/74
A.S. 29 11 YES NO 154/90 154/90
R.D. 51 8 YES NO •  •  • •  •  •
K.W. 34 5 NO NO 144/82 120/82
D.C. 29 9 NO NO •  •  • •  •  •
P.M. 23 5 YES NO 130/80 128/80
P.C. 34 7 YES NO 122/78 110/76
G.W. 42 9 YES NO •  M •  •  •
G.H. 23 5 YES NO 120/80 104/70
R.G. 22 14 YES YES 130/70 102/68
S.J. 23 4% YES NO 160/80 134/78
D.N. 23 5h YES YES 110/70 108/72
R.O. 31 6h YES NO 140/86 120/84
D.B. 30 eh YES YES 130/70 126/80
R.D. 51 5 YES NO 128/74 116/70
P.W. 30 10 YES NO 140/92 134/88
P.C. 34 4h YES NO 126/70 120/86
P.M. 23 5 YES NO 130/80 116/84
investigations. Erythrocyte survival is better maintained in 
CPD, associated with lower plasma potassium and haemoglobin con­
centrations (Limbird and Silver, 1974). Altered haemoglobin is a 
very important problem associated with massive transfusions (Collins, 
1974) and is correlated with 2,3DPG levels in erythrocytes. 2,3,DPG 
is an effective regulator of oxygen release by haemoglobin, a 
reduced 2,3,DPG level being associated with an increased oxygen 
affinity, thus affecting oxygen dissociation (Benesch and Benesch,
1969). 2,3 DPG levels are especially well maintained in CPD (Collins,
1974; Limbird and Silver, 1974; Marshall et al., 1975.)» possibly 
due to the sodium dihydrogen phosphate content maintaining a more 
physiological pH. The higher pH favours the activity of DPG mutase 
which catalyses the conversion of 1,3 DPG to 2,3 DPG (Mollison, 1972). 
Platelets aggregate more readily in CPD than in ACD during the first 
few days of storage, possibly because the lower pH of ACD is less 
favourable for aggregation (Solis et al., 1974b). However because 
of better erythrocyte preservation, CPD is probably the anticoagulant 
of choice in most transfusion centres and so it was the anticoagulant
used in this investigation.
Recipe: Dextrose 25.5 g
Trisodium citrate (dihydrate) 26.3 g
Sodium dihydrogen phosphate (monohydrate) 2.22 g
Citric acid (Monohydrate) 3.27 g
Made up to 1L with distilled water.
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2.5 METHODS
2.5.1 THE BLOOD COLLECTION PROCEDURE
This procedure was the same throughout the investigation.
After resting for 10 minutes, in a supine position, the venous blood 
pressure in the arm of the volunteer was raised to 80 mmHg using 
a sphygmomanometer cuff. Topical application of Hibitaine was 
used to cleanse the needle entry site followed by the intradermal 
administration of 0.05 ml of Xvlocaine as a local anaesthetic.
450 ml of blood was collected from the antecubital vein via a 
standard 15 gauge needle into a polyvinylchloride (PVC) blood pack 
containing 63.5 ml of CPD as the anticoagulant. The packs (McGaw 
Laboratories, USA) were specially prepared, and consisted of two 
packs connected by a Y junction, enabling simple division of the 
blood during or after collection (Figure 5). The packs were gently 
agitated by hand during the entire collection period, to ensure even 
mixing of the blood with the CPD.
2.5.2 BLOOD COLLECTION RESULTS (Table t)
In total, there were 45 donations, of which 35 were undertaken 
in our laboratories. Of these, 15 donors volunteered twice, 38 had 
previously given blood and 33 were non-smokers. Donor age ranged 
between 19 and 55 years with a mean of 30 years. The bleeding time 
ranged between 4 and 21 minutes with a mean of 9 minutes. No dif­
ficulties were experienced during any donation in the laboratory, 
with the exception of one instance when we were unable to obtain
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450 ml. This donation was excluded from the results. On 26 occasions 
the donor's blood pressure was taken before and after blood collection. 
Diastolic pressure showed little fluctuation with a mean of 78 mmHg, 
but systolic pressure fell by a small but statistically significant 
amount (students paired 't' test p^0.05) from a mean of 131 to 121 
irmHg.
2.5.3 SAMPLING FOR CATECHOLAMINE ESTIMATIONS
Samples of blood for catecholamine estimations at the start and 
finish of blood collection were taken iron special sanpling sites 
contained on the blood pack tubes (Figure 5). 15 ml samples were
taken into sterile syringes containing 2.1 ml CPD.
Samples taken at the Transfusion Service Centres were taken from 
volunteers whose permission for sanpling blood had been obtained.
The objects of the research were briefly explained to the donors in 
order to alleviate any fears that might have developed, if they 
considered they had been singled out for undisclosed medical reasons. 
Sampling sites are not found on normal packs and so on these occas­
ions, the first sample was taken immediately prior to collection 
directly from the vein, and the second sample iron the blood pack 
tube after it had been clampled proximally to the sanpling point at 
the end of collection. This meant a total of 480 ml of blood was 
taken from these donors, and so the same volume was taken from our 
own laboratory volunteers during the catecholamine experiments.
Subsequent blood collection, however, where separate sanpling 
was not undertaken, involved the normal collection of 450 ml only.
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2.5.4 PREPARATION OF SAMPLES FOR CATECHOLAMINE ESTIMATION
To minimize the loss of plasma catecholamines due to cellular 
uptake, blood samples were immediately cooled on ice and platelet 
free plasma (PFP) separated by centrifugation at the eariliest opp­
ortunity, usually within 15 minutes of collection. The addition 
of an antioxidant to fresh sanples, such as sodium metabisulphite, 
which is recommended by seme investigators (Anton and Syre, 1962; 
Shellenberger and Gordon, 1971; Diamont and Byers, 1975) was found 
to be unnecessary; a finding later endorsed (Callingham, 1977 pers­
onal conmunication; Sever et al., 1977). PFP plasma vas separated 
by centrifugation at 2,500 g for 15 minutes at 4°C. PFP was 
carefully removed taking care not to disturb the 'buffy coat' layer 
on tep of the erythrocytes. Subsequent microscopic examination of 
the PFP disclosed only trace contamination with residual platelets. 
It nay be possible to freeze plasma sanples (Callingham, 1975) with­
out loss, though the effects of long storage are variable (Carruthers 
et al., 1970) and so all sanples were assayed on the day of 
collection keeping the PFP at 4°C until required.
2.6 ASSAY FOR PLASMA CATECHOLAMINES
The concentrations of dopamine, adrenaline and noradrenaline in 
human plasma are normally very low, and therefore, require a highly 
sensitive and reliable procedure for their estimation. They can 
be estimated by biological or chemical assay, though, because of 
greater reliability and ease of execution, chemical methods are 
more desirable. For plasma sanples, only methods based on spectro- 
photofluorimetry and radioisotope labelling have been claimed to
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provide the required sensitivity. The isotope method is based on 
the o-methylation of the catecholamines using catechol-o-methyl 
transferase (OCMT) and labelled S-adenosyl methionine (SAM) as the 
methyl donor, converting the catecholamines to labelled methoxy- 
tyranine,.normetanephrine and metanephrine (Engleman and Portnoy,
1970; Siggers et al., 1970; Coyle and Henry, 1973; de Champlain 
et al., 1976; Ben-Jonathon and Porter, 1976; Callingham and Barrand, 
1976). The fluorometric method is based on either oxidation of 
catecholamines to their respective trihydroxyindole derivatives, or 
the less specific ethylenediamine condensation. The trihydroxyindole 
procedure involves oxidation of adrenaline and noradrenaline to adren- 
ochrome and noradrenochrcme at a slightly acid pH, followed by the 
addition of a strong alkali and reducing agent resulting in rearrange­
ment to fluorescent lutines. As the method operates near its limit 
of sensitivity with small plasma samples, many modifications have 
been proposed to improve sensitivity (Vendsalu, 1960; Haggendal,
1963; Anton and Sayre, 1962; McCullough, 1968; Jones and Robinson, 
1975; Diamont and Byers, 1975).
Although greater sensitivity is claimed for the isotope method, 
the procedure is complex, costly, and for unknown reasons, low recov­
eries have sometimes been obtained (Siggers et al., 1970). As a 
consequence a spectrophotofluorimetrie method was first used, and 
because of reported better specificity, the trihydroxyindole method 
was selected.
2.6.1 FLUORIMETRIC METHOD FOR THE DETERMINATION OF PLASMA CATECHOL­
AMINES
The method used was a modification of the improved sensitivity
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method described by Diamont and Byers (1975). However, catechol­
amines were extracted from plasma by ion exchange chromatography 
(Dowex 50W-X8) rather than alumina, as it was easier to activate and 
could be reactivated in the column (Jones and Robinson, 1975). Dif­
ferentiation between adrenaline and noradrenaline was catered for 
by selective oxidation based on the differential influence of 
tautcmerization temperature as detailed by Diamont and Byers (1975).
The method, however, was never found to be suitably sensitive 
to measure plasma samples, possibly due to the instability of the 
fluorescent products making readings necessary in an impossibly short 
time.
A more recent fluorcmetric method has been described using 
fluorescamine (Roche) which is claimed to yield intense fluorescence 
with many primary amines of biological importance including the cat­
echolamines (Udenfriend et al., 1972). Fluorescamine reacts directly 
to give a stable fluorescent pyrrolinone product. The reaction 
proceeds at room temperature and any unreacted fluorescamine is 
rapidly hydrolysed naturally (Felix and Jiminez, 1974; Bohlen et al, 
1973; Klein and Standaert, 1976). Its simplicity of reaction 
made it an ideal candidate for estimation of plasma catecholamines. 
However, preliminary studies showed the method to be insensitive 
to concentrations below 1 ng/ml and therefore it was unsuitable for 
estimating plasma levels.
2.6.2 DETERMINATION OF PLASMA CATECHOLAMINES BY THE RADIOLABELLED 
O-METHYLATIGN METHOD
As a consequence of the inadequacy of the fluorimetric methods
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for assaying plasma catecholamines, it was decided to use the more 
sensitive but more expensive and difficult radiometric method. The 
procedure was a modification of the methods, described by Ben- 
Jonathon and Porter (1976) and Callingham (1977 - personal commun­
ication). The enzyme, COMT is available commercially, but to reduce 
costs, it was prepared in the laboratory.
2.6.2.1 PREPARATION OF CQMT
The method of preparation was as described by Nikodejevic et al., 
(1970) but using ammonium sulphate fractionation of fresh pig's 
liver rather than rats liver. The procedure followed that described 
but with the following modifications. The paper refers to percentage 
saturation steps maintaining a temperature around 0°C, when the 
calculation was based on room temperature solubility. This was 
corrected. Also, prior to the dialysis step, the dialysis tubing 
was boiled for 5 minutes in 1mM EDTA followed by thorough rinsing 
with deionised water. This helps to eliminate any heavy metal imp­
urities (Umbreit, 1964). The dialysate vas divided into suitable 
aliquots and stored at -20°C. Further purification through 
Sephadex gel columns, via calcium phosphate gel adsorption and 
ultracentrifugation, as suggested by Nikodejevic et al., (1970) 
failed to provide a more sensitive assay (Callingham, 1977, personal 
communication). The dialysate concentration represented about 
50 mg protein per ml of 1mM phosphate buffer pH 7.
2 .6 .2 .2  MEASURME3SIT OF COMT ACTIVITY
The method used was as described by McCaman (1965) using dihdroxy- 
benzoic acid as the substrate as this was more active than adrenaline
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for testing COMT activity. Enzyme activity was calculated on the
. . 3basis of the known specific activity of H SAM (Radiochemical Centre) 
and expressed as /moles of product formed per g of tissue per hour. 
Enzyme activity was linear for at least one hour. Stored CQMT at 
-20°C remains active for at least a year and only one batch was 
required. This had a calculated activitv of 68 nmol.mg-* protein. 
hour”\  Therefore, with a protein concentration of 50mg.ml~^, 50 jjI 
(2.5 mg) should, in theory, be sufficient to o-methylate 2.5 x 68 
nmol of dihydroxybenzoic acid.
2.6.2.3 RADIOLABELLED SAM
The method described makes use of 3H labelled SAM as the methyl 
group donor. Unfortunately, 3H SAM is extremely unstable unless 
stored at -140°C or below (over or in liquid nitrogen). ^4C 
labelled SAM is very much more stable and has been used as the 
methyl donor (de Champlain et al., 1976), but in the author's 
hands, it had a specific activity too low to allow the measurement 
of very low catecholamine concentrations. As a consequence, the 
use of SAM was unavoidable with resultant use of liquid nitrogen 
and its concomitant difficulties. Even at -140°C, decomposition 
is estimated to be in the region of 1% per month, but a stock was 
never maintained for more than two to three months and so it was 
not considered necessary to assess radiochemical purity during 
storage. (The sudden and inexplicable rapid decomposition notorious
O
with H compounds after prolonged storage, had never been observed 
in less than six months for SAM - Radiochemical Centre^ personal
communication, 1976).
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2.6.2.4 ASSAY PROCEDURE
PEP sanples were prepared as described. Samples were not 
deproteinised so that protein bound catecholamines were included. 
(Although binding, particularly of noradrenaline, takes place very 
quickly, mainly to albumin (Powis, 1975), and can account for up to 
70% of the plasma level, it is uncertain to what extent released 
catecholamines are bound during blood collection). One ml of 
plasma was incubated in the presence of 85 mM TRIS buffer (pH 8.6),
20 /jM magnesium chloride, 3.9 irM EGTA, 0.5 mM dithiothreitol, 2 pCi 
S-adenosyl ("*H methyl) methionine (specific activity 5 to 15 Ci/mmol) 
and 50 jil OOMT (about 2.5 mg, protein), in a final volume of 1144 pi 
for 45 minutes at 37°C. 0.5 ng each of dopamine, adrenaline and
noradrenaline (Sigma) added to an appropriate plasma sample served 
as internal standards. Blank values were obtained using plasma 
previously mixed with activated aluminium oxide (100 mg/ml PFP) 
at pH 8.4 for 10 minutes. This effectively removes catecholamines. 
Addition of 250 pi, 2M borate buffer (pH 11) terminated the incub­
ation period, followed by the addition of 10 pg each of normetane- 
phrine, metanephrine and 3 methoxy-tyramine (Sigma) as markers.
The methylated catecholamines were extracted into 7ml toluene: 
isoamyl alcohol, (3:2 v/v); the solvent was washed with 0.5 ml of 
0.5 M borate buffer (pH 10), and back extracted into 250 pi of 
0.1 N HC1. The HC1 was dried off under a stream of nitrogen gas 
and the residue dissolved in acidified ethanol (40 pi). Each sample 
was spotted onto separate thin layer chromatography (TLC) plates 
(20 cm x 20 cm coated with 25 mm gypsum free, silica gel) and run in 
a two way TLC system to separate the catecholamines as detailed by
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Ben-Jonathon and Porter (1976). After air drying, the spots were 
exposed with iodine vapour, scraped into scintillation vials, and 
eluted with 2 ml ethoxyethanol for 2 hours. Ten ml of toluene/PPO/ 
POPOP were then added as the scintillation cocktail and the radio­
activity counted on a liquid scintillation counterfPackard Tricarb). 
As with any technique for the measurement of radioactivity in 
biological samples, the efficiency of counting must be known. This 
is because efficiency may vary urpredictably from one sample to the 
next, due to chemical or colour quenching. Counting efficiency was 
calculated using automatic external standardisation (AES) which 
utilises an external gamma radiation source whose electrons are 
affected by quenching in the same way as the beta spectrum from 
the isotope being used. Efficiency was found to vary little frcm 
about 35%.
2.6.2.5 CALCULATION OF PLASMA CATECHOLAMINES
The assay has been reported to be linear for all three catechol-
_i
amines up to at least 5 ng. ml (Ben-Jonathon and Porter, 1976), 10
—1 —1 ng.ml (de Champlain et al., 1976) and even 30 ng.ml, (Coyle
and Henry, 1973). This has been confirmed by the author up to
5 ng.ml- .^ As a result, the concentration of the unknowns was
calculated fron the standard. The plasma sample which contained the
standard was also assayed without the standard, so that calculation
of the counts per minute (cpm) due to the standard itself, was
obtained by subtracting the cpm of the sample without the standard
from the sample with the standard. The plasma blank cpm was
subtracted frcm all samples. The assay was found to be particularly
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sensitive to dopamine, but showed similar mean counts for the 
same concentration of adrenaline and noradrenaline. 500 pg/ml 
of adrenaline and noradrenaline resulted in counts of 235 + (SE3M)
36 cpm and 238 + (SEM) 41 cpm respectively. Blanks were found 
to be 18 + (SEM) 2 cpm for noradrenaline and 16 + (SEM) 2 cpm for 
adrenaline. All cpm were above the ambient background.
Calculation of the unknown samples corrected for blanks were 
compared with the standard. All results were then corrected 
for assay dilution and dilution due to the anticoagulant, 
i.e.
catecholamine
cpm of unknown 1000pl 513.5ml
concentration = --- *—    — - —  x 500pg x -----—  x --- ---
, cpm of standard 1144^ 31 450ml
(in pg.ml PFP)
The limit of sensitivity was taken as a sample to blank
i
ratio of 2, giving an assay sensitivity of 25 to 35 pg.ml"^ for 
adrenaline, and 30 to 50 pg.ml for noradrenaline. The assay 
was very specific for adrenaline and noradrenaline, and the small 
interference by DQPA reported by Ben-Jonathon and Porter (1976), 
affected only the dopamine assays. Intra assay variation between 
duplicates was less than 15%.
2.6.3 RESULTS OF CATECHOLAMINE ASSAYS DURING BLOOD COLLECTION 
(Table 2)
Dopamine is only a very weak potentiating agent for aggregation 
and probably does not aggregate platelets at all. As dopamine was 
found to have a plasma level only marginally higher than adrenaline,
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TABLE 2
CATECHOLAMINE CONCENTRATIONS DURING BLOOD COLLECTION
Plasma Catecholamine 
Concentrations (pg/ml.)
Duration Nervous (N) Ad NAd
Donor Age of Donation 
(min)
or Relaxed (R) Beginning End Beginning End
P.C. 33 14 N 0 55 23 108
C.H. 23 14 N 197 72 285 190
N.C. 34 9 R 44 57 224 236
S.J. 22 9 N 40 52 94 181
A.S. 28 7 N 49 53 86 102
D.B. 29 4 N 85 29 368 302
M.S. 21 6 N 17 26 87 44
A.B. 23 8 R 8 8 58 102
R.B. 32 7 R 14 97 114 323
J.D. 42 8 R 0 0 204 256
D.B. 24 17 R 77 175 174 335
J.H. 25 6 N 112 77 265 242
M.H. 23 15 N 0 23 52 247
F.G. 55 7 N 39 21 253 349
R.B. 23 5 N 14 29 210 233
K.G. 39 6 R 6 0 154 189
Mean 30 9 44 48 166 215
Range 21 - 55 4 - 1 7 0-197 0-175 23-368 44-349
S.E.M. +12.8 +10.6 +23.8 +22.1
having a combined mean of 53 pg.ml , the results have been excluded.
The plasma concentration of adrenaline and noradrenaline varied
considerably between donors. The mean and standard errors at the
beginning and end of blood collection were 44 + 12.8 pg.ml”  ^and
48 + 10.6 pg.ml"^ for adrenaline, and 166 + 23.8 pg.ml“  ^and 215
+ 22.1 pg.ml“1 for noradrenaline. These figures were well within the
"normal" ranges reported by seme workers (Aronow et al., 1973;
Hortnagl et al., 1977) but lower than others (Anton and Sayre, 1962;
Carruthers et al., 1970; Fluck and Salter, 1973; Rawlinson et al.,
1978). A paired Students 't' test revealed a significant difference
(p 4  0.05) for noradrenaline only. In nine donors, the plasma
noradrenaline concentration was relatively higher at the end of
blood collection, and in three donors, it was relatively lower.
There were no changes in the other four cases (the criteria for "no
change" being within the minimum sensitivity limits). The adrenaline
concentration rose in only four donations and remained the same in
nine. Donor ages ranged between 21 and 55 years, and bleeding times
between 4 and 17 minutes. There seemed to be no relationship
between age or bleeding time, and catecholamine concentrations at
the beginning or end of blood collection.
In six experiments, platelet counts were conducted. These always
9showed a small rise during blood collection, from a mean of 205 x 10 
—1 9 —1L to 219 x 10 L (Table 4i). However, the rise was variable and 
a paired Students 't' test showed it to be significant at the 6% level 
only.
In the six laboratory experiments, the main volume of blood was 
collected in two halves. The object was to examine the change in cat­
echolamine concentration at different stages of blood donation. This
_1
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might demonstrate whether a smaller blood volume was associated with 
a lower catecholamine concentration increase and reduced platelet 
aggregation. Blood samples were taken from the packs immediately 
after collection. Generally, the pattern was similar for noradrenaline 
and adrenaline, the concentrations inceasing in two cases, falling in 
two, and remaining unchanged in the remaining two (Figure 6). Plate­
let aggregation occurred to the same extent in both packs, reaching 
a measurable maximum screen filtration pressure of 600 mmHg, within 
24 hours.
2.6.4 DISCUSSION
Although errors involved in catecholamine assays, and variation 
between individuals make it difficult to give precise values (Cal- 
lingham, 1975), the results obtained demonstrated only small changes 
in peripheral plasma catecholamine concentrations during blood 
collection. The increased platelet count, possibly due to splanchnic 
contraction (Magilligan and Schwartz, 1975), and the reduced systolic 
blood pressure suggest that the blood collection procedure stimulates 
adrenal medullary and neural synapse release of catecholamines.
However, peripheral circulating, venous plasma catecholamine concent­
rations represent only that which remains after the interaction of 
many processes that tend to lower the concentrations. It has been 
estimated that catecholamine concentrations are reduced by 90% 
after only one passage of blood through the vascular beds of a hind 
limb (Critchley and West, 1977). A mild stimulus might be expected 
therefore, to produce little or no change in the peripheral venous 
blood concentration of adrenaline, and ante-cubital blood may 
contain only the noradrenaline washed out of tissues drained by this
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ml-1 Figure 6 HISTOGRAM SHOWING PLASMA CATECHOLAMINE CONCENTRATIONS AT VARIOUS 
STAGES OF THE BLOOD COLLECTION
Sequence: 1st 15ml )
Next 225ml )
2nd 225ml )
Last 15ml )
Total of 480 ml (excluding anticoagulant)
1
Noradrenaline
Adrenaline
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vein (Critchley and West, 1977). An increase in plasma noradrenaline 
concentrations during blood collection was frequently measured. How­
ever, changes in plasma catecholamine concentrations were probably 
affected by very variable individual responses to stress. The decrease 
in plasma noradrenaline concentrations measured in a few donors 
may have been produced as a result of a higher degree of emotional 
stress at the start of blood collection. This could have been due 
to fear or aggression, which is normally the predominant stimulus 
for noradrenaline release (Carruthers, 1975). These same donors 
produced a similar decrease, or no change, in plasma adrenaline con­
centrations. Of the sixteen volunteers, only six thought they had 
been subjected to no apparent stress. Five of the six showed an 
increased noradrenaline concentration from the beginning to the end 
of blood donation, and one, no change. In the four cases, in when the 
plasma adrenaline concentration increased by the end of the collection, 
the noradrenaline concentration had also increased. It may be that 
these donors had a sufficiently high response to haemorrhage to 
be measurable in peripheral plasma.
It is possible that plasm catecholamines were liberated as a 
response to blood collection, but only in some donors. However, 
the plasm concentrations in ante-cubital blood never became hiqh 
enough to potentiate ADP induced platelet aggregation according to 
in-vitro measurements (Born, 1967). This is particularly so, as 
protein bound catecholamines were included in the measurements, and 
these m y  not be physiologically active (Callingham and Barrand, 1976). 
There was no apparent relationship between the changes in catecholamine 
concentrations and the rate of platelet aggregation which occurred in
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all the blood packs stored in the cold (see SEP results, chapter 
three).
It is possible that the measurement of peripheral blood plasma 
catecholamine concentrations are inadequate to test the hypothesis 
that catecholamines released during blood collection induce, or 
potentiate platelet aqgregation. This is because the platelets may 
have been exposed to higher, local concentrations of adrenaline in the 
arterial blood (Callingham, 1975). Measurement of plasma free fatty 
acids might be a better index, as they would not be removed quickly, 
and increased catecholamines would cause a concomitant rise in plasma 
free fatly acids (Gordon et al., 1973).
However, as aggregation occurred to the same extent in the two 
halves of the collected blood, the indications are that the collec­
tion of 450 ml of blood (with the possible associated increase in 
catecholamine concentration) is not likely to induce platelet aggre­
gation.
2.7 PLASMA CATECHOLAMINE CONCENTRATIONS IN STORED BLOOD
Blood platelets take up and carry all three catecholamines, 
releasing them in response to appropriate stimuli (Weil-Malherbe 
and Bone, 1954) to a level that may potentiate platelet aggregation 
(Thomas, 1967). Any catecholamines released from the adrenal medulla 
and nerve endings as a consequence of blood collection, may, as has 
been discussed, be taken up into platelets, and would add to any 
concentration that may already be there. During the platelet release 
reaction or degradation, this store of catecholamines would be released, 
and may potentiate secondary aggregation (see chapter one). Because
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of this possibility, catecholamines were estimated at intervals 
during blood storage, to monitor platelet release and/or deqradation. 
and to see if the concentration reached the level that has been 
shown, in-vitro, to potentiate aggregation.
2.7.1 BLOOD STORAGE
Blood packs were stored in a refrigerator. Samples of blood for 
catecholamine assay were taken after gentle agitation by hand to 
ensure even mixing. Samples were taken by simple drainage through 
a short length of the blood pack tubing left on the packs after col­
lection. These tubes were normally clamped during storage, and 
residual blood in the tube was drained away before collecting the 
samples.
Storage temperature was maintained at 4°C, the temperature used 
by blood banks for long-term blood storage. During the early 
experiments, the rate of increase in SEP was found to be higher 
than it had been previously reported (Wright and Sanderson, 1974). 
After several experiments, it was discovered that a fault in the 
refrigerator thermostat was maintaining a temperature nearer 1°C 
than 4°C. Although cold itself is thought to be a stimulus for 
platelet aggregation (see chapter three), a temperature difference of 
only 3°C has not previously been noted as an important difference 
in the onset and rate of aggregation in blood. (Though a marked dif­
ference has been noticed between 0° to 1°C and 6°C in the extent 
of cold induced aggregation in PRP (Kattlove and Alexander, 1971)).
It should be noted that at least one blood pack manufacturer recommends 
that blood should be stored at any temperature between 1°C and 6°C.
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Sane preliminary comparative studies on SFP at 1°C, 4°C and ambient 
roan temperature were subsequently undertaken. Since the rate of 
platelet aggregation differed markedly at the three storage tenper- 
atures, it was thought that it would be informative to study this 
further. Also, to include measurements of plasma catecholamine 
concentrations and other factors during blood storage to see what 
contribution, if any, they made to the overall extent of platelet 
aggregation.
The early studies were, therefore, inadvertently undertaken at 
1°C. Comparative studies at 4°C and room tenperature were carried out 
in later experiments. In experiments in which platelet aggregation 
and catecholamine release were compared at all three temperatures, 
blood was collected into one pack. This vas then subdivided into the 
adjoining pack, and via the sanpling site into a third pack. Weighing 
the packs allowed equal division of the total blood volume.
2.7.2 MEASUREMENT OF PLASMA CATECHOLAMINE CONCEMRATIONS DURING 
BLOOD STORAGE
Catecholamine measurements were performed at 2 and 4 day 
intervals primarily because of the logistic problems of shorter 
intervals. Sanpling was undertaken at 0, 2. 4 and 8 days. No 
chancres were measured after 8 days of blood storage because in 
early experiments at 1°C, the SFP had reached its measurable maximum 
of 600 mmHg after only 24 hours, so that subsequently measured 
plasma catecholamine concentrations could not be related to the SFP.
In addition, the significance of such a relationship probably becomes 
less important as platelet viability decreases (see chapter three).
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Subsequent measurement of catecholamines at 1 °C, 4°C and roam 
temperature were, therefore, also limited to 8 days.
2.7.3 RESULTS OF CATECHOLAMINE CONCENTRATIONS DURING BLOOD STORAGE
In three experiments at the three storage temperatures, the 
plasma catecholamine concentrations were measured as previously 
described. On all occasions, noradrenaline was the catecholamine 
present at the highest concentration by a factor of at least 2.5 
at the time of blood collection, and by a factor of 4.5 after 4 days 
of storage. Only noradrenaline concentrations changed significantly 
during this storage period (Table 3i). The changes in adrenaline and 
dopamine concentration were often within the sensitivity limits of 
the assay method and so were not reliable. The concentrations of 
adrenaline and noradrenaline never reached the minimum (1800 pg.ml”'*
_i
for adrenaline, and 2 to 10 times 1800 pg.ml for noradrenaline) that 
have been shown to be required to potentiate ADP induced platelet 
aggregation in-vitro (Born, 1967; Mills and Roberts, 1967).
However, it is not known to what extent, platelet aggregation may 
be potentiated by synergism between two or more aggregation inducers, 
or how cold affects catecholamine release. Nevertheless, noradrenaline 
was the predominant catecholamine measured in plasma, and was the 
only one whose concentration changed significantly during blood stor­
age. Significant changes in total plasma catecholamines (the sum of 
the measured dopamine + adrenaline + noradrenaline concentrations) 
mainly represented changes in plasma noradrenaline. Measurement of 
total catecholamines in plasma is considerably more economical than 
measurement of individual catecholamines, and the separation procedure
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TABLE 3
PLASMA CATECHOLAMINE CONCENTRATIONS DURING THE STORAGE OF WHOLE BLOOD
i) INDIVIDUAL CATECHOLAMINE MEAN CONCENTRATION (+ SEM) IN pg/ml PFP
Sampling time = 0 2 4 8 days
Catecholamine Temp n
1°C 3 48 + 6 58 + 11 7 1 + 7 66 + 9
Adrenaline 4°C 4 49 + 20 35 + 13 52 + 19 47 + 12
RT 3 31 + 13 38 + 17 17 + 5 22 + 7
1°C 3 117 + 9 190 + 44 333 + 35 295 i 10
Noradrenaline 4°C 4 284 + 100 240 + 83 489 + 89 353 + 108
RT 3 255 + 136 248 + 69 275 + 101 187 + 36
1°C 3 41 + 2 38 + 6 42 + 5 43 + 4
Dopamine 4°C 4 42 + 14 32 i 7 38 + 4 43 + 10
RT 3 47 + 18 41 + 21 27 + 2 28 + 7
TABLE 3 (cont)
ii) TOTAL CATECHOLAMINE CONCENTRATIONS IN pg/ml PFP
0 2 4 8
1°C 212 324 478 371
199 246 412 436
165 723 904 996
172 428 487 651
135 242 731 984
186 435 988 971
mean + SEM 177 + 12 400 + 73 666 + 99 735 + 118
4°C 480 239 669 239
656 527 796 763
118 109 350 262
229 350 499 507
165 474 672 1061
172 234 315 492
135 133 265 496
186 455 210 185
mean + SEM 268 ±  69 315 + 57«Ml 472 + 77 501 +104
Room 656 398 522 292
Temperature
119 155 179 171
226 426 253 248
165 251 487 827
172 219 301 558
135 213 568 932
186 158 163 484
mean + SEM 237 + 71 260 + 41 353 + 64 502 + 110
Storage time inFigure 7. PLASMA CATECHOLAMINE CONCENTRATIONS (+ SEM) DURING BLOCD STORAGE days
is sinplified. In subsequent experiments, therefore, only total 
catecholamines were measured. Instead of utilising a two-way TLC 
system to separate the three methylated catecholamines, a one-way 
system was adopted usinq the first solvent system described by 
Ben-Jonathon and Porter (1976). This allowed differentiation of the 
three spots in one plane, though there was considerable overlap, 
particularly between metanephrine and normetanephrine. All three 
spots were scraped into one vial and counted as previously des­
cribed. With this system, up to six sarrples were run on the same 
TLC plate.
During the storage period there was an increase in the total plasma 
catecholamine concentration at all three temperatures (Table 3ii,
Figure 7), but a paired Students 't' test showed that the difference 
between consecutive readings were significant (p£0.05) only between 
days 0 and 2 at 1°C, between days 2 and 4 at 1°C, and between days 
2 and 4 at 4°C. A Students 't' test to compare differences in cat­
echolamine concentration between consecutive measurements at 
different tenperatures showed a significant difference between 1°C 
and rocm temperature at days 0 to 2 only. As figure 7 shows, there 
was an increase in the plasma concentration of catecholamines during 
the storage period, and this was most marked at 1°C and least at roan 
temperature, particularly during the first 4 days of storage. The 
increase became less marked after 4 days at 1°C and 4°C. This 
suggests that there may have been a slow breakdown of catecholamines 
in plasma, and that plasma levels of catecholamines were being increa­
sed at the highest rate during the first 4 days of storage, probably 
as a consequence of platelet release and degradation. The continued 
upward trend in plasma catecholamine concentrations during blood
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storage at roan temperature nay have been due to more prolonged 
preservation of platelet integrity.
As detailed earlier, catecholamines have been found to be 
quite stable in blood plasma, degrading only slowly, and the main 
source of their removal in fresh blood, in-vitro, is uptake into 
platelets, and to seme extent, erythrocytes. Reuptake into remaining 
viable platelets is unlikely to be significant after several days 
storage and so the degradation of released catecholamines during 
blood storage probably occurs mainly in the plasma. The mechanism 
may be oxidation to adrenochrcme and noradrenochrcme catalysed by 
ceruloplasmin (Sharman, 1975)
2.7.4 DISCUSSION
The potential total catecholamine concentration in platelets
has been estimated to be about 10% that of 5HT (Pletscher, 1968).
This theoretical level is well above that required for the induction
of platelet aggregation in-vitro (about 4 to 26 ng.ml-1, assuming
9 -1an average platelet count of 200 x 10 L ; of blood). However, the 
measured total plasma catecholamine concentrations were well below 
those that might be expected to potentiate platelet aggregation.
The slowness of plasma catecholamine degradation and the rapidity of 
platelet aggregation in the cold, might have been expected to result 
in a higher level of plasma catecholamines during storage. It is 
possible that this discrepancy was due to catecholamines remaining 
bound to the platelet membranes and since these membranes were 
removed during PFP preparation, the bound catecholamines were not 
assayed.
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However, it seems unlikely that this possibility would account 
for the very large difference between the plasma catecholamine 
concentration measured during blood storage, and the concentration 
thought to be required to potentiate platelet aggregation. Therefore, 
it seems unlikely that catecholamines released during blood storage, 
significantly influence platelet aggregation. However, it is not 
known to what extent released catecholamines may act synergistically 
with other released factors in extending platelet aggregation.
2.8 PLATELET COUNTS DURING BLOOD STORAGE
Platelet counts were conducted at two day intervals during 
blood storage. However, after four days at 1°C and 4°C, the counts 
became unreliable, probably due to platelet aggregate formation, 
and were not continued.
The method for counting platelets was as described by Fiessly 
and Ludin (1949), in which erythrocytes were haemolysed using 3% 
cocaine in 0.25% sodium chloride and the platelets counted in a 
haemocytcmeter using dark phase microscopy.
On blood collection, the mean platelet count (+ SEM) was 
191 + 11.2 x 109L_1 (n = 13). The platelet count fell during blood 
storage, but was most apparent at 1°C and least apparent at room 
temperature. Only the fall in count between days 0 and 2 at 1°C and 
4°C were statistically significant (Students paired 't' test P40.05), 
the count falling frcm a mean of 210 x 109L-  ^ to 149 x 109L*^ at 1°C, 
and frcm 175 x 109L_1 to 153 x 109l“1 at 4°C. After 2 days the 
platelet count fell less dramatically. At room temperature, there 
was a gradual, but insignificant decline in the platelet count over 
4 days of blood storage (Table 4ii).
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TABLE 4 PLATELET COUNTS (x 109.L”1)
PLATELET COUNTS DURING BLOOD COLLECTION
First 250 ml Second 250 ml
174 181
175 184
245 264
228 230
208 214
197 239
mean + SEM 205 + 11.6 219 + 13.2
TABLE 4 (cont)
ii) PLATELET COUNTS DURING BLOOD STORAGE
Storage time in days
0 2 4
177 138 106
179 147 162
254 181 191
229 129 109
211 155 144
218 142
mean + SEN 210 + 11.8 149 + 7.4 142 + 16.1
142 121 120
245 212 216
218 193 164
164 149 145
191 164 153
138 121 120
129 108 98
mean + SEM 175 + 16.7 153 + 14.8 145 + 14.6
Room Temperature 142 138 116
245 246 230
218 202 201
164 164 149
191 178 163
138 130 104
129 105 98
175 + 16.7 166 + 18.0 152 + 18.9mean + SEM
2.9 THE RISE IN PLASMA CATECHOLAMINES AND THE FALL IN THE PLATELET
COUNT DURING BLOOD STORAGE
The decline in the platelet count during blood storage was 
probably due to platelet aggregation and platelet destruction. At 
1°C, the rapid fall in the platelet count can be compared with the 
measured rapid rise in SEP during the first 2 days of blood storage 
(see chapter three). The rapid increase in plasma catecholamine 
concentrations at 1°C may also be compared with the fall in platelet 
counts over the first 2 days storage. At this temperature, aggregation 
occurred rapidly with a seemingly concomitant decline in the platelet 
count, and concomitant increase in plasma catecholamines released 
from platelets. Smaller, but similarly comparable changes, were 
observed at 4°C. At roam temperature there was no measured increase 
in SEP, and it may be that the slow decline in the platelel count, 
combined with the gradual increase in plasma catecholamines, was 
mainly due to degrading platelets. The continued rise in catecholamine 
concentrations after 2 days storage, particularly at 1 °C, was not 
comparable with the less pronounced fall in platelet counts. It is 
possible that the rise in plasma catecholamine concentrations in the 
first 2 days was mainly due to platelet aggregation, when the 
platelet count would decline rapidly, but that subsequent release 
was from degrading platelets, seme of which may have been counted as 
normal platelets.
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CHAPTER 'THREE
THE EFFECTS OF BLOOD STORAGE TEMPERATURE AND pH UPON 
PLATELET AGGREGATION
3.1 COLD INDUCED PLATELET AGGREGATION
Cold induced platelet aggregation in PRP and platelet concen­
trates has been reported by Murphy and Gardner (1969), Shively et al., 
(1970), Kattlove and Alexander (1971), Hardeman and Heynens (1974a), 
and Baldini et al., (1976). It also occurs in whole blood (Benner 
and Brunner, 1973) where a greater volume of microaggregates were 
found in blood stored at 4°C than in blood stored at room temperature 
(Solis et al., 1974b). However, there is much debate as to whether 
short term storage, particularly of platelet concentrates should be 
at 4°C or room temperature. Long term storage of whole blood is still 
carried out at 4°C, probably because of the unknown affects of 
long term storage at room temperature, and to reduce any bacterial 
proliferation. Whole blood and platelet concentrates are transfused 
for different purposes. The majority of whole blood transfusions are 
used to replace erythrocytes lost during haemorrhage (Becker and Asker,
1972), whereas platelet concentrates are often used to control severe 
bleeding. The haemostatic mechanism depends upon platelet viability 
(Baldini et al., 1960), so that the maintenance of platelet viability 
during the storage of platelet concentrates is of paramount inportanee.
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Viability is often defined as the platelets' ability to survive in
the blood circulation after transfusion, and generally, viability
is well maintained if normal discoid morphology is retained (Murphy
and Gardner, 1975). Unfortunately, rapid platelet shape changes
occur when platelet concentrates are stored either in the cold, or
at 37°C (Hardeman and Heynens, 1974a). It seems that platelet
viability is better maintained at 22°C, and measurement of platelet 
51survival by Cr labelling has shown that any temperature less 
than 20°C or above 24°C results in reduced survival (Murphy and 
Gardner, 1976). Following platelet storage for 72 to 96 hours, at 
22°C, platelet survival was measured as 9 to 10 days after trans­
fusion, whereas following storage at 4°C, the duration of platelet 
survival in the blood circulation was much shorter (Baldini et al., 
1960; Murphy and Gardner, 1969; Lim et al., 1973). Baldini et al., 
(1960) suggested that the observed reduction in the number of circul­
ating platelets after infusion of cold stored platelets, was due to 
surface damage making the platelets more susceptible to sequestration 
and phagocytosis by monocytes. Later evidence showed that this 
surface damage was due to a symmetrical loss of lipids, followed by 
the incorporation of unsaturated fatty acids which are primary targets 
for lipid peroxidation (Baldini etal., 1976).
The effects of cold are rapid. Changes in the intracellular 
levels of cAMP and cGMP have been detected after only 15 minutes 
storage at 4°C. cAMP showed a pronounced, but transient increase 
preceded by a rapid decrease in cGMP (Baldini et al., 1976). The 
association of platelet microtubule protein into tubular structures 
may be indicated by cyclic nucleotide dependent phosphorylation.
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Baldini et al., (1976) found that microtubule protein is a hetero- 
dimer and that GTP is covalently bound to one of the subunits. He 
also found that chilling of platelets enhanced the incorporation of 
32P phosphate into microtubule protein. Because dissocation of micro­
tubules occurs in the cold (Murphy and Gardner, 1969), it is possible 
that phosphorylation may be responsible for depolymerisation and 
resultant dissassociation of microtubule protein.
However, there is controversy as to the haemostatic effective­
ness of platelets stored at room temperature. Thouqh coolinq destroys 
platelet function (Lim et al., 1973), immediate haemostatic function 
is alleged to be better preserved for 24 hours in platelets stored at 
4°C than those stored at roam temperature. However it was found that 
platelets stored at room temperature would shorten the bleeding time 
(a test of haemostatic effectiveness), 24 hours after transfusion 
(Aster et al., 1976). This delayed function is possibly due to a 
lesion developing in platelets stored at room temperature, 
prohibiting them from acting haemostatically for the first few 
hours after transfusion. This could be a consequence of a reduction 
in membrane sulphydryl groups involved in platelet adhesion, since 
this is particularly evident at room temperature. (Baldini et al., 
1976). Therefore, it seems that immediate platelet function and 
lonq-term effectiveness are separate considerations, to the extent 
that, at least, American regulations allow platelet concentrate 
preparations at both 4°C and room temperature. 4°C storage for 
acute haemorrhage, because of its presumed rapid action, and 
room temperature for prophylaxis, because of the longer platelet 
survival at this temperature. However, a recent study presented new 
evidence. Studies on haemostatic effectiveness and survival have
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usually been measured in thrombocytopenic patients who often have 
additional problems such as fever, sepsis, drug therapy, and dissemin­
ated intravascular coagulation, each of which may influence platelet 
behaviour. In Filip and Aster's (1978) study, patient selection was 
aimed at the minimisation of variables. It was found that platelets 
stored for 24 hours at 4°C or room temperature were equally effective 
in elevating circulating blood platelet levels, and in shortening 
bleeding times. Because at 72 hours only those platelets stored at 
room temperature were haemostatically effective, Filip and Aster 
(1978) suggest that there is no justification for routine platelet 
storage at 4°C.
Aggregation of platelets in the cold is thought to require no 
other stimulus (Hardeman and Heynens, 1974a), though the pattern of 
cold induced platelet aggregation, as seen in an aggregcmeter, 
resembles that of ADP induced platelet aggregation (Figure 2, 
chapter one). Also the exposure of platelets in PRP to a temperature 
of 4°C resulted in conformational changed in specific membrane 
proteins, similar to those changes postulated to occur during ADP 
induced platelet aggregation (Kattlove and Alexander, 1971). However, 
it does not appear that ADP is directly involved in cold induced 
platelet aggregation, because ADP was not released frcm chilled 
platelets and because the ADP inhibiting agent, apyrase, did not 
prevent cold induced platelet aggregation. On the other hand, the 
facts that calcium ions and fibrinogen are required, and that met­
abolic inhibitors prevent cold induced platelet aggregation, suggests 
that a specific energy requiring pathway exists. It is possible that, 
following the initial stimulus, whether cold or ADP, the biochemical 
pathways are identical (Kattlove and Alexander, 1971).
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3.1.1 COLD AGGLUTININS
Cold agglutinins are naturally occurring, usually harmless, 
cold autoantibodies, which are most active at low temperatures (up 
to 15°C). They are usually igM globulins, having specificity within 
the Ii antigen system found on erythrocytes and platelets (Lalezari 
and Murphy, 1967 - cited Kattlove and Alexander 1971). These cold 
agglutinins can cause haemagglutination of erythrocytes at low 
tenperatures, and Kattlove and Alexander (1971) considered 
their possible role in cold induced platelet aggregation. However, 
a mediatory role for cold agglutinins and any other plasma proteins 
was excluded when Kattlove and Alexander (1971) demonstrated that 
cold induced platelet aggregation occurred in washed platelets 
resuspended in Tyrodes buffer.
3.2 PLATELET AGGREGATION DURING BLOOD STORAGE
The preliminary results for platelet aggregate formation in 
blood in the cold supported the findings of other workers, though the 
difference in the rate of aggregate formation between 1?C and 4°C was 
a new observation. Because a difference of only 3°C appeared to 
have such a narked affect on the rate of platelet aggregation, it was 
important for comparison purposes to maintain the storage tenperatures 
accurately at 1°C and 4°C. This was achieved by using cooled incub­
ators (Gallenkanp) which maintained a temperature range of + 0.5°C 
of the set temperature. It was not possible to maintain room temp­
erature at 22°C, and so a maximum/minimum thermometer was used to 
monitor daily fluctuations in temperature. It was found that amb­
ient room tenperature fluctuated between 14°C and 21°C, tenperatures 
close to the upper end of the range being more common.
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3.2.1 THE METHOD FOR THE MEASUREMENT OF PLATELET AGGREGATION
The presence of platelet/granulocyte aggregates in blood was 
detected by the SFP technique described by Swank (1962). In this 
technique, the pressure generated proximal to a 20 _pmscreen filter 
is measured as a 2 ml blood sample is passed through a 6.25 nun2 area 
of the screen at a constant flow rate of 0.33 ml.sec” The more 
cellular aggregates that were present in the blood, the higher the 
SFP, to a measurable naximum of 600 mmHg. Fresh human, venous blood 
samples had a SFP of 30 + (S.E.M.) 1.9 mrriHg (n = 29).
3.2.2 SFP RESULTS (Tables 5a,b,c Figure 8)
SEP measurements were performed during blood storage on days 
0, 1, 2, 3, 4, 8 and 14. The samples were obtained as described 
for catecholamines, except that samples were collected in polystyrene 
tubes, and SFP measurements were performed within a half hour of col­
lection. Preliminary tests showed that SFP measurements were similar 
whether samples were maintained at the storage temperature, or 
allowed to warm to ambient temperature before the measurements were 
made.
The SFP results demonstrated a rapid rise in platelet aggreg­
ation at 1°C reaching the measurable maximum in 17 out of 19 blood 
packs within 24 hours (Table 5a). At 4°C, the results were variable, 
but showed a general increased rate of aggregation, usually reaching 
600 mmHg between days 4 and 14 (Table 5b). At room temperature, 
minimal aggregation was observed, with no significant difference 
between results during the entire storage period (Table 5c). For 
the purpose of calculating statistical significance, the maximum 
measurable SFP of 600 mmHg was considered as 600 mrriHg, even though
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TABLE 5a
a) 1°C
SEP CHANGES DURING BLOOD STORAGE (mm/Hg)
Sampling Time
mean 
+ SEM 
n
0 1 2
38 600 600
32 600 600
27 600 600
27 600 600
22 600 600
28 600 600
20 600 600
18 600 600
20 600 600
30 600 600
26 600 600
23 600 600
20 600 600
32 580 600
42 600 600
50 485 600
48 600 600
42 600 600
52 600 600
31 593 600
2.3 6.1 0
19 19 19
days
\TABLE 5b 
SEP (cont)
4°C
Sampling Time 0 1 2 3 4 8 14
38 83 380 - 600 600 600
26 33 47 - 48 60 167
37 43 52 - 76 85 108
26 - 40 - 82 152 600
43 - 31 - 61 240 340
20 57 165 - 600 600 600
20 75 340 - 600 600 600
20 36 60 - 65 145 231
20 28 60 - 83 190 600
26 92 185 330 600 600 600
20 54 178 330 ' 540 600 600
18 43 75 105 215 430 600
20 30 42 132 370 600 600
30 34 45 95 130 240 460
26 120 190 240 420 600 600
23 30 25 - 160 600 600
20 36 28 45 55 460 600
32 130 255 325 350 - 600
42 58 50 58 86 233 600
50 53 65 112 170 290 600
48 140 155 180 180 260 -
42 133 600 600 600 600 600
52 67 345 * 600 600 600 600
mean 30 65 148 242 290 399 523
+ SEM 2.3 8.1 30.9 52.1 47.2 44.0 33.6
n 23 21 23 13 23 22 22
days
TABLE 5c
SEP (cont)
c) FT
pling Time 0 1 2 3 4 8 14
37 40 35 - 35 37 53
26 30 32 - 27 25 23
37 40 26 - 33 26 29
26 - 32 - 30 27 29
43 - 26 - 32 23 33
20 32 25 - 25 20 46
20 19 22 - 20 20 18
20 18 19 - 21 22 25
20 19 27 22 20 - 55
18 23 30 28 26 25 27
20 25 25 30 28 27 19
30 32 29 30 26 26 26
23 20 20 25 23 26 24
20 22 20 27 24 29 28
32 38 53 63 55 - 42
42 48 44 40 55 38 35
48 35 - 60 - 57 -
42 - 42 - 40 36 38
mean 29 31 29 36 31 29 32
+ SEM 2.4 3.0 2.3 5.1 2.6 2.3 2.7
n 18 15 17 9 17 16 17
days
SFP imiHg
Figure 8 CHANGES IN SFP DURING BLOOD STORAGE (1 SEM)
the true SEP may have been higher than that. The difference between 
consecutive SFP results at 4°C was significant throughout blood 
storage (Students paired 't* test, p^ 0.05). Because of the rapid 
increase in SEP at 1°C, it was not possible to calculate dif­
ferences between consecutive readings after 24 hour storage. The 
differences between the changes in SFP values at different tenperatures 
were significant between 1°C and 4°C, 4°C and room temperature, and 
1°C and room temperature. The results have been published (Oakes 
et al., 1978).
3.2.3 DISCUSSION
The apparent lack of aggregation at room temperature, as measured 
by SFP was not found in blood by Solis et al., (1974b) though he 
did report that platelet aggregation was much less marked at roan 
temperature than at 4°C. It is possible that by using a Coulter 
counter, Solis et al., (1974b) achieved a higher sensitivity that 
allowed him to detect small platelet aggregates not affecting the SFP 
measurement. However, Benner and Brunner (1973), using a photo­
electric method to measure platelet aggregates (based upon the higher 
transparency of platelet aggregates compared with that of surrounding 
erythrocytes) observed no aggregation in blood at 22°C. Cold induced 
platelet aggregation began at 20°C and was found to reach a maximum 
at 15°C (Benner and Brunner, 1973). In the present study, however, 
no aggregation was detected by the SFP technique with an ambient 
tenperature between 14°C and 21°C. The critical temperature for 
platelet aggregation was not determined, but it appeared to be below 
14°C. The rate and- extent of platelet aggregation at 4°C (Table 5b)
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was found to vary between individual blood packs, and so it is likely 
that the critical temperature for cold induced platelet aggregation 
is also variable.
3.3 BLOOD HYDROGEN ION CONCENTRATION DURING BLOOD STORAGE
Hydrogen ion concentration (pH) is an important factor for 
platelet aggregation. This occurs more readily in CPD than in ACD 
(Solis et al., 1974b; Wright and Sanderson, 1974) and may be due to 
the lower pH in ACD preserved blood (Solis et al., 1974b). Platelet 
aggregation and release are progressively inhibited as the pH is 
reduced (Murphy and Gardner, 1975) and at pH 6.7, platelet aggregation 
in PRP has been found to be totally inhibited (Kattlove and Alexander,
1971). Between pH 6.9 and 7.2, adrenaline induced platelet aggreg­
ation in PRP was very much reduced compared with aggregation at pH
7.4 (Rogers, 1972) and biphasic platelet aggregation, induced by 
ADP, has been shown to be gradually inhibited at pH values below 
7.29 (Lamberth et al., 1974). On the other hand, platelet aggreg­
ation in PRP has been shown to be increased at pH values above 7.4 
(Rogers, 1972; Rodman and Penick, 1972). Therefore, it appears 
that platelet aggregation is progressively inhibited at pH values 
below 7.4, but is enhanced at pH values above 7.4, with the rate of, 
at least, ADP and adrenaline induced platelet aggregation, reaching 
a maximum between pH 7.7 and 8 (Rodman and Penick, 1972; Coller et 
al., 1976).
During blood storage, both the plasma pH (Limbird and Silver,
1974) and whole blood pH (Bailey and Bove, 1975; Mishler et al., 1978) 
decreases. This decline was also observed during the storage of PRP,
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when the decrease in pH at roan tenperature was greater than at 
lower temperatures, due partly to carbon dioxide retention arising 
from glucose and fatty acid oxidation, but mainly frcm lactate 
formation in glycolysis (Hardemen and Heynens, 1974a). (Platelet 
intermediate metabolism is mainly glycolytic, and resting platelets 
accumulate glucose and degrade it, almost exclusively, to lactate.
Even on stimulation with rapidly increased glycogenolysis, lactate 
remains the predominant end product (Akkerman, 1978)).
Whole blood pH was monitored during stoage at 1°C, 4°C and room 
tenperature.
3.3.1 THE MEASUREMENT AND THE.RESULTS OF pH DURING BLOOD STORAGE
pH was measured in blood using a Radiometer pH meter with a 
combined electrode. Sairples for pH measurement were taken as des­
cribed for catecholamines, but into small polystyrene tubes and 
pH measurements were made immediately. The electrode was immersed in 
the blood for precisely 30 seconds before reading the pH. Measurements 
were taken on days 0, 1, 2, 3, 4, 8 and 14.
The results confirm that pH decreases during blood storage, 
particularly at room tenperature. The pH decreased from a mean of 
7.37 to 7.11 at 1°C, frcm 7.37 to 6.99 at 4°C and frcm 7.38 to 
6.65 at roan tenperature during 14 days blood storage (Table 6,
Figure 9). The decline in pH at 4°C vas greater in this study 
than that observed by Bailey and Bove (1975) who measured a decrease 
from pH 7.1 at the beginning of storaqe to only 7 after 14 days blood 
storage. In contrast, Mishler et al., 1978, measured a mean decrease 
frcm pH 7.28 to 6.76 after 14 days blood storage at 4°C, though
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TABLE 6
CHANGES IN BLOOD pH DURING BLOOD STORAGE AT 1 °C, 4°C AND ROOM TEMP.
Sampling Time 0 1 2 3 4 8 14 days
i) 1°C 7.41 7.24 7.12 7.11 7.10 - 7.03
7.40 7.38 7.20 7.20 7.13 7.11 7.09
7.39 7.32 7.25 7.22 7.22 7.21 7.12
7.37 7.33 7.25 7.23 7.21 7.20 7.10
7.32 7.28 7.28 7.25 7.24 7.24 7.17
7.33 7.31 7.28 7.21 7.18 7.16 7.16
mean 7.37 7.31 7.23 7.20 7.18 7.18 7.11
+ SEM 0.02 0.02 0.02 0.02 0.02 0.02 0.02
ii) 4°C 7.40 7.35 7.31 7.26 7.21 7.10 7.00
7.31 7.30 7.24 7.20 7.15 7.14 7.01
7.41 7.34 7.28 7.25 7.21 7.11 6.88
7.35 '7.24 7.22 7.21 7.21 7.12 6.98
7.32 7.32 7.21 7.19 7.17 7.10 7.01
7.41 7.36 7.26 7.25 7.24 - 7.09
7.40 7.31 7.28 7.25 7.19 7.13 7.00
mean 7.37 7.32 7.26 7.23 7.20 7.12 6.99
+ SEM 0.02 0.02 0.01 0.01 0.01 0.01 0.02
iii) Roan Tenp. 7.40 7.32 7.21 7.11 7.03 6.81 6,71
7.31 7.21 7.09 7.00 6.90 6.73 6.69
7.41 7.26 7.11 7.05 6.95 6.79 6.61
7.41 7.30 7.21 7.14 7.09 - 6.70
7.40 7.25 7.21 7.08 7.00 6.71 6.57
7.32 7.18 7.06 6.99 6.90 6.77 6.60
mean 7.38 7.25 7.15 7.06 6.98 6.76 6.65
+ sm 0.02 0.02 0.03 0.02 0.03 0.02 0.02
pH Units
Figure 9 pH OF CPD ANTI COAGULATED BLOOD DURING STORAGE
measurements were made on sanples warmed to 37 °C before the pH was 
read.
On blood collection, the pH was in the range 7.31 to 7.41 with 
a mean of 7.36 + (SEM) 0.02 (n * 11). These figures were within 
the "normal" range of 7.27 to 7.43 (mean 7.35) for adult male venous 
blood (Singer and Hastings, 1950 - cited Documents Geigy Scientific 
Tables, 1962).
The decrease between consecutive daily pH values was significant 
(Students paired 't* test, p$0.05) at all three storage temperatures 
for the first 3 days, and during the entire 14 days storage at 4°C 
and room tenperature After 3 days, however, there was no significant 
decrease in pH at 1°C. The decline in blood pH was significantly 
different between 1°C and 4°C after 4 days of blood storage (Students 
unpaired 't' test, p^0.05), though between 1°C and room temperature, 
and 4°C and room temperature, the decline in pH was significantly 
different during all of the first 8 days of storage.
3.3.2 A DISCUSSION OF THE CHANGES IN BLOOD pH DURING BLOOD STORAGE
The results suggest that the pH changes at 1°C and 4°C are 
indistinguishable during the first few days of blood storage, but that 
subsequently there is more metabolic activity in blood at 4°C. Blood 
stored at room temperature appears to have been very much more metab- 
olically active, with the pH declining rapidly during the first 8 days 
of storage, reaching a mean pH of less than 7 after only 4 days. 
Presumably, the reduced pH also reduced the rate of glycolysis and 
may explain the slower decrease in pH after 4 days of blood storage.
Although it appears that the reduction in pH at 1 °C and 4°C
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would make the platelets less aggregable, it did not prevent platelet 
aggregation in the cold. The SFP results showed that platelet aggre­
gation occurred rapidly in the cold, particularly at 1°C. Of course, 
the cold stimulus was not present at roan tenperature and the 
absence of measurable platelet aggregation at this temperature suggests 
that no other stimulus was present during the early part of storage.
It is probable that aggregating agents released frcm degrading plate­
lets nay be of sufficient concentration to induce aggregation in rem­
aining viable platelets. That this did not occur at room tenperature 
may have been due to the slow rate of platelet breakdown (see platelet 
counts, chapter two) and the rapidly reduced pH, which may have prev­
ented platelet aggregation.
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CHAPTER FOUR
THE PLASMA CONCENTRATION OF 5-HYDROXYTRYPTAMINE 
DURING BLOOD STORAGE
4.1 BIOCHEMISTRY AND PHYSIOLOGY
A secondary pathway (< 2%) for tryptophan metabolism is hydro­
xylation to 5-hydroxytryptcphan in a process analogous to the con­
version of phenylalamine to tyrosine. In fact, in the liver, the 
phenylalamine hydroxylating enzyme will also accomplish hydroxylation 
of tryptophan. Similarly to the catecholamines, 5-HT is formed by a 
pyridoxal phosphate dependent, amino acid decarboxylase reaction, 
in this case from 5-hydroxytryptophan (Figure 10). 5-HT is formed 
in many tissues, but mainly in the enterochrcmaffin cells of the gastro­
intestinal tract and in the brain (5-HT, like the catecholamines, does 
not cross the blood/brain barrier). The main rate limiting step in 
the synthesis of 5-HT is the hydroxylation step to 5-hydroxytrypto- 
phan (Lovenberg et al., 1968).
5-HT is produced in the organs where it is found, rather than 
being produced in one organ and carried by the blood to other organs. 
The presence of large amounts of 5-HT in the gastro-intestinal 
tract led to the suggestion that it acted there as a local hormone 
and is involved in the regulation of the motor activity of gastro­
intestinal smooth muscle (Lewis, 1965). The distribution of 5-HT in 
the brain has led to the view that it has a physiological function
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in the central nervous system. Its distribution in the brain is ass­
ociated with that of the enzymes 5-hydroxytryptophan decarboxylase and 
monoamine oxidase so that it appears that the brain areas which 
contain 5-HT can both synthesize and degrade it. There is a parallel 
between the distribution of 5HT and noradrenaline in the brain, and 
5HT may be present as a humoral transmitter which functions either to 
stimulate parasympathetic centres or to inhibit synpathetic ones 
(at which noradrenaline is the transmitter), (Lewis, 1965).
5-HT is only released into the blood circulation under certain 
pathological conditions, for example, from malignant carcinoid tumours 
(Vane, 1969). 5-HT is also released frcm the lungs and frcm platelets 
during antigen/antibody reactions and anaphylaxis (Waalkes et al.,
1957 - cited Franzen and Eysell, 1969), and frcm platelets by 
bacterial endotoxins (Rosenberg et al., 1959 - cited Garner, 1972). 
Severe haemorrhagic and traumatic shock induced in dogs, have been 
shown to cause an increase of 5-HT in the blood, probably released 
frcm hypoxic enterochrcmaffin cells, and frcm unstable platelets 
(Swank, 1968; Kusajima et al., 1974). Released 5-HT has a marked 
effect on smooth muscle. It is a powerful broncho-constrictor, and 
may be the cause of asthmatic attacks in patients suffering from 
malignant carcinoids (Lewis, 1965). The actions of 5-HT on the heart 
and circulation are complex and there are marked variations in 
effects between species. In man, 5-HT usually causes the systemic 
blood pressure to rise and cardiac output to increase, though the 
effects are variable (Franzen and Eysell, 1969). 5-HT also causes 
vasoconstriction of the pulmonary circulation, particularly the 
pulmonary arterioles, and constriction of the coronary blood vessels. 
5-HT is thought to activate the pressor reflex to the atrium and the
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great blood vessels in the thorax through stimulation of the chemo- 
receptors of the carotid sinus (Kusajima et al., 1974). The per­
ipheral blood vessels of the body are less sensitive to 5-HT than 
the pulmonary arterioles, but experimental findings of the effects of 
5-HT are not consistent. In man, 5-HT introduced intra-arterially 
in the arm, seemed to be effective in causing constriction of the 
arteries and arterioles of the arm and hands, but dilated the 
cutaneous blood vessels (Roddie et al., 1955 - cited Franzen and 
E^sell, 1969). In contrast, Bock et al (1957 - cited Franzen and 
E^sell, 1969) found intra-arterial injections of 5-HT increased the 
blood flow in the forearm, and decreased the blood supply in the 
skin. Intra-venous injections of 5-HT were found to be similarly 
effective but only at much higher doses (above 100 ^ ig).
Released 5-HT has a half life of only one to two minutes. It 
is removed from the plasma in the lungs where it is probably stored, 
and in the liver, where it is mainly oxidatively deaminated to 5-hydro- 
xyindole 3-acetic acid (Vane, 1969) (Figure 10). Newly formed plate­
lets contain no 5-HT, and are probably not capable of synthesizing 
their own 5-HT. However, mature platelets contain high concentrations 
of 5-HT (Pletscher, 1968). Platelets do not remove 5-HT from the 
circulation very rapidly, but the liver and lungs reduce the plasma 
5-HT concentration to less than 1% after only one circulation.
5-HT i s  taken up in to  p la t e le t s  mainly from the lungs and frcm the  
gu t mucosa. P la te le t s  normally contain  from about 0.2 to  1.3 ¿jg 
5-HT.109 p la t e le t s ,  but th e ir  capacity  for 5-HT i s  much higher 
(Baumgartner, 1969).
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Figure 10 THE MAIN PATHWAYS OF 5-HT METABOLISM
Tyyptophan 5-hydroxytryptophan
Hydroxylase Decarboxylase
Tryptophan----------► 5-hydroxytryptophan
<  2% ♦5-HT
Monoamine
Oxidase
> 98%
5-methoxyindole 3-acetic acid 4 - — .. 5-hydroxyindole 3-acetic acid
(Other products of 5-HT catabolism include, bufotenine (abnormal), 
melatonin, 5-methoxytryptamine, and 5-hydroxytryptophol).
4.2 5-HT AND PLATELET AGGREGATION
Although human blood platelets are only weakly stimulated by 
5-HT (Swank et al., 1963), a possible role for 5-HT in platelet 
aggregation and potentiation has been discussed (chapter one). As 
blood collection is only a mildly stressful procedure, it is unlikely 
that plasma 5-HT concentrations will be markedly raised as a 
consequence of blood collection alone. The release of 5-HT during 
blood storage may be more important in the potentiation of platelet 
aggregation. Although erythrocytes may contain up to 10% the plate­
let concentration of 5-HT (Franzen and Eysell, 1969), the integrity 
of erythrocytes is thought to be maintained for at least several 
days of storage, even at 4°C (Mollison, 1972). Any release of 5-HT 
during the early stages of blood storage would, therefore, be from 
platelets.
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There is evidence that a low, though fairly stable, level of 
free 5-HT exists in plasma (Somerville and Hinterberger, 1975), 
although platelets contain the majority of circulating 5-HT. How­
ever, 5-HT concentrations were measured in plasma, rather than in 
platelets, since it has been found that an increase of 5-HT in plasma 
is complementary to a decrease in platelets in PRP (Hardeman and 
Heynens, 1974b).
4.2.1 METHODS OF ASSAYING PLASMA 5-HT CONCENTRATIONS
The assay procedures described in the literature for the est­
imation of 5-HT are varied, with specificity being the most common 
problem. Spectrcphotofluorimetry is the basis for the more common 
techniques, though a more specific method is radioimmunoassay, which 
when compared with a fluorimetric method was found to be equally 
sensitive (O'Brien and Spector, 1975). However, this fluorimetric 
method, which depends on the natural fluorescence of 5-HT in strong 
acid, is thought to be eight times less sensitive than another 
fluorimetric method, that depends upon the formation of a fluorescent 
5-HT derivative with ninhydrin (Snyder et al., 1965). A bioassay 
method is available and is claimed to be sensitive to Ing of 5-HT in 
plasma (Vane, 1957). However, as with all bioassay procedures, it 
can be affected by the biological variability of the test system. 
Measurements that depend upon the interaction of chemical 
reagents are more reliable. The formation of natural fluorescence 
in strong acid with and without ultraviolet irradiation has been 
used, but both methods lacked sensitivity (Udenfriend et al., 1955; 
Anden and Magnusson, 1967). It is claimed that a method based upon
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the formation of a fluorescent 5-HT/orthcphthalaldehyde (OPT), 
derivative, makes possible the measurement of minute quantities of 
5-HT in body fluids (Maickel and Miller, 1966; Thompson et al.,
1969, 1970; Somerville and Hinterberger, 1975). According to Maickel 
and Miller (1966), this method provides the greatest sensitivity, but 
lacks specificity, since many related substituted indoles fluoresce 
with OPT as strongly as 5-HT. These include melatonin, 5-methoxy- 
tryptamine, 5-methoxyindole 3-acetic acid, and N-acetyl 5-HT. This 
lack of specificity may be partly overcome by including a purification 
process using a weak cation exchange resin (Thompson et al., 1970).
In fresh plasma samples, the interference due to substituted indoles 
may not be important because their plasma concentrations are very low 
conpared with the concentration of 5-HT in platelets (Franzen and 
Gross, 1965; Rao et al., 1976). However, during blood storage, 
greater conversion of 5-HT to its metabolites nay occur and so specif­
icity is important. The formation of a fluorescent derivative of 
5-HT with ninhydrin has been described (Vanable, 1963; Snyder et 
al., 1965; Shellenberger and Gordon, 1971) and has been shown to be 
very specific for 5-HT (Snyder et al., 1965). Only bufotenin and 
5 -hydroxytryptophan caused interference, and this was only 3% and 2% 
respectively. All other compounds that might interfere, including 
related indoles, aromatic amino acids, and biogenic amines, gave no 
measurable fluorescence.
The method probably depends upon the formation of a tetrahydro- 
carbaline derivative formed by condensation of the ketone groups 
of ninhydrin with the amino group of 5-HT.
- 103 -
The 5-HT concentration was measured in PEP prepared as described 
for catecholamines. It has been shown that small amounts of 5-HT 
can bind to plasma proteins in-vitro (Clarke et al., 1959). However, 
the small error in not measuring these amounts has to be accepted 
because it is necessary to precipitate the plasma proteins in 
order to reduce interference with fluorescence.
The method used was a modification of that described by Snyder 
et al., (1965), involving the solvent extraction of 5-HT from a 
salt saturated solution at pH 10. Blood for PEP preparation was taken 
frcm the blood packs immediately after collection and at intervals 
during storage as described for catecholamines. Plasma for 5HT 
estimation may be stored, though it is necessary to adjust the pH to
5.6 (Shellenberger and Gordon, 1971). However, all samples were assayed 
immediately after withdrawal iron the blood packs.
PFP sanples (2.5 ml) were deproteinised with the same volume 
of 1N perchloric acid. After thorough mixing, the protein was 
precipitated down by centrifugation at 2,500g for 10 minutes. The 
supernatants (3 ml) were carefully adjusted to pH 10+0.1 with 
sodium hydroxide, and 0.5M borate buffer pH 10 (0.5 ml) added. Each 
sample was then equally divided for duplicate assays, and sufficient 
salt was added to ensure saturation (about 0.5g; too much was found 
to result in gel formation on addition of the solvent). This was 
followed by the addition of n-heptanol (8 ml) as the solvent, n- 
heptanol was used in preference to the butanol/heptane solvent used 
by Snyder et al., (1965) as Shellenberger and Gordon (1971) found 
it gave better selectivity between 5-HT and 5-hydroxytryptophan,
4.2.2 THE METHOD USED FOR ASSAYING PLASMA 5-HT CONCENTRATIONS
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lower solubility in water and therefore lower loss during the 
washing stage, and a lower blank value. The mixture was vigorously 
shaken by hand for two minutes and separated by brief centrifugation. 
To the organic phase, salt saturated 0.1M borate buffer (2ml) was 
added as the wash, followed by further vigorous mixing and centrif­
ugation. 0.05M phosphate buffer pH 7 (5ml) was then added to the 
organic phase, mixed and centrifuged and followed by careful 
removal of the aqueous phase (3ml). Fresh 0.1M ninhydrin (0.3 ml) 
was added to the aqueous phase and incubated at 100°C for 25 minutes. 
This was followed by cooling the tubes to room temperature for one 
hour, during which time the condensation reaction with ninhydrin is 
thought to occur. The fluorescence was read at an activation wavelen­
gth of 385 nm and emission, 490 nm in a spectrophotofluorimeter 
(Perkin-Elmer). Fluorescence has been found to be relatively stable 
for up to 6 hours (Snyder et al., 1965). After heating with ninhydrin 
and reading at the above wavelengths, only 5-HT fluoresces with any 
intensity compared with related indoles.
One of the problems found by several workers estimating 5-HT 
has been to select a suitable blank. This problem was overcome by 
using alkaline sodium sulphite which rapidly decays 5-HT fluorescence 
(Shellenberger and Gordon, 1971). After measuring the fluorescence 
in the samples, 2.5% alkaline sodium sulphite (0.1ml) was added. The 
samples were then left for several minutes and measured again. In 
this way, the samples acted as their own blanks.
5-HT creatinine sulphate standards were prepared fresh in buffer, 
so that 10 pi added to one of the plasma samples gave a final 5-HT 
concentration of 100 ng/ml. A linear relationship between fluores­
cence and concentration has been observed up to 500 ng.ml”^
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(Somerville and Hinterburger, 1975), and this has been confirmed by 
the author. The plasma sample in which the standard was included 
was also assayed without the standard, so that the subtraction of the 
fluorescence due to the plasma from the fluorescence of the plasma 
plus standard gave the fluorescence due to the standard itself. In 
this way, the standard was subjected to the same assay procedure as 
the plasma 5-HT. Therefore, by comparing the fluorescence of the 
unknown plasma sanples with that of the standard, the concentration 
of 5-HT in the plasma samples was calculated. The spectrqphoto- 
fluorimeter was set to measure a fluorescence of 100 (arbitrary 
units) with the standard in place. All of the unknown samples and 
blanks were then read off the scale without further adjustment.
After correcting for blanks and allowing for the plasma dilution with 
CPD, the concentration of 5-HT was calculated:
, fluorescence of the unknown 513.3 ml
5-HT ng.ml” = ---------------------------- x 100ng x --------
fluorescence of the standard 450 ml
The resolving power of the spectrophotofluorimeter was not cal­
culated, as the monochrcmator slit widths were not adjustable by 
the casual user. However, they were considered suitable for precise 
detection and optimum 5-HT sensitivity. Before each assay, the 
instrument was adjusted to a constant value for sensitivity by 
utilizing the Raman band for water (excitation wavelength of 365 nm 
and activation, 418 nm). Standards were set to 100 on the 8 x 10 
scale, which was within the limits of sensitivity of the instrument. 
Because the samples were diluted, it was necessary to irradiate them 
only during the measurement period in order to reduce photo-decomposi­
tion (Rhys-Williams, 1976). The precision of the method was found
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to be good, with the intra-assay variation between duplicates of 
both standards and unknowns ranging between 0% and 10%.
4.2.3 THE RESULTS OF PLASMA 5-HT OONCEMRATIONS DURING BLOOD 
STORAGE (Table 7, Figure 11)
During the first two experiments at 4°C and room temperature, 
measurements were made on days 0, 2, 4, 8 and 14. However, this 
sequence was altered to days 0, 1, 2, 3, 4, 8 and 14 when it was 
found that the 5-HT concentration decreased sharply on day 3.
The concentration of plasma 5-HT in the blood packs at the end 
of blood collection was in the range 104 to 303 ng.ml with a 
mean of 206 + (SEM) 20.8 ng.ml-1 (n = 11). This was higher than 
the normal free plasma 5-HT level reported by Somerville and 
Hinterburger (1975) who found a concentration range between 13 and 
31 ng.ml-1. Though a review by Franzen and Eysell (1969) reported 
that serum 5-HT concentrations were normally in the range between 
20 and 150 ng.ml-1, and an information handbook published by Lilly and 
Co., (1971) gives a normal serum 5-HT concentration in the range bet­
ween 100 and 320 ng.ml-1 (Eli Lilly and Co., personal communication
1979).
It is not known why the concentration was in the order of ten 
times that found by Somerville and the Hinterburger (1975), though 
the different methods may have contributed to the contrast. A 
problem associated with the minhydrin method is the instability 
of the reaction, as it is sensitive to small changes in pH, and also 
minor changes in the concentration of ninhydrin. Maximum efficiency 
is dependent upon the final concentration of ninhydrin being close
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TABLE 7
CHANGES IN PLASMA 5-HT CONCENTRATIONS DURING BLOOD STORAGE AT 1°C, 
4°C AND ROOM TEMPERATURE (ng.ml ^)
0 1 2 3 4 8 14
301 203 202 146 256 241 163
218 131 264 153 367 246 179
197 147 233 174 368 297 218
303 241 271 161 253 172 139
241 127 251 202 206 196 153
180 189 271 148 221 192 149
mean 240 173 249 164 279 224 167
+ SEM 21.3 18.2 11.1 8.6 29.2 18.8 11.6
104 98 191 142 162
148 112 105 87 104
128 112 100 90 119 101 124
170 1 8 5 176 142 223 365 264
279 143 146 113 171 377 302
197 171 210 146 348 289 209
303 300 254 163 210 166 126
- 241 135 265 200 198 167 139
mean 196 174 170 142 195 212 179
+ SEM 25.5 27.3 23.8 15.7 28.4 ' 40.8 25.5
TABLE 7 (cont)
Roan Temperature 0 1 2 3 4 8 14
104 149 203 138 152
148 110 127 89 129
128 104 107 90 130 112 112
170 173 184 149 199 362 280
218 144 268 126 342 269 217
197 173 204 150 316 274 232
303 269 217 165 225 166 129
241 115 230 191 210 183 142
mean 188 163 184 145 219 199 174
23.0 24.2+ SEM 20.4 14.1 27.3 33.2 21.5
5-HT Concentration ng.ml-1
Figure 11 CHANGES IN PLASMA 5-HT CONCENTRATION (+ SEM) DURING 
THE STORAGE OF BLOOD
to 0.01M. A reduction in concentration by only 25% markedly reduces 
fluorescence, and, as only small volumes are added, care must be 
taken to avoid loss. Conversely, increasing the concentration would 
result in quenching of fluorescence in the standards (Shellenberger 
and Gordon, 1971). Considerable care was taken to avoid such errors, 
however, and therefore other possibilities must be considered.
Perhaps the exceptionally high reagent blanks sanetimes shown in the 
OPT method used by Somerville and Hinterburger (1975) may have resulted 
in artificially low 5-HT concentrations.
If the measured levels are taken as absolute, they were con­
siderably less than those thought to be required to aggregate 
human platelets in blood and PRP. The required concentration of 
5-HT has been found to be within the range 1 to 5 ^ g.ml-  ^ (Swank 
et al., 1963; Swank and Fellman, 1967; Takano, 1975).
Although a considerable variation in concentration was 
measured between individual donors, there was much less variation 
in plasma 5-HT concentration changes during blood storage. The 
only significant differences between consecutive readings were found 
when days 2 and 3, and days 3 and 4 were compared at all three 
temperatures. However, at 1°C, a significant difference was found 
between all consecutive readings (Students paired 't' test, 
p >  0.05). These differences were not all of the same sign, as 
there were consecutive decreases and increases in plasma 5-HT con­
centrations during the first 5 days of blood storage at 1°C (Table 
7, Figure 11). There was no statistically significant difference in 
the changes in plasma 5-HT concentrations between 1°C and 4°C, 1°C 
and room temperature, or 4°C and room temperature.
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4.2.4 A DISCUSSION OF TOE PLASMA 5-HT CONCENTRATIONS
The small changes in plasma 5-HT concentrations were not surpris­
ing as the mean concentration of normal 5-HT levels in human platelets
O
has heen estimated to be only 50 ng.10 platelets (Baumgartner, 1970).
This is about one half the average platelet count in one ml of whole 
8 —1blood (2 x 10 platelets, ml ), and therefore,- would only allow 
for a mean total difference of about 100 ng.ml (although individual 
variation could be higher) assuming all the platelets 5-HT was released. 
Because erythrocytes have a capacity for 5-HT storage only about one 
tenth that of platelets (Franzen and Eysell, 1969), and remain viable 
for considerably longer during blood storage, they are unlikely to 
contribute to plasma 5-HT concentrations during the early stages of 
storage.
The 5-HT found in platelets, associated with platelet membranes 
is unlikely to be liberated as 5-HT, but rather as 5-hydroxytrypto- 
phol and 5-hydroxyindole acetic acid. This is due to the presence of 
monoamine oxidase and both alcohol and aldehyde dehydrogenases in 
platelets. However, the 5-HT in platelet storage granules is pro­
tected frcrn these enzymes, though small quanitities may be converted 
on liberation during the release reaction (Pletscher, 1968).
Although there was no statistical difference in the changes in 
plasma 5-HT concentrations between the three storage temperatures, 
the pattern of change appeared to be most pronounced at 1°C during 
the first 4 days of blood storage (Figure 11). 5-HT degradation 
was measured in plasma and found to be less than 10% during the first 
24 hours, at both 1°C and room teirperature, though it was higher at 
room teirperature. After 3 days storage, the degradation of 5-HT in
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plasna was even less. This gradual degradation lends support to the 
results of Pletscher (1968) who found that 60% to 80% of endogenous 
5-HT in plasma remained unchanged. It was, therefore, difficult 
to account for the observed declines in the plasma 5-HT concentrations 
by plasma degradation alone, particularly as the decline during 
the first 24 hours was most apparent at 1°C. It is possible that 
this decline was due to the uptake of 5-HT into platelets, and that 
the ADP produced as a result of the ATP consumed in this uptake, was 
responsible for platelet aggregation, as suggested by Baumgartner 
(1970). However, there is no reported evidence that cold as an 
aggregating stimulus requires 5-HT, and there was no statistically 
significant difference in the changes in plasma 5-HT concentrations 
between any of the three storage temperatures. Indeed, the changes 
in 5-HT concentration at 4°C were less than those at roan temperature, 
at which no measurable platelet aggregation occurred. Also, the rate 
of 5-HT uptake into platelets has been found to decrease when the temp­
erature is decreased (Maynert and Isaac, 1968) possibly due to reduced 
platelet viability (Hardeman and Heynens, 1974b). Therefore, if any 
importance is to be attached to the greater decrease in 5-HT con­
centration during the first 24 hours, at 1°C, it is likely to be 
nainly due to another factor, perhaps increased binding to plasma 
proteins, which would have been removed in the assay.
An increase in the plasma 5-HT concentration after 2 days 
storage may have been due to release from platelets, and this was 
also particularly apparent at 1°C. However, the SFP had reached its 
measurable maximum after only 24 hours at 1°C. Therefore, if 
5-HT release is a marker for platelet release, then cold induced 
during the first 24 hours did not appear to be associated with platelet
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release. After 3 days blood storage, a marked decrease in 
plasma 5-HT concentrations was measured in all samples at all three 
temperatures, but particularly at 1°C. This again suggested the 
binding of released 5-HT to plasma proteins or perhaps to 
erythrocytes. The increased plasma 5-HT concentrations measured at 
4 days blood storage, and again most apparent at 1°C, may have been 
due to general platelet degradation.
A gradual decrease in the plasma 5-HT concentration after 4 days 
or 8 days storage may have been due to slow degradation or binding of 
the released 5-HT. Daily samples were not taken after 4 days blood 
storage, because platelets were not likely to contribute to the 
plasma 5-HT pool after this time, particularly at the lower temp­
eratures.
Although the changes in 5-HT concentrations during blood storage 
were more apparent at 1°C, they also occurred at 4°C and room 
temperature, indeed seemingly least so at 4°C. Because platelet 
aggregation did not occur at roan temperature, there did not 
appear to be a direct relationship between the plasma concentration 
of 5-HT and platelet aggregation measured by the SEP technique.
4. 4. 3.1 ELECTRON MICROGRAPHS OF PLATELET AGGREGATES FORMED IN 
STORED BLOOD AT 1°C
Electron micrographs were taken of aggregates collected on the 
discs during the measurement of SEP. The discs were prepared for 
microscopy as follows. The discs were fixed in 3% glutaraldehyde 
(in 0.16M phosphate buffer, pH 7.1) for about 1 hour and the 
aggregate mass lifted off the disc and fixed for a further 2 to 3 
hours. The aggregate mass was then rinsed in the same phosphate buffer
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and post fixed in 1% osmium tetraoxide (in phosphate buffer) for 45 
minutes. After rinsing in distilled water for 5 minutes, the aggreg­
ate mass was then dehydrated in 30% acetone for 10 minutes. This 
was followed by block staining in 2% uranyl acetate (in 30% acetone) 
for 15 minutes, and then dehydration continued in 60% acetone for 
10 minutes, 90% acetone for 10 minutes, and 100% acetone (three 
times) for 10 minutes. The aggregate mass was then impregnated 
in three changes of Spurr's resin and polymerised at 60% for 24 hours. 
Sections were cut on an ultramicrotone (silver sections) and viewed 
in a Phillips electron microscope (E.M. 200) at 60 KV.
The final form of the platelet aggregates may not have been 
the original form because of deformation of the aggregates in the 
SFP apparatus. Nevertheless, marked morphological differences can 
be seen between platelets stored for 1 day and those stored for 4 
days at 1°C. After 24 hours of blood storage, most of the platelets 
appeared to be morphologically intact but they were deformed (cf. 
a normal unactivated platelet in chapter one). The aggregates seemed 
to be only loosely packed, and the dense granule content of individual 
platelets appeared to be centralised (Figures 12 and 13). After 
4 days blood storage at 1°C, the aggregates were more densely packed 
and the grossly deformed platelets were surrounded by a mass of 
amorphous material. This was probably platelet debris from degraded 
platelets. Although dense bodies were still apparent, they were much 
fewer in number (figures 14 and 15). The electron micrographs 
demonstrate that platelet degradation seemed to have occurred more 
extensively after 4 days blood storage at 1°C than after 24 hours. 
Nevertheless, the granular content of several platelets after 24 hours 
do appear to have been discharged and might have been expected
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FIG. 12 Platelet aggregates from blood stored for 24 hours at 1°C
(x 8,900)
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FIG. 13 Platelet aggregates from blood stored for 24 hours at 1°C
(x 19,700)
FIG.14 Platelet aggregates from blood
(x 8,900)
stored for 96 hours at 1°C
FIG.I 5 Platelet aggregates from blood stored for 96 hours at 1°C
(x 19,700)
to cause an increase in the plasma concentration of 5-HT. This did 
not usually occur (Table 7) and suggest that any released 5-HT from 
platelets is rapdily removed. If this is so, then the measurement 
of plama 5-HT is probably not a suitable marker for platelet 
release during the early stages of blood storage.
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CHAPTER FIVE
CHANGES IN ADP, ATP AND PLASMA HAEMOGLOBIN CONCENTRATICNS 
DURING BLOOD STORAGE AT 1°C, 4°C AND ROCM TEMPERATURE
5.1 ADP CONCENTRATIONS DURING BLOOD STORAGE
ADP is a nucleotide of primary biological importance, as an 
immediate precursor of polynucleotides, and, with ATP, as a particip­
ant in oxidative phosphorylation. ADP is the molecule that captures, 
in the form of high energy phosphate bonds, some of the energe resul­
ting from catabolic processes. The resultant ATP passes on this evergy 
to drive processes requiring energy, resulting in ADP and AMP formation.
ADP is a potent platelet aggregating agent and a mediator of 
secondary aggregation by several other aggregating agents in-vitro 
(see chapter one). Its role in platelet aggregation during the storage 
of whole blood, therefore, may be important as a consequence of platelet 
release. However, platelet aggregation in anticoagulated whole blood 
is associated with a loss of potassium ions from erythrocytes (Swank 
and Porter, 1963), a phenomenon which also occurs with ADP release 
from erythrocytes (Harrison and Mitchell, 1966). This ADP is thought 
to play an important role in platelet aggregation in haemostasis 
(Gaarder et al., 1961). Also drug inhibition of ADP release from 
erythrocytes has been shown to increase bleeding times from a small 
hole in a plastic tube circuit containing circulating blood (Born 
et al., 1976). The increase bleeding times were due
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to slower platelet activation, and, therefore, an important contrib­
ution to platelet aggregation in blood may be ADP released from 
erythrocytes.
5.1.1 ASSAY PROCEDURE FOR ADP
It is difficult to measure absolute values of ADP in blood and
plasma, because it is rapidly degraded in plasma at a rate calculated
-1 -1to be about 0.1 nmol min ml (Haslam and Mills, 1967). Also, the
best available method, enzyme assay, is not specific for ADP as 
it is affected by all nucleoside diphosphates (Haslam, 1964). How­
ever, guanosine diphosphate (GDP), inosine diphosphate (IDP) and 
uridine diphosphate (UDP) react at considerably lower rates, and 
since their normal blood concentrations are very low compared 
with ADP (D'Souza and Glueck, 1977), they are unlikely to significantly 
interfere.
The method used was as described by Adam (1970), based on the 
enzymic conversion by pyruvate kinase of ADP (in the presence of 
phosphoenolpyruvate) to ATP and pyruvic acid, the latter in quantities 
equivalent to the available ADP. In the presence of lactate dehydro­
genase, this pyruvate is reduced to lactic acid with NADH, the amount 
used of which is equivalent to the pyruvate and hence the ADP con­
centration. NADH was determined in a spectrophotometer by the 
absorption change at 366 nm against an air blank. The procedure dep­
ended upon deproteinisation of the blood or plasm sample using 0.5 M, 
perchloric acid (final concentration). Excess perchlorate was 
removed using potassium carbonate, which precipitates out as pot­
assium perchlorate in the cold, and separated by centrifugation.
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Care was taken to maintain a tenperature around 2°C during separation 
since potassium perchlorate becomes increasingly soluble as the temp­
erature rises and would interfere with the assay. Whole blood and PFP 
were assayed identically.
5.1.1.1 CALCULATION
The concentration of ADP was calculated using the general formula
molecular
change in absorption x weight of x final volume
concentration =  ^ _______  ADP__________________ mg.L” 1
extinction coefficient x cuvette light x sample 
of NADH at 366 nm path length volume
This was corrected for dilution taking into account the specific 
gravity and water content of blood and plasma, though these made 
only minimal differences to the overall concentrations (specific 
gravity of-blood is about 1.06, and of plasma, about 1.03; the 
water content of blood is about 80% and of plasma, about 90%),
5.1.1.2 ACCURACY OF THE ADP ASSAY
The assay was tested using a known concentration of ADP 
added to buffer and run through the procedure. Calculation of the 
change in absorption gave a mean result greater than 95% of the 
original concentration. This demonstrated that the use of the formula 
was suitable, and that the use of standards for comparison were 
unnecessary.
5.1.2 PLASMA AND BLOC» ADP CONCENTRATION RESULTS (Tables 8, 9, 10, 
Figures 16, 17, 18)
ADP concentrations were measured daily during the first week
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CHANGES IN ADP CONCENTRATION DURING BLOOD STORAGE AT 1°C, 4°C AND
ROOM TEMPERATURE
TABLE 8
1°C
a) Whole Blood (ug.ml-1)
0 1 2 3 4 8 14
21.8 - 24.0 - 15.0 24.5 -
25.5 - 41.0 - 24.5 - -
30.0 - 35.0 - 27.0 - -
17.1 18.9 20.3 16.5 12.7 - 3.3
22.1 - 28.2 25.3 20.6 29.1 17.5
24.8 32.3 35.4 26.9 20.7 24.5 33.7
22.8 32.0 30.6 25.5 20.1 29.2 33.3
34.0 50.0 39.4 38.8 39.8 47.6 21.1
28.2 33.7 31.6 25.5 17.0 29.9 33.3
mean 25.1 33.4 31.7 26.4 21.9 30.8 23.7
+ SEM 1.7 4.5 2.3 2.9 2.7 3.5 5.0
b) PEP (ug.ml ^)
10.5 0 13.6 14.8 2.4 0 11.6
0 0 19.0 0 3.1 0 3.4
2.4 0 0 7.5 0 1.4 2.9
0 7.5 6.8 0 0 3.4 5.1
3.1 5.4 0 9.5 18.7 0 2.1
5.9 2.4 6.8 0 0.3 5.1 1.0
mean 3.7 2.6 7.7 5.3 4.1 1.7 4.3
+ SEM 1.6 1.3 3.1 2.6 3.0 0.9 1.6
c ) I n t r a c e llu la r  le v e l (c a lc u la te d  fro m  b lo o d  - PEP means)
21.4 30.8 24.0 21.1 17.8 29.1 19.4
TABLE 9
ADP concentrations (cont) 
4°C
a) Whole Blood
0 1 2 3 4 8 14
19.9 - 20.8 - 34.1 24.2 41.2
18.1 - 17.0 - ' 27.0 22.9 21.5
14.4 - 25.7 - 29.5 23.7 24.2
16.3 - 20.0 - 17.0 18.5 26.1
20.0 - 53.7 - 27.9 25.7 34.4
26.0 17.0 20.3 - 18.9 28.6 -
10.2 5.7 12.3 19.4 28.8 19.4 -
17.1 14.0 14.9 15.1 13.0 - 11.6
22.1 19.4 21.0 22.9 22.9 26.6 10.9
24.8 22.8 23.1 23.1 19.7 30.3 38.5
22.8 22.4 21.4 23.8 17.7 30.9 34.0
34.0 36.4 42.8 37.4 39.1 36.0 42.8
mean 20.5 19.7 24.4 23.6 24.6 26.1 28.6
+ SEM 1.8 3.6 3.4 3.1 2.3 11.6 3.7
PEP
7.6 0.3 0 - 9.3 2.6 0.8
3.8 0 0 - 0.9 3.8 0
1.5 0 6.2 7.8 9.6 7.6 -
0 0 16.7 2.4 0.7 0 1.7
2.4 0 0 10.9 2.7 2.4 3.4
o . 1.7 7.1 1.0 0.7 6.8 7.3
mean 2.6 0.3 5.0 5.5 4.0 3.9 2.6
+ SEM 1.2 0.3 2.7 2.3 1.8 1.2 1.3
Intracellular Level (calculated)
17.9 19.4 19.4 18.1 20.6 22.2 23.9
TABLE 10
ADP Concentrations (cont)
Roan Temperature
a) Whole Blood
0 1 2 3 4 8 14
18.1 - 12.7 - 25.6 34.8 20.8
14.4 - 25.3 - 34.4 26.9 24.9
16.3 - 15.9 - 24.6 28.0 11.3
20.0 - 49.5 - 37.8 44.6 29.1
26.0 14.0 28.6 - 26.9 44.4 0.4
17.1 8.7 24.1 25.0 12.7 - 11.8
22.1 13.1 18.3 25.8 24.1 36.3 19.5
24.8 16.7 20.4 25.8 23.8 53.0 42.2
22.8 15.3 20.1 22.1 22.8 47.9 29.6
34.0 28.6 44.9 46.9 53.0 64.6 28.9
mean 21.6 16.1 26.0 29.1 28.6 42.3 21.9
+ SEM 1.8 2.7 3.8 4.5 3.4 4.1 3.7
b) PEP
7.6 0 0 5.3 0.9 3.4
3.8 0 0 - 0 2.3 2.8
10.5 0 3.7 15.2 0 1.0 14.6
0 0 16.7 1.0 3.1 0 2.0
2.4 0 0 8.5 8.2 0.7 3.0
0 0 4.4 0 0 3.4 5.1
mean 4.1 0 4.1 6.2 2.8 1.4 5.2
+ SEM 1.7 0 2.6 3.6 1.4 0.5 1.9
c) Intracellular Level (Calculated)
17.5 16.1 21.9 22.9 25.8 40.9 16.7
ADP Concentration pg.ml
Figure 16 CHANGES IN PLASMA CONCENTRATIONS OF ADP (+ SEM) DURING 
BLOOD STORAGE
0 1 2 3 4 8 14
Storage time in days
Figure 17 CHANGES IN WHOLE BLOOD CONCENTRATIONS OF ADP (+ SEM) 
DURING BLOOD STORAGE
ADP Concentration pg.ml
1ADP Concentration pq/ml
Figure 18 CALCULATED CHANGES IN INTRACELLULAR ADP CONCENTRATIONS 
DURING BLOOD STORAGE
of storage and then after 8 and 14 days.
Increases in blood ADP concentrations are most likely to be a 
consequence of ATP consumption. ADP leaking f ran erythrocytes or 
platelets would have been measured as plasma ADP concentrations.
To give an impression of events occurring within blood cells, intra­
cellular ADP concentrations were calculated by deducting the mean of 
the plasma ADP fran the mean of the blood ADP concentrations.
In blood, the ADP concentrations showed fluctuations only at 
1°C and roan tenperature (tables 8 and 10). At 4°C, there were con­
siderable inter-individual variations and the mean concentrations did 
not differ significantly between consecutive days of measurement 
(Students paired 't' test) (table 9). However, there was an apparent 
gradual increase in the mean blood ADP concentration throughout blood 
storage at 4°C, increasing from 20.5 pg ml”1 on day 1, to 28.6 pg ml”1 
on day 14. At 1°C, there was a significant increase in blood ADP 
concentrations during the first 24 hours (pi 0.05). This was in 
contrast to the significant decrease (pi 0.05) measured during the 
same period at room tenperature. However, measurement of plasma 
ADP concentrations showed that this decrease in blood ADP concentrat­
ions at room tenperature was mainly due to changes in plasma con­
centrations. These plasma ADP concentrations at 24 hours at room 
temperature, were all zero. Calculation of the intracellular ADP 
concentrations showed only a slight decrease at room tenperature, 
a slight increase at 4°C, but still a large increase at 1°C during 
the first 24 hours of blood storage (Figure 18).
There was considerable variation in the plasma ADP concentrations 
between individuals during blood storage. With the exception of the 
decrease in plasma ADP concentration during the first 24 hours at
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room temperature, there was no statistically significant difference 
between consecutive readings at any tenperature. There was also 
no significant difference in the rate or extent of ADP release into 
plasma between the storage temperatures (Students unpaired 't' 
test), all showing increased concentrations mainly between 48 hours 
and 96 hours. This increase reached an apparent peak after 48 hours 
at 1°C, but only after 72 hours at both 4°C and room temperature.
The mean values for blood ADP concentrations gradually declined 
after 2 days at 1°C, a significant decrease being measured between 
days 2 and 3, and between days 3 and 4. However, a significant 
increase in blood ADP concentrations then occurred between days 4 
and 8 (p^0.05) followed by another decrease between days 8 and 14. 
This increase was also measured between days 4 and 8 at room temper­
ature and again was statistically significant. However, in this group, 
the increase was a continuation of a significant increase measured 
between days 1 and 2, and days 3 and 4. Hence, the two patterns of 
blood ADP concentration changes at 1°C and room tenperature differed. 
With the exception of the first 24 hours, the pattern of change in 
blood ADP concentrations at all storage temperatures was the same 
for the calculated intracellular ADP concentrations. The difference 
in blood ADP concentration changes was significant (Students unpaired 
•t' test p^0.05) between all the storage temperatures at 24 hours, 
and also at 48 hours between 1°C and room temperature, and between 
4°C and room temperature. Between 48 and 72 hours, the change in 
blood ADP concentration was significantly different between 1°C and 
4°C, and between 1°C and room tenperature, but not between 4°C and 
room tenperature. However, only between 4°C and room tenperature were
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any further significant differences seen in blood ADP concentration 
changes, and these were iron days 4 to 8, and from days 8 to 14.
During the first 4 days of blood storage, therefore, a 
contrasting pattern can be seen between blood ADP concentration 
changes at 1°C and at rocrn temperature with the changes at 4°C 
being scmewhere inbetween.
The mean ADP concentration in whole blood immediately after
„1
collection was 24.1 + (SIM) 1.6 pq ml , and the range was 10.2 
to 36.4 pg ml . This was lower than the "normal" range reported to 
be from 21 to 48 pg ml by Laudahn (1959) (though of the 19 
samples in the range, 14 had a concentration over 20 pg ml~^).
The possibility that the increases in plasma ADP concentrations 
during the first few days of blood storage were due to activities in 
platelets, was examined by performing ADP assays during the storage 
of platelet rich plasma (PRP) at 4°C (Table 11a). PRP was prepared 
by centrifugation of blood at 100 g for 10 minutes at 4°C, followed 
by careful removal of the PRP, under aseptic conditions, into sterile 
polystyrene jars for storage. There was considerable variation in 
the results with an apparent, though statistically insignificant, mean 
increase in the plasma ADP concentration after 24 tours storage.
There was a significant decrease in the plasma ADP concentration 
between days 1 and 2 (p<$0.05) followed by no significant change bet­
ween days 2 and 3, and between days 3 and 4, and then (in those 
samples that were measured) a decline to zero after 8 days of PRP 
storage. Results with PRP must be treated with caution, as the 
PRP preparation procedure may be a stimulus for platelet release 
(Barrett et al., 1976), and may have accounted for the apparent 
increase in ADP concentration during the first 24 tours. However,
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TABLE 11
a) Changes in Plasma ADP Concentrations During Storage of PRP at 4°C
Storage time in days Platelet Count
0 1 2 3 4 8
Q  _ 1
(x 10 .L )
3.2 8.1 4.3 5.5 0.4 0 293
3.0 11.3 2.1 - 1.2 - 247
5.4 3.7 0 10.2 17.0 - 261
7.1 16.0 5.1 5.1 0 0 324
5.8 - 5.8 1.0 15.3 0 340
2.1 0.3 5.1 13.2 0 0 291
3.1 16.3 3.7 3.7 0 0 308
mean 4.2 9.3 3.7 6.5 4.8 0 295
±  SEM 0.7 2.7 0.8 1.8 2.9 0 12.4
b) SFP Changes in PRP Stored at 1°C
Storage Time in Days Platelet Count
0 2 4 8 14
Q _ 1
(x 10 .L ')
7 11 55 600 600 329
14 23 26 110 600 193
11 600 600 600 600 244
10 110 285 600 600 261
mean 11 186 241 478 600 257
+ sm 1.4 140 133 123 0 28
the overall pattern of plasma ADP concentrations during PRP 
storage, suggests that platelets may have contributed to plasma 
ADP concentrations during the first few days of blood storage at 
4°C. The higher mean plasma ADP concentrations in stored PRP compared 
with stored blood may have been due to the higher platelet count of 
PRP.
5.1.3 DISCUSSION OF THE ADP RESULTS
During the first 24 hours of blood storage, the concentration of
ADP in plasma decreased particularly at room temperature. This may
be explained as being due to the more rapid ADP degradation at higher
tenperatures. The different rates of ADP degradation were confirmed
by comparing the breakdown rates of ADP added to plasma at 1°C with
those at room temperature. ADP, dissolved in 0.05M phosphate buffer,
pH 7, was added to fresh blood plasma under aseptic conditions to
-1give a final concentration of 100 i^g ml . The concentration of ADP 
was measured after 24 hours and was found to be reduced by a mean of 
91% at room temperature and 58% at 1°C. This rate of degradation was 
still apparent in plasma prepared after 48 hours and stored with added 
ADP, for 24 hours.
If ADP were being released from erythrocytes during this period, 
then it must have been at a slower rate than the rate of ADP degrad­
ation. However, whether it was due to a reduced rate of degradation 
or to an increased rate of ADP leakage from erythrocytes, the concen­
tration of plasma ADP was generally higher at 1°C than at 4°C or 
roan tenperature after 24 hours blood storage.
The subsequent increase in plasma ADP concentrations occurred
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at all three temperatures, and, with the exception of room temperature 
between 24 and 48 hours, seemed to generally follow increases in 
intracellular ADP. The plasma concentration then decreased as ADP 
was degraded. Perhaps the sharp increase in plasma ADP concentrations 
at room temperature, and to an extent at 1°C and 4°C, during the 
24 to 48 hour period was due to the dephosphorylation of ATP 
during the first 24 hours (see Figure 23).
The plasma ADP concentration in some samples at 24 hours at
1°C, and on occasions throughout blood storage at all temperatures,
-5 -1reached a value of about 10 M (4.3 ¿rg.ml ). Platelet aggregation
has been shown to occur following the exposure of platelets in PRP
—8to ADP concentrations as low as 3 x 10 M (Takano, 1975). However, 
higher ADP concentrations are usually required. Born (1962) found 
that 10 M was the lowest concentration that would induce irreversible 
platelet aggregation in PRP, and Swank et al. (1963) observed that 
ADP concentrations in the range 1 to 5 /ig.ml’^  were necessary to 
aggregate platelets in whole blood in-vitro. This concentration, 
however, caused only a loose reversible aggregation, that required 
the presence of other factors such as 5-HT or adrenaline before the 
aggregates became tightly bound. Indeed, increases in the concentra­
tion of ADP alone up to 15 jjg.ml  ^had no further affect on the extent 
of platelet aggregation in blood (Swank and Fellman, 1967).
Using the absolute values measured in plasma it appears that 
the ADP concentrations were not high enough to initiate platelet 
aggregation. It should be born in mind, though, that the high rate 
of ADP degradation was a problem in measuring absolute values. Very 
marry more measurements, perhaps hourly, would be required to reduce 
this problem. However, this was impractical. It is possible that
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the measurement of plasma ADP was not a suitable indicator of the 
effect of ADP as it did not account for any locally high concentrations. 
This might have occurred in stagnant blood in which sedimentation 
results in the concentration of platelet populations. This hypo­
thesis may also be forwarded for other released factors such as 5-HT 
and catecholamines and could be prevented by constant, gentle agit­
ation of stored blood, thus reducing the close proximity of platelets. 
The value of agitation in reducing platelet aggregation during CPD 
anticoagulated blood storage was suggested by Arrington and McNamara 
(1975). However, agitation also destroys platelets and breaks down 
aggregates, so that the extent of this reduction is now in doubt 
(Gervin et al., 1978). The effect of many aggregating agents is 
thought to be the relase of ADP following the consumption of platelet 
ATP (Haslam, 1964) possibly due to the stimulation of ATPase 
(O'Brien, 1964b). The importance of ADP has been shown particularly 
by the use of enzymes to remove released ADP, such as creatine phos- 
phate/creatine phosphokinase (Izrael et al., 1974; Tschopp and 
Baumgartner, 1976), apyrase (Wang et al., 1975) and pyruvate kinase/ 
phosphoenolpyruvate (Haslam, 1964). A possible exception however, 
is cold, which has been shown to aggregate platelets without the 
mediation of released ADP (Kattlove and Alexander, 1971). Indeed,
ADP is thought not to be able to induce platelet aggregation in the 
cold (O'Brien, 1962). However, it has also been observed that plate­
lets stored as PRP for 10 days at 5°C showed a response to high ADP 
concentrations that was above that induced by cold (Shively et al.,
1970), though the authors considered that platelets exposed to 
temperatures between 0°C and 4°C aggregate "spontaneously".
To complicate the problem further, any ADP involved in aggregation
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may be bound to platelets and not assayed as plasma ADP, but would 
be included in the calculation of intracellular concentrations.
It was shown that intracellular ADP concentrations were higher after 
24 hours at 1°C than at 4°C or room temperature (at which a decline 
occurred) (Figure 18). It was assumed that intracellular ADP 
concentration increases were due to ATP consumption, and indeed 
at 1°C this appeared to be so (Figure 24). However, ADP consumption 
was also observed equally at 4°C and roan temperature, without the 
expected resultant increases in ADP. This suggested more rapid 
breakdown which would occur more readily in plasma. Therefore, the 
"intracellular" ADP levels at 24 hours may be a measure of bound 
ADP which was highest at 1°C, and lowest at roan temperature as 
would be expected with the different rates of degradation. In 
an attempt to further elucidate the role for ADP, specific inhibit­
ors were employed.
5.1,4 INHIBITION OF ADP AND ADP RELEASE
Chlorprcmazine, used clinically as a tranquilliser, is known 
to inhibit platelet function in-vitro, particularly the release 
of ADP (Warlow et al., 1976), in the platelet release reaction 
(Born et al., 1976). It is not thought to interfere with the 
platelet aggregation mechanism (Born, 1967) and therefore, was 
a suitable candidate for judging the importance of released ADP 
in platelet aggregation during blood storage in the cold. Apyrase 
is an enzyme that breaks down ADP, thus preventing its activating 
effect on platelets (Wang et al., 1975; Born et al., 1976) and 
was used to complement the studies with chlorprcmazine.
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5. 1.4.1 ADDITION OF CHLORPROMAZINE
Chlorpranazine was prepared fresh in 0.05M phosphate buffer
pH7, and suitably diluted so that the addition of 1 ml to 20 ml
of blood gave the required concentration. A concentration of 2.8 
-4x 10 M was used which would inhibit the release reaction in-vitro 
(Born et al., 1976). 20 ml blood sanples were taken from blood
packs by drainage into sterile polystyrene "Universal" jars 
under aspetic conditions. The drug solution was sterilised 
by microfiltration through 0.02 /jm pore diameter "Millipore" filters. 
The containers were stored in the same conditions as the blood packs, 
and sanples taken aseptically when required. It was not known 
to what extent the drug would deteriorate during storage, and so 
no further addition of chlorpranazine could be made, lest the 
final concentration be higher than required. The drug was tested 
on blood stored at 1°C.
5.1.4.2 THE EFFECTS OF CHLORPRCMAZINE AT 2.8 x 10~4M ON PLATELET 
AGGREGATION IN BLOOD STORED AT 1°C
Using the SFP technique, chlorpranazine was shown to inhibit 
platelet aggregation for at least 8 days of blood storage (Table 12a, 
Figure 19). The difference between consecutive readings was 
significantly reduced by chlorpromazine,(Students paired *t' test, 
p ^ 0.05), though statistical significance could not be calculated 
after 24 hours, as the SFP measurable maximum had been reached 
for all of the untreated sanples. The results seem to demonstrate 
that, either platelet aggregation at 1°C depends upon the platelet 
release of ADP, or that chlorpromazine at 2.8 x 10”4M interferes
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TABLE 12
EFFECTS OF CHLORPROMAZINE AND APYRASE ON PLATELET AGGREGATION 
IN BLOOD STORED AT 1 °C (SFP - mm/Hg)
0 1 2 3 4 8 14
a) Chlorprcmaz ine
2.8 x 10~4M 18 20 25 40 65 185 -
20 37 80 130 168 220 260
30 43 55 60 75 120 190
20 53 65 25 25 75 530
32 47 48 50 40 64 435
42 43 85 80 82 78 198
mean 27 41 60 64 76 124 323
+ SEM 3.8 4.6 9.0 15.2 20.4 26.5 68.3
b) Chlorpromazine
2.8 x 1Cf5M 26 275 600 600 600 600 600
22 230 600 600 600 600 600
42 45 75 145 162 600 600
50 62 84 266 275 330 600
48 340 600 600 600 600 600
42 600 600 600 600 600 600
mean 38 259 427 469 473 555 600
+ SEM*39 4.7 83.3 109.7 84.6 81.7 44.9 0
c) Chlorpromazine
2.8 x 10"6M 50 58 112 190 270 360 600
48 460 600 600 600 600 600
42 600 600 600 600 600 600
52 70 177 190 290 600 600
mean 48 297 372 395 440 540 600
+ SEM 2.2 137.5 132.1 118.4 92.5 60.0 0
TABLE 12 (cont)
d) Apyrase
0 1 2 3 4 8 14 «
50 ug.ml-1 42 60 98 100 110 190 385
50 45 66 112 162 450 600
48 270 385 600 600 600 600
42 600 600 600 600 600 600
52 75 95 180 220 360 600
mean 47 210 249 318 338 440 . 557
+ sm
■W
2.1 106.0 105.6 116.1 108.5 77.7 43.1
Extent of Aggregation without inhibitor (for all comparisons)
31 600 600 600 600 600 600
SFP mm/Hg
Figure 19 EFFECT OF CHLORPROMAZINE AND APYRASE ON PLATELET AGGRE­
GATION (SFP + SEM) DURING BLOOD STORAGE AT 1°C
_____ SFP Without Inhibitor
.___. SFP With Inhibitor
SFP mm/Hg
400
300
200
100
600
500
400
300
200
100
500
Storage time in days
Figure 20 EFFECT OF CHLORPROMAZINE AND APYRASE ON PLATELET
AGGREGATION (SFP + SEM) DURING BLOOD STORAGE AT 4°C
___ . SFP Without Inhibitor
SFP With Inhibitor
with the aggregation mechanism.
5.1.4.3 ADDITION OF APYRASE
The possibility that platelet aggregation in blood stored 
at 1°C, depends upon released ADP, was tested usinq apyrase. 
Lyophilised potato apyrase was prepared as described for chlorprom- 
azine. It was used at a concentration of 50 pgml-  ^which has 
been found to maximally inhibit platelet activation by ADP (Born 
etal., 1976).
5.1.4.4 THE EFFECTS OF APYRASE AT 50 /^.ml"1 ON PLATELET AGGRE­
GATION IN BLOOD STORED AT 1 °C
Apyrase was found to inhibit increases in SFP, when compared 
with samples without apyrase. However, there was considerable inter­
individual variation and inhibition was only significant (p< 0.05) 
for the first 24 hours of blood storage (Table 12d, Figure 19).
These results suggest that ADP is involved in platelet 
aggregation at 1°C, but if ADP were the central mediator for aggre­
gation, then apyrase might have been expected to have a more marked, 
and less variable effect. It is possible that the effect of apyrase 
was not rapid enough to remove released ADP in the presence of a 
strong stimulus. The use of an alternative enzyme, such as creatine 
phosphate/creatine phosphokinase, which is thought to act more 
rapidly than apyrase (Izrael et al., 1974) was not tried. However, 
ADP frcm erythrocytes may also contribute to platelet aggregation 
and it may have been this ADP which was inhibited by apyrase.
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5.1.5 THE ROLE OF ERYTHROCYTES IN PLATELET AGGREGATION DURING BLOOD 
STORAGE
Platelet aggregation has been shown to occur in PRP in the 
cold (Kattlove and Alexander, 1971). This was confirmed by the 
author in PRP stored at 1°C in "Universal” jars (Table 11b).
However, the rate of aggregation was not as rapid as in whole blood 
at 1°C, and this suggests that factor(s) other than plasma and 
platelets contribute to platelet aggregation in blood at 1 °C. This 
may, in part, be the presence of granulocytes (see chapter one), and 
the volume of cells in blood compared with PRP. However, it may 
also have been ADP from erythrocytes which accelerated platelet 
aggregation in blood at 1°C. This possibility was tested using 
chlorpromazine and apyrase.
At low concentrations, chlorpromazine will increase the res­
istance of erythrocytes to haemolysis, and may alter their membranes 
so as to diminish or prevent ADP leakage (Born et al., 1976). 
Chlorpramazine, prepared as previously described, was used at a
_5
concentration of 2.8 x 10 M, which was about half the concentration 
required to reduce the platelet release reaction by 50% in-vitro.
5.1.5.1 THE EFFECTS OF CHLORPROMAZINE AT 2.8 x 10”5M ON PLATELET 
AGGREGATION IN BLOOD STORED AT 1°C AND 4°C
Chlorpromazine inhibited platelet aggregation, as measured by 
SFP, at 1°C (Table 12b, Figure 19). However, the difference bet­
ween the SFP's of treated and untreated blood samples were signif­
icant only after the first 24 hours storage (Students paired ’t’ 
test, p^0.05). After 24 hours, the SFP in the treated samples
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increased rapidly. These results suqgest that ADP released from
erythrocytes may contribute to platelet aqqregation in blood stored
at 1°C. It was possible that the reduced platelet aggregation in
chlorpromazine treated blood might have been due to partial
inhibition of the release reaction. To test this possibility,
—6chlorprcmazine was used at 2.8 x 10 M, at which concentration,
platelet release was unlikely to be inhibited. Only 4 experiments
were conducted using this concentration, but the results (Table
12c) showed an apparently similar effect on platelet aggregation as
-5chlorprcmazine at 2.8 x 10 M., It was therefore unlikely that
-5chlorprcmazine at 2.8 x 10 M inhibited the platelet release reac­
tion, and so reduced platelet aggregation in stored blood at 1°C 
was probably due to inhibition of ADP release from erythrocytes.
The observations with chlorprcmazine at 4°C showed no signif­
icant inhibition of platelet aggregation (Table 13a, Figure 20).
This suggests that at 4°C, erythrocytes make no significant con­
tribution of ADP.
5.1.5.2 THE EFFECTS OF APYRASE AT 50 JJg.ml"1 ON PLATELET AGGREGATION 
IN BLOOD STORED AT 1°C AND 4°C
It has been shown that in blood stored at 1°C, apyrase reduced
the rate of platelet aggregation (section 5.1.4.4). This therefore
supports the observations with chlorprcmazine at 2.8 x 10~5M and 
—62.8 x 10 M, that platelet aggregation during blood storage at 
1°C was partly activated by ADP from erythrocytes.
Like chlorprcmazine, apyrase had no significant effect on 
platelet aggregation in blood stored at 4°C (table 13b, Figure 20)
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TABLE 13
EFFECTS OF CHLORPRQMAZINE AND APYRASE ON PLATELET AGGREGATION IN BLOOD STORED AT 4°C (SFP - mm/Hg)
a) Chlorprcmazine, 2.8 x 10“5M -
0 1
D ND D ND
18 20 23 36
20 20 25 28
25 26 45 92
20 20 38 36
32 32 58 130
42 42 55 58
mean 26 27 41 63
+ SIM 3.8 3.6 6.0 16.4
with (D) and without (ND) drug
2 3
D ND D ND D
35 60 - - 36
36 60 - - 130
123 185 235 330 600
35 28 31 45 86
175 255 122 325 100
80 50 104 58 141
81 106 123 189 182
23.7 37.3 42.2 79.7 84.9
8 14
ND D ND D ND
65 165 145 280 231
83 340 190 600 600
600 600 600 600 600
55 235 460 600 600
340 165 - 600 600
86 195 233 265 600
205 283 326 491 537
90.4 68.7 87.7 69.1 63.1
days
TABLE 13 (cont)
EFFECTS OF CHLORPRCMAZINE AND APYRASE ON PLATELET AGGREGATION! IN BLOOD STORED AT 4°C (SEP - mm/Hg)
_1b) Apyrase, 50pg.ml
0 1 2 3 4 8 14
D ND D ND D ND D ND D ND D ND D ND
24 26 60 92 320 185 600 430 600 600 600 600 600 600
42 42 55 58 50 50 60 58 80 86 255 233 385 600
50 50 55 53 60 65 120 112 155 170 265 290 600 600
48 48 75 140 110 155 133 180 186 180 265 260 445 -
42 42 125 133 560 600 600 600 600 600 600 600 600 600
52 52 67 67 75 345 290 600 350 600 450 600 600 600
mean 43 43 73 91 196 233 301 330 329 373 406 431 538 600
+ SEM 4.2 3.8 10.9 15.5 83.6 85.1 99.6 99.9 93.1 102.4 68.2 76.2 39.8 0
days
and suggests that these platelets are not. in part, stimulated 
by ADP released from erythrocytes. Althouqh only speculative, it 
is possible that the difference in the rates of platelet aggregation 
between blood stored at 1°C and at 4°C may have been due to this 
ADP contribution from erythrocytes.
The apparent role of erythrocytes in platelet aggregation 
during blood storage at 1°C, was further tested by measuring 
plasma haemoglobin concentrations as an index of haemolysis.
5.2 PLASMA HAEMOGLOBIN CONCENTRATIONS DURING BLOOD STORAGE
ADP release is not necessarily associated with erythrocyte 
haemolysis, as it may leak out from erythrocytes that are struct­
urally and metabolically normal. For example, ADP leaks out during 
reversible erythrocyte deformation, and experimentally, the 
adhesiveness of platelets to glass was increased in the presence of 
erythrocytes without evidence of haemolysis (Born, et al., 1976). 
However, the plasma haemoglobin concentration is increased during 
blood storage at 4°C in CPD (Limbird and Silver, 1974; Bailey and 
Bove, 1975; Mishler et al., 1978) which would be associated with 
the release of erythrocyte constituents including ADP.
5.2.1 HAEMOGLOBIN ASSAY
The method used to estimate haemoglobin in plasma separated from 
whole blood was as described by Crosby and Furth (1956). This 
method is based on the catalytic action of heme containing proteins 
bringing bout the oxidation of benzidine by hydrogen peroxide, to
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give a green colour which changes through blue to violet. The 
colour intensity can be compared with a known standard in a spectro­
photometer. In the experiments, a cyanmethaemoglobin standard 
solution was used containing 57.2 ng.dl-1. As a control, water 
was substituted for the plasma.
Methods using the peroxidase activity of heme as the basis of 
colorimetric procedures are subject to variable interferences, and 
they do not distinguish between different heme containing compounds, 
which may show different degrees of peroxidase activity. A 
spectrophotametric scanning technique is available, and it is claimed 
that this measures plasma haemoglobin accurately, even in the pres­
ence of the usual interferences by bilirubin, turbidity and methaem- 
albumin (Blakney and Dinwoodie, 1975). However, without scale 
expansion facilities on the scanning spectrophotometer, the method 
was found to be unsuitable for measuring low concentrations, and, 
therefore, despite its advantages, was not used.
5.2.2 THE RESULTS OF PLASMA HAEMOGLOBIN CONCENTRATION MEASUREMENTS. .
Haemoglobin measurements were made after 0, 2, 4, 8 and 14 
days storage. Concentrations varied between donors but showed a 
gradual increase throughout the storage period at 1°C, 4°C and 
room temperature (Table 14, Figure 21). On collection, plasma 
haemoglobin concentrations had a mean of 1.7+ (SEM) 0.3 mg.dl“1 
(n = 19), a concentration also found in another study (Bailey and 
Bove, 1975). The extent of haemolysis was most apparent at 1°C, 
increasing to a mean of 81.1 rng.dl“1 after 14 days blood storage.
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TABLE 14
PLASMA HAEMOGLOBIN CONCENTRATION DURING BLOOD STORAGE AT 1°C, 
4°C, ROOM TEMPERATURE (in mg.dl“1 of PEP)
a) 1°C 0 2 4 8 14 days
4.3 10.6 - 20.7 39.4
2.1 9.0 11.2 18.9 38.7
1.9 19.9 27.0 39.6 67.5
5.2 13.9 40.2 82.9 168.7
1.6 - 18.8 30.8 58.8
1.6 12.9 11.1 18.8 61.5
1.4 11.8 8.2 18.2 -
0.3 4.6 14.1 46.8 132.9
Mean 2.3 11.8 18.7 34.6 81.1
+ SEM 0.6 1.8 4.3 7.9 18.8
TABLE 14 (cont)
: o 2 4 8 14
0.6 9.1 13.5 22.5 31.9
0.1 8.4 19.2 34.0 105.0
1.2 3.6 3.8 9.8 18.8
0.3 2.8 5.7 6.2 21.3
1.1 3.4 4.3 8.7 13.3
1.7 3.7 7.3 10.2 14.4
1.2 4.6 8.2 14.7 33.8
3.9 8.7 12.7 21.7 47.1
2.1 13.8 19.8 21.8 32.5
1.9 13.8 21.9 31.4 50.6
1.4 8.9 13.1 18.9 -
0.3 16.3 45.0 58.6 91.5
1.1 7.7 12.0 29.5 36.1
0.9 11.8 15.3 30.4 45.8
1.7 10.0 18.1 34.0 51.2
mean 1.3 8.4 14.7 23.5 42.4
+ SEM 0.2 1.1 2.6 3.5 7.2
TABLE 14 (cont)
on
up.
0 2 4 8 14
0.6 4.2 6.1 8.6 23.2
0.1 4.1 6.7 18.1 61.0
1.2 3.8 4.1 11.9 21.7
0.3 2.6 7.6 8.0 21.8
1.1 2.9 3.4 7.3 20.7
1.7 3.5 5.7 9.9 14.3
1.2 4.7 7.9 12.1 27.3
2.1 6.9 7.7 17.6 30.2
1.9 7.5 18.3 20.4 49.9
1.6 - 3.7 8.4 18.1
1.4 13.4 9.7 18.2 -
0.3 6.7 9.4 13.5 57.6
mean 1.1 5.5 7.5 12.8 31.4
+ SEM 0.2 0.9 1.1 1.3 5.0
1Haemoglobin Cone, mg.dl
Figure 21 CHANGES IN PLASMA HAEMOGLOBIN CONCENTRATION (+ SEM) 
DURING BLOOD STORAGE
At 4°C, the plasma haemoglobin concentration increased to 42.4 mg.
—1 -1dl , and at room temperature, to 31.4 mg.dl . The increase in
concentration was significant (Students paired *t* test, p* 0.05) 
between most consecutive readings at all three temperatures, with 
the exception of the apparent mean increase between 2 days and 4 
days at both 1°C and room tenperature. The increase in plasma 
haemoglobin concentration at 1°C during the first 2 days of blood 
storage was only significantly different to the increase at roan 
tenperature (Students unpaired *t' test, p^ 0.05). Between 2 days 
and 4 days, there was no significant difference in the increased 
concentration at any of the three storage temperatures. However, 
between days 4 and 8 and days 8 and 14, the increase in plasma 
was significantly higher at 1°C when compared with both 4°C and 
room tenperature (py0.05). There was no significant difference 
in the increase in concentration at any time during storage between 
4°C and room tenperature when comparing consecutive readings, though 
the increase between days 0 and 4 was significantly higher at 4°C, 
than at room tenperature (p£0.05).
No published data is available to compare with the above plasma 
haemoglobin concentrations during blood storage at 1°C and room tenp­
erature. However, the increase in plasma haemoglobin concentration 
at 4°C contradicted the findings of some other workers who used CPD 
anticoagulated blood. Bailey and Bove (1975) observed a gradual
_ i
increase to a mean of only 12.5 ng.dl after 14 days blood storage. 
Limbird and Silver (1974) found little change during the first 14 
days blood storage but recorded a plasma haemoglobin mean concentrat­
ion of about 42 mg.dl” 1 after only 1 day of storage. The increase in
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plasma haemoglobin concentrations reported here are, however, very 
close to the results of Mishler et al., (1978) who measured a mean 
concentration of 43.5 mg.dl-1 after 14 days blood storage.
The extent of haemolysis was only very small, even at 1°C. 
Considering a maximum haemoglobin concentration of about 16 g.dl“  ^
of venous blood in the average adult male, then the mean extent of 
haemolysis after 14 days blood storage was only about 0.5% at 1°C, 
about 0.25% at 4°C and about 0.2% at room tenperature. Thus 
haemolysis in stored blood was most evident at 1°C and least evident 
at room tenperature with the plasma haemoglobin concentrations at 
4°C being closer to those at room tenperature than at 1°C. Although 
ADP release frcm erythrocytes alone was not measured, because haem­
olysis was most evident during blood storage at 1°C, it is probable 
that ADP was released more readily from erythrocytes stored at 1°C, 
than frcm erythrocytes stored at 4°C or rocm tenperature.
5.3 ATP CONCENTRATIONS DURING BLOOD STORAGE
ATP probably plays two essential roles in platelet aggregation. 
Firstly it provides the energy required, and the consunption of met­
abolic ATP is the earliest biochemical effect of aggregating agents 
so far detected (MacFarlane and Mills, 1975). Secondly, it is the 
precursor of the majority of ADP released frcm platelets (Haslam, 
1964), with resultant second stage aggregation.
ATP is a nucleotide of primary biological importance not 
only providing energy for the various kinds of work performed by 
living cells, but also as a precursor of the coenzymes NAD and NADP.
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These operate as hydrogen and electron transfer agents by virtue of 
reversible oxidation and reduction essential in dehydrogenase 
reactions.
ATP itself is released from platelets aggregated by thrombin 
(Detwiler and Feinman, 1973) by as much as 40% of its platelet cont­
ent (D'Souza and Glueck, 1977) Evidence is available that AIP 
will inhibit ADP induced aggregation, possibly, like AMP, by 
carpeting for specific aggregating sites on the platelet membrane 
(Born, 1962). However, a high concentration is required (about 200 
times the concentration of ADP, in-vitro) and only involves first 
stage aggregation (MacFarlane and Mills, 1975).
ATP was measured to see to what extent it was utilised during 
blood storage at 1°C, 4°C and room temperature, and to try and 
relate changes in ADP concentrations to energy utilisation.
5.3.1 ASSAY FOR ATP IN PLASMA AND WHOLE BLOOD
Enzymic estimation of ATP presents the same problems as it does 
for ADP. Inosine triphosphate, uridine triphosphate and guanosine 
triphosphate are also determined, but like their diphosphate relatives, 
they are only present in very small quantities. ADP may be estimated 
by recording luminescence resulting iron the reaction of ATP with 
firefly luciferin/luciferase (Detwiler and Feinman, 1973), though 
this has no advantage over the enzymic method of Adam (1962). This 
method is based on ATP phosphorylation of glycerate-3-phosphate 
to glycerate 1,3 diphosphate in a reaction catalysed by 3-phospho- 
glycerate kinase (Figure 22). The glycerate 1,3 diphosphate is 
reduced with NADH, and glyceraldehyde 3 phosphate dehydrogenase to
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form glyceraldehyde 3 phosphate which is converted to dihydroxy- 
acetone phosphate by triosephosphate isanerase. Finally, dihydroxy- 
acetone phosphate is reduced to glycerol 1.1 phosphate by glycero­
phosphate dehydrogenase and NADH. The method is in effect, a 
reversal of part of glycolysis and gluconeogenesis and normally the 
equilibrium of the first reaction lies to the left. However, by the 
use of an excess of glycerate 3 phosphate and removal of the glycer- 
ate 1,3 diphosphate in the second reaction, the equilibrium of which 
lies to the right, ATP can be completely converted. The NADH used 
in this reaction is equivalent to the glycerate 1,3 diphosphate 
and hence to the ATP concentration. The further reactions double 
the rate of conversion. NADH is the reaction indicator.
Spectrcphotometric measurements and application of the cal­
culation are as detailed for ADP.
ATP ADP
Glycerate 3 phosphate ^ - glycerate 1,3 diphosphate
1 I J9 NADH + H+/"
V
dihydroxyacetone phospha te -
a  « '
fi glyceraldehyde 3 phosphateA
C NADH + HNAD
glycerol 1 phosphate
Figure 22
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(Tables 15, 16 and 17, Figures 23 and 24). ATP concentrations 
were measured at the same intervals as for ADP, ard similarly, 
'intracellular' levels were calculated from the measured plasma 
and whole blood concentrations. These showed large individual 
variations, though the mean whole blood concentrations at all three 
storage temperatures showed a similar trend throughout blood storage. 
There was no statistically significant difference between any 
consecutive reading of ATP in PFP (Students paired 't' test) 
at any temperature, nor was there any significant difference in 
the change in concentration, at any time during storage, between any 
tenperature. Therefore, because there was little to distinguish 
between the ATP concentrations in PFP, no graph has been included.
Whole blood concentrations of ATP immediately after collection 
were in the range 26.7 to 37.7 mg.dl”1 with a mean of 31.0 + SEM
1.7 mg.dl 1. (n = 6). This was marginally higher than the 'normal'
_i
reported range of 19 to 32 mg.dl (Boehringer), though lower than
the range of 38 to 54 mg.dl“1 reported for adult males (Buell,
1935 - cited Documents Geigy Scientific Tables, 1962). in whole
blood, a significant decrease in concentration (Students paired
*t* test, p ^  0.05) was observed during the first 24 hours of
storage at all three terrperatures, but with a significantly larger
decrease at 1°C (mean 31.0 to 17.8 mg.dl“1) (p,$0.05). The decreases
in concentration at 4°C and room tenperature were similar (mean,
-1 -131.0 to 20.6 mg.dl at 4°C, and to 20.5 mg.dl at roam tenperature). 
Because of the lack of difference between plasma ATP concentrations 
at different tenperatures, the calculated intracellular concentrations 
showed similar changes to whole blood levels. All consecutive
5.3.2 RESULTS FOR PLASMA AND WHOLE BLOOD ATP CONCENTRATIONS
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TABLE 15
ATP CONCENTRATIONS DURING BLOOD STORAGE AT 1°C, 4°C AND ROOM
4 -1TEMPERATURE ( x 10 ug.L )
1°C
a) Whole Blood 0 1 2 3 4 8 14 days
26.7 7.4 17.5 24.1 38.1 - 15.8
27.6 - 23.2 20.6 9.6 26.3 27.2
33.3 17.1 27.6 27.6 25.8 19.7 3.1
32.0 16.2 25.8 24.1 15.3 14.5 4.8
37.7 25.4 13.6 25.8 24.1 17.9 14.0
28.4 22.8 15.3 21.9 13.6 29.3 13.6
mean 31.0 17.8 20.5 24.0 21.1 21.5 13.1
+ SEM 1.7 3.1 2.4 1.0 4.2 2.7 3.5
b) PEP 6.6 3.9 4.4 3.0 2.2 2.6 0.9
5.7 3.1 5.3 2.0 0 3.1 1.1
0 0.9 0 0 0 12.7 0
0 3.1 11.8 0 0 4.4 0
0 0 0.4 4.4 0 0 0
0.9 0 0 1.8 0 0 0
mean 2.2 1.8 3.7 1.9 0.4 3.8 0.2
+ SEM 1.3 0.7 1.9 0.7 0.4 1.9 0.2
Intracellular Level (calculated from whole blood minus PFP)
28.8 16.0 16.8 22.1 20.7 17.7 12.9
TABLE 16
ATP CONCENTRATIONS (cont)
Whole Blood 0 1 2 3 4 8 14 days
26.7 13.1 19.3 27.2 35.9 - 17.1
27.6 21.0 25.0 25.0 9.6 25.4 24.1
33.3 21.9 31.1 28.0 27.6 24.1 12.7
32.0 17.6 24.5 21.9 14.0 19.7 11.8
37.7 27.2 21.0 26.7 28.5 25.4 14.0
28.4 22.8 17.5 21.9 17.5 26.3 20.6
mean 31.0 20.6 23.1 25.1 22.2 24.2 16.7
+ sm 1.7 2.0 2.0 1.1 4.1 1.1 2.0
PEP 6.6 2.6 4.8 2.0 1.3 2.2 1.2
5.7 2.6 4.4 1.9 1.3 3.9 1.8
0 0.9 0 0 0 7.9 0
0 0 9.6 0 0 0.9 0
0 0 3.9 4.4 2.6 0.4 0
0.9 0 0 1.8 0 0 0
mean 2.2 0.6 3.8 1.7 0.9 2.6 0.5
+ SEM 1.3 1.2 1.5 0.7 0.4 1.2 0.3
c) Intracellular Level (calculated)
21.3 21.6 16.228.8 20.0 19.3 23.4
TABLE 17
ATP CONCENTRATIONS (cont)
Roan Tenperature
a) Whole Blood 0 1 2 3 4 8 14 days
26.7 13.1 17.5 26.3 51.2 - 3.9
27.6 17.5 26.7 24.1 17.1 17.5 9.6
33.3 21.5 29.3 28.0 23.6 17.5 0
32.0 17.1 25.8 21.9 9.2 15.3 1.3
37.7 30.7 20.1 25.4 27.6 16.2 0
28.4 22.8 19.2 23.2 14.0 23.2 4.4
mean 31.0 20.5 23.1 24.8 23.8 17.9 3.2
+ SEM
"tajB
1.7 2.5 2.0 0.9 6.1 1.3 1.5
b) PEP 6.6 1.8 4.4 1.9 1.8 2.6 0.8
5.7 2.2 3.5 1.8 1.3 3.1 1.1
0 0.9 0 0 0 7.9 0
0 0 4.8 0 0 0 0
0 0 4.8 2.6 1.3 0 0
0.9 0 0 2.2 •0 0 0
mean 2.2 0.8 2.9 , 1.4 0.7 2.3 0.3
+ SEN 1.3 0.4 0.9 0.5 0.3 1.3 0.2
c) Intracellular Level (calculated)
28.8 19.7 20.2 23.4 23.1 15.6 2.9
ATP Concentration x 104 pg.L
1ATP concentration x 10 jjg.L4
Figure 24 CALCULATED CHANGES IN INTRACELLULAR ATP CONCENTRATIONS 
DURING BLOOD STORAGE
readings from 1 to 8 days at 1 °C, 4°C and roan temperature showed 
a similar pattern of change for ATP concentrations in whole blood 
and calculated intracellular levels. There was no significant dif­
ference in the changes in ATP concentration between any of the 
storage temperatures. There was an apparent, though statistically 
insignificant increase in blood ATP concentrations from 1 day to 
2 days, and from 2 days to 3 days, increasing to a mean of about 
24 mg.dl”1 at all three storage temperatures. However, the increase 
in concentration from 1 day to 3 days was significant (p^0.05).
The whole blood ATP concentration gradually decreased after 3 days 
blood storage at 1°C and particularly at room temperature. The 
decrease at 4°C was less apparent until after 8 days blood storage 
when the decrease in the blood ATP concentrations was significant 
(p^ 0.05) at both 4°C and room temperature.
5.3.3 A DISCUSSION OF THE CHANGES IN ATP CONCENTRATIONS DURING 
BLOOD STORAGE, AND A COMPARISON WITH THE CHANGES IN ADP 
CONCENTRATIONS.
It is known that, during blood storage at 4°C, red cell 
organic phosphates, namely ATP and 2,3 DPG become depleted (Mollison,
1972). In a recent study, the ATP concentrations in erythrocytes 
have been measured during blood storage in CPD at 4°C, and were rep­
orted to show a "gradual decline during storage" when measured 
after 1 day, 3 days, 7 days and 14 days (Mishler et al., 1978). In 
fact, a closer examination of the reported mean ATP concentrations 
shows a marked decrease between the "pre-donation" and the 1 day 
concentration, and a small increase in erythrocyte ATP concentration
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between 1 day and 3 days blood storage. The results reported here 
show a very narked decrease in whole blood and intracellular ATP 
concentrations during the first 24 hours of storage and a significant 
increase in concentration between 1 day and 3 days blood storage 
at all three storage temperatures. Does this suggest measurable 
activity in blood cells other than erythrocytes? Erythrocytes 
require energy to maintain structure, shape and membrane functions, 
and this energy is usually furnished by ATP produced fran glycolysis 
(Sasakawa and Tokunaga, 1976). Although erythrocytes are directly 
permeable to the dextrose in the CPD anticoagulant, glycolysis would 
be very much reduced in the cold and hence existing ATP might well 
be rapidly depleted. Platelets are also metabolically very active, 
even in their resting state. One process that constantly consumes 
ATP in the resting platelet is the rapid utilisation of ATP by 
actin to keep this molecule in the G-form (Holmsen, 1977a).
Platelet aggregation has been shown to occur very rapidly in blood 
stored in the cold (chapter three) and although this aggregation 
has been described by Kattlove and Alexander (1971) as "spontaneous", 
the use of metabolic inhibitors such as potassium cyanide, consid­
erably reduced cold induced platelet aggregation in PRP. Not only 
aggregation, but even the very early phases in platelet function - 
shape change and pseudqpod formation - involve the activation and/or 
relaxation of a contractile mechanism. It is well known that in
platelet function, energy metabolism and the content of metabolically
\
active ATP play an important role (Schneider, 1974). It is, there­
fore, likely that the ATP content of platelets would also be rapidly 
depleted. During blood storage in ACD at 4°C, it has been shown 
that polymorphonuclear neutrophils remain functionally active for
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between 1 day and 4 days, and lynphocytes for much longer (McCullough 
et al., 1969). It is therefore likely that energy would be required 
by these cells to maintain functional activity.
Nevertheless, the significantly larger decrease in the con­
centration of intracellular ATP at 24 hours blood storage at 1°C 
(Figure 24) where platelet aggregation was very rapid suggests 
that at least a part of the decrease was due to platelet activity. 
However, White (1974) has suggested that pseudopod extension and 
‘ platelet shape change (i.e. primary aggregation) in cold activated 
platelets are passive phenomena resembling relaxation, while the 
internal transformations caused by other aggregating agents are 
probably active processes similar to contraction. Thus ATP may 
not be involved in this stage of aggregation which precedes the plate­
let release reaction. The results in this study have shown that plate­
let release probably does not occur concomitantly with the rapidly 
increased SFP after 24 hours blood storage at 1°C. Plasma ADP,
(Table 8b) plasma ATP (Table 15b) and plasma 5-HT (Table 7) all 
showed a mean decrease in concentration after 24 hours, and Kattlove 
and Alexander (1971) demonstrated that at low temperatures, plate­
lets in PRP become sticky and aggregate spontaneously, without 
releasing endogenous stores of ADP. But if this is the case, then 
why did the concentration of intracellular ATP decrease significantly 
more in blood stored at 1°C than in blood at 4°C2
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There is no evidence that erythrocyte or leucocyte ATP con­
sumption should be greater in blood stored at 1°C. Also, the increase 
in intracellular ATP concentration mainly between 2 days and 3 
days blood storage is very much greater in the results reported 
here than the erythrocyte ATP concentrations in Mishler et al.'s 
(1978) study. Because of the uncertainty it is worth speculating that 
sane of the changes in ATP concentration measured during the early 
stages of blood storage were due to platelet activity. The reason 
for the consumption of energy during the first 24 hours of blood 
storage probably depended upon the storage temperature. In the cold, 
platelet aggregation may have been a major energy consumer, and this 
would have been most apparent at 1°C where platelet aggregation was 
very rapid when corpared with aggregation at 4°C. At room temperature, 
where no platelet aggregation occurred, the maintenance of cell 
function might have accounted for the decrease in ATP. The decrease 
in the intracellular ATP concentration was similar in blood stored for 
24 hours at 4°C and room temperature, and an alternative explan­
ation for the decrease in ATP concentration could be as follows. 
Platelets in stored blood were exposed to the same aggregating 
stimulus regardless of tenperature, but that aggregation at roam 
terrperature was inhibited. The main degradation products of ADP are
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AMP, adenosine, inosine, inosine monophosphate and hypoxanthine.
Both AMP and adenosine are powerful inhibitors of ADP induced 
platelet aggregation (Born and Cross, 1963; Born, 1967), possibly 
by activation of platelet adenyl cyclase with resultant c.AMP 
mediated inhibition (Haslam and Lynham, 1973). If a stimulus other 
than cold were involved in the initiation of platelet aggregation in 
stored blood, then, as a consequence of ATP consumption, the above 
products would be formed very quickly at room tenperature and might 
inhibit aggregation. However, it seems unlikely that ATP consumption 
at room temperature was due to platelet stimulation, as energy 
consumption for platelet aggregation would have occurred during the 
aggregation process itself, and not just as a result of the presence 
of an aggregating agent. There was no evidence for platelet aggreg­
ation, as measured by the SFP technique, in blood stored at roan 
tenperature (Table 5c, chapter three), though it is possible that 
any aggregation which took place within the first 24 hours was 
reversed by the increasing presence of aggregation inhibitors before 
the 24 hour SFP measurement was taken. This possibility was not 
investigated, but would not explain why ATP consumption during the 
first 24 hours in blood stored at 1°C was significantly greater than 
ATP consumption at 4°C and room temperature (Figure 23).
The decrease in the concentration of intracellular ATP in 
blood stored at 1°C for 24 hours appeared to be associated with an 
increased intracellular ADP concentration. However, the increase 
in intracellular ADP concentrations apparent at 1°C was very much 
less obvious at 4°C and was decreased at room temperature. This 
may, in part, have been due to different ADP degradation rates, 
dependent upon tenperature, and, particularly at room temperature,
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rephosphorylation of ADP to ATP during glycolysis.
When the comparative concentrations are considered, it is 
evident how much degradation of ADP took place. The concentrations 
of ATP were measured in units ten times those of ADP, and hence 
a relatively small fall in ATP concentrations might have been expec­
ted to produce a relatively large increase in intracellular ADP.
This did not occur at any of the three storage temperatures. It 
may be explained at 1°C and 4°C by the observation that so called 
"release energy" ATP may have both of its energy rich phosphoryl 
groups used during the release reaction, resulting in the eventual 
formation of ribose-1-phosphate and hypoxanthine which leave the cell 
(Holmsen et al., 1969a). However, this is thought to account 
for all the ATP consumed in the release reaction (Holmsen et al., 
1969b) and yet the intracellular ADP concentration was highest at 
1°C (Figure 18) where platelet aggregation had occurred most 
rapidly. This suggests that the platelet release reaction did not 
take place during the first 24 hours of blood storage in the cold.
As mentioned earlier, this possibility is endorsed by the other par­
ameters that were measured, as the release reaction might have been 
expected to cause a concomitant increase in the plasma concentration 
of ADP, ATP and 5-HT after 24 hours blood storage in the cold.
(Plasma catecholamines were not measured at 24 hours). The plasma 
concentration of these three factors decreased during the first 
24 hours, and only showed an increase in concentration at 48 hours 
storage. It is not likely that these increases were due to the 
release reaction because they occurred to a greater or lesser extent
f
at all three storage temperatures and were not paralleled by a furt­
her decrease in the intracellular ATP concentration. This might have
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been expected since the release reaction is an energy dependent 
process (Holmsen et al., 1969a, b). In fact, the intracellular 
ATP concentration showed an apparent increase between 24 and 72 hours 
blood storage at all three temperatures. It is possible that the 
platelet release reaction, per sq, took place gradually and was not 
recognised as a distinct event by 24 hour monitoring.
The increase in plasma ADP concentrations after 48 hours blood 
storage seemed to follow the utilisation of ATP during the first 
24 hours. Although the increase in the concentration of plasma 
ADP was similar at all three storage temperatures, it is likely that 
this was apparent and not real. There was considerable variation 
in the results between individuals and ADP degrades more quickly 
in plasma at room temperature than in the cold. It was possible 
that the source of plasma ADP varied at different storage temperatures. 
At roan temperature possibly the main source was from metabolic 
energy demands in blood cells. At 1°C, ADP released from erythro­
cytes may have contributed, and plasma ADP concentrations at 1°C and 
4°C would probably have been contributed to by platelet destruction, 
the platelet release reaction, and ADP from ATP utilisation in 
primary aggregation. Some ADP released from platelets and erythro­
cytes in blood stored in the cold may also have been bound to plate­
lets and measured as intracellular ADP.
The increase in intracellular ATP concentrations observed 
particularly between 2 and 3 days blood storage were similar at 
all three storage temperatures. Platelets are known to be very 
sensitive to changes in adenine nucleotide levels so that reduced 
ADP or ATP concentrations results in increased phosphorylase activity 
and hence glycogenolysis (Mustard and Packham, 1970). This may
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have caused the increase in intracellular ATP concentrations.
Although the electron micrographs seemed to show that the majority 
of platelets were morphologically intact during the early stages 
of blood storage in the cold (Figures 12 to 15, chapter four), 
platelet viability is thought to be much reduced after 24 to 48 
hours storage at 4°C (Lim et al., 1973). Therefore, increased ATP 
concentrations after 48 hours blood storage in the cold were unexp­
ected, particularly as they appeared to be similar to the increases 
observed at room temperture. However, Estes et al., (1962) recorded 
continued glycolysis in platelets stored for considerably longer 
than 48 hours at 4°C even though viability (as measured by the 
platelets life in the circulation, after reinfusion) was much 
reduced. The differences in the intracellular ADP concentrations 
between 24 and 96 hours in blood stored at the different temperatures 
might have been due to the use of this increased ATP. At 1°C, 
with a much reduced normal cellular metabolism, and with already 
extensive platelet aggregation, there would have been little demand 
for energy. Hence, the decrease in the intracellular ADP concen­
tration (Figure 18). Whereas at room temperature with nearer normal 
blood cell functions to maintain, there would have been a greater 
demand for energy with a resultant increase in the intracellular ADP 
concentration. At 4°C, the cellular metabolic requirements would 
have been much reduced but platelet aggregation was still taking 
place and hence the ccnparatively small change in the ADP concen­
tration. Therefore, the similarity in intracellular ATP concentration 
increases at 3 days blood storage at the three storage temperatures 
might only have been apparent. Had no ATP been consumed, then ATP 
production might well have been seen as a considerably higher
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concentration at room temperature than in the cold.
The intracellular ATP concentration decreased after 3 days 
blood storage at 1°C and at 4°C, and after 4 days at room temperature. 
This decrease is in accord with other recent reported studies, 
(Sasakawa and Tokunaga, 1976; Mishler et al., 1978). The decline 
in ATP is associated with parallel alterations of red cell deform- 
ability in blood stored at 4°C with disc to sphere transformation 
as the cells become more rigid (Haradin et al., 1969). The rate of 
decrease was particularly rapid at room temperature and probably 
accounted for the rapid increase in the intracellular ADP concent­
ration between 3 and 8 days blood storage followed by the rise in 
the plasna ADP concentration between 8 and 14 days storage. However, 
the decrease in the intracellular ATP concentration at room temp­
erature may have been largely contributed to by the rapidly decreasing 
pH observed in blood stored at room temperature (Figure 9, chapter 
three). This decreased pH would have interfered with the function 
of glycolytic enzymes and quickly halt glycolysis. At all three 
storage temperatures, the decrease in intracellular ATP concentrations 
after 3 or 4 days storage was associated with an increase in the 
plasma ATP concentration at 8 days storage. This was most apparent 
at 1°C and probably paralleled reduced cell viability. However, 
the increased intracellular ADP concentration at 8 days blood storage 
at 1°C suggested either continued ATP consumption or degradation.
It was not clear why the changes in ADP and ATP concentrations in 
blood stored at 4°C were less pronounced than those at 1°C or room 
temperature. At 4°C there was an apparent very slow decrease in the 
concentration of intracellular ATP up to 8 days blood storage with 
a concomitant small increase in the intracellular ADP concentration.
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After 8 days blood storage, the intracellular ATP concentration 
began to decrease more rapidly. It seems that the changes seen at 
1°C and room temperature were delayed in blood stored at 4°C.
Only an extensive investigation probably involving the separ­
ation and storage of individual blood cell types would make clear 
what contribution blood platelets make to overall ADP and ATP 
concentration changes. It is not possible from the investigations 
undertaken in this study to state whether platelet aggregation in 
cold stored blood is an energy dependent process, though the evid­
ence seems to favour this possibility. However, it does seem that 
platelet aggregation in blood stored at 1°C and 4°C did not depend 
on the platelet release reaction.
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CHAPTER SIX
THE MEASUREMENT OF THE OVERALL EFFICIENCY OF THE 
INTRINSIC AND EXTRINSIC BLOOD CLOTTING SYSTEMS
6.1 THE BLOOD COAGULATION PATHWAYS
The following introduction is not intended as a comprehensive 
review of the blood coagulation sequence as it is understood today, 
but as a brief revision of the relationships of the various coagu­
lation factors as described by Bennett and Ratnoff (1972). The 
extrinsic clotting system is basically the mechanism responsible for 
the clotting of plasma when it is mixed with tissue extract (throm­
boplastin) and calcium. It is likely that the extrinsic system 
provides the first traces of thrombin necessary for the initiation 
of vascular repair, for unlike the intrinsic system, the reaction is 
complete in a few seconds. The nature of the tissue factor is unknown, 
perhaps being some lipoprotein complex. The triggering mechanism 
responsible for intrinsic prothrombin activation probably involves 
the activation of factor XII by negatively charged surfaces with a 
particular spatial arrangement of charges. The intrinsic pathway 
is so named to contrast with the extrinsic as no material extrinsic to 
the blood is known to be involved. The two systems are only different 
up to the formation of activated factor X (Xa)
The sequence of reactions culminating in the production of fibrin 
has interested many workers though two hypotheses are favoured. One 
is the "autocatalytic theory" (Seegers et al.. 1967 - cited Garner,
1973) and the other is known as the "sequential theory" (Macfarlane
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1964 - cited Garner, 1973). The essential difference between the 
theories concerns the interpretation of the nature of prothrombin 
(factor II). In the autocatalytic theory, prothrombin is regarded 
as a single complex molecule composed of several sub-units which 
are liberated by traces of thrombin (produced as the result of a 
chemical change of the parent molecule occurring after contact with a 
foreign surface). Other specialised proteins and phospholipids present 
in the plasma, or derived from platelets, accelerate the reaction.
The sequential theory regards prothrombin as a single protein, a 
pro-enzyme, with only one product, thrombin. The other clotting 
factors are distinct entities present as inactive precursors. Each 
factor is activated by the preceding one in a chain of events that 
ultimately leads to the production of thrcmbin.
Neither theory is thought to provide a completely satisfactory 
explanation and a modification was suggested, which regarded the 
different stages of the coagulation pathway as active complexes.
(Mammen, 1971 - cited Garner, 1973). There have been other modific­
ations, such as the possible activation of factor IX by factor VII 
(Di Scipio et al., 1978). However, the general concept, as detailed, 
is still acceptable (Figure 25).
6.2 PLATELET AGGREGATION AND BLOOD COAGULATION
Platelet activation and aggregation by ADP and collagen have 
been shown to result in activation of factor XII in the intrinsic 
coagulation pathway (Walsh, 1973). The interaction of platelets 
with ADP also leads to activation of PF3 which functions in the 
interaction of coagulation factors Xa and V. Thus by activating
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factor XII, ADP initiates coagulation and this reaction can proceed 
to completion through interaction between PF3 and the intermediate 
clotting factors which are adsorbed onto the platelet membrane (Ardlie 
and Han, 1974). Thrombin may therefore, be generated in association 
with platelet aggregates and can cause release of platelet constitu­
ents (Holmsen et al., 1969a). It has been suggested that blood 
coagulation and platelet aggregation are inseparable phenomena (Ardlie 
and Han, 1974) and therefore, tests of coagulation have been performed 
to see if there were an increased tendency of anticoagulated blood to 
clot in association with platelet aggregate formation. In the pres­
ence of CPD anticoagulant, it seemed unlikely that sufficient calcium 
ions would be available for blood coagulation and this was shown by 
Born and Cross (1963), who found that ADP added to citrated PRP did 
not lead to blood clotting. However, during blood storage, a reduced 
pH may alter binding affinities and allow the release of small amounts 
of ionised calcium (Limbird and Silver, 1974) and there is a rapid 
release of calcium ions during the platelet release reaction (see 
Chapter 1). Therefore, sufficient calcium for coagulation may become 
available during blood storage and blood clots have been observed in 
dogs' venous blood stored in ACD for 7 days at 4°C (Wright, 1975). 
Fibrin, the end product of blood coagulation, is considered important 
for stabilising platelet aggregates (Mustard et al., 1966) and has been 
observed in stored blood after about 10 days storage (Arrington and 
McNamara, 1974).
The two basic methods that measure the overall efficiency of the 
intrinsic and extrinsic blood coagulation pathways are the kaolin 
partial thromboplastin time and the prothrcmbin time, respectively.
Both of these test times are prolonged during the storage of CPD
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anticoagulated blood at 4°C (Limbird and Silver. 1974; Mishler et 
al., 1978) which may be interpreted as either activation of the 
coagulation cascades or as reduced efficiency of the coagulation fac­
tors. The tests were repeated in this investigation so as to compare 
any changes in the coagulation test times with platelet aggregation 
at 1°C, 4°C and rocm temperature.
6.3 METHODS
The efficiency of the extrinsic clotting system was measured 
using the one stage prothrombin time test described by Hardisty and 
Ingram (1965). In this test, the time taken to clot is measured after 
addition of 0.025M calcium chloride to a mixture of the test anti­
coagulated plasma with rabbit brain thromboplastin (Diagen diagnostics) 
at 37°C. The normal range for fresh plasma is 12 - 17 seconds.
The efficiency of the intrinsic clotting system was measured 
using a development of the partial thromboplastin time, recalcifi­
cation time and whole blood clotting time tests, known as the kaolin 
cephalin clotting time. In this test, platelet activity is standard­
ised by the use of a platelet substitute, and contact activation of 
factors XI and XII is standardised by preincubation of the plasma and 
platelet substitute mixture with a suspension of kaolin for a standard 
time before recalcification. The method used was as described by 
Dacie and Lewis (1975) in which the clotting time was measured on 
the addition of calcium chloride, two minutes after mixing kaolin/ 
platelet substitute (Diagen diagnostics) with the test plasma and 
incubated at 37°C. The normal time for fresh plasma is within the 
range of 40 to 55 seconds.
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In both tests, plasma samples were assayed in duplicate after 
testing the procedures with "normal" plasmas (Diagen diagnostics) 
standardised to give control times of 12 to 14 seconds for the pro­
thrombin time, and 40 to 45 seconds for the kaolin cephalin clotting 
time. The duplicates never varied by more than 2 seconds for the 
prothrombin time and 5 seconds for the kaolin cephalin clotting time.
6.4 RESULTS
Both of the blood coagulation tests were undertaken at 0, 2, 4,
8 and 14 days of storage. Prothrombin times on plasma sanples pre­
pared immediately after blood collection were sometimes higher than the 
extreme of the normal range. The reason for this is not known, though 
longer times were observed in plasma from blood samples with the lower 
platelet counts. Prothrombin times after blood collection had a mean 
of 15.6 + (SEM) 0.76 seconds, and a range of 12 seconds to 19.5 seconds 
(n = 10). Plasma prothrombin times generally increased during blood 
storage at all three tenperatures (Table 18). This was only statis­
tically significant between the times recorded at blood collection and 
at 2 days storage (Students paired 't* test, p-C-0.05), the times 
increasing from a mean of 16 seconds to 19 seconds at 1°C and at 4°C, 
and to 18 seconds at room temperature. Prothrombin times continued 
to increase slowly reaching a mean of about 22 seconds at all three 
tenperatures. There was no significant difference in the prothrombin 
times between 1°C, 4°C or room temperature throughout the 14 days of 
blood storage and so no graph has been presented.
Kaolin cephalin clotting times in plasma sanples after blood 
collection all lay in the normal range with a mean of 42.5 + (SEM) 0.77 
seconds, and a range of 40 seconds to 46 seconds (n = 10), The kaolin
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TABLE 18
ONE STAGE PROTHROMBIN TIME (seconds)
Storage Time in Days Platelet Count
On Blood Collection
1°C 0 2 4 8 14 (x 109.L“1)
17.5 19.5 19.5 21 21 177
18.5 20.5 20 21.5 20 179
15 17 18 20 21.5 254
14 16 16.5 19 19 229
12 16 16.5 18 - 211
19.5 25 25.5 28 29
mean 16 19 19.5 21.5 22
+ SEM 1.2 1.4 1.3 1.4 1.7
4°C 15.5 19.5 20 20 22
14.5 17 16.5 17.5 17.5
17 19 21 19 21 142
15 17 17 19 19 245
13 17 17 17 21 218
19.5 26 27.5 29 29
mean 16 19 20 20 21.5
+ SEM 1.1 1.6 1.9 2.0 1.8
Roan 14 16 18 18.5 20.5
Temperature 16 18 20 19 23 142
18 20 22 22.5 24.5
15 16 17 18 20 245
13 15 16 17 18 218
19.5 23.5 27 28 29
mean 16 18 20 20.5 22.5
+ SEM 1.4 1.9 2.5 2.5 2.4
cephalin clotting times also increased during blood storage at all 
three temperatures (Table 19, Figure 26) though the increase during 
the first 2 days storage was only significant at 1°C and 4°C 
(p4 0.05), increasing frcmamean of 43 seconds to 54 seconds at 1°C 
and to 50 seconds at 4°C. There was no mean change at roan temperature. 
There were no further significant increases between consecutive read­
ings, the kaolin cephalin clotting times remaining at about the same 
level at 1°C and 4°C, but slowly rising to a mean of 51 seconds after 
14 days storage at room temperature. The increased time during the 
first 2 days storage was significantly higher at both 1°C and 4°C 
compared with room temperature (Students unpaired 't' test p^0.05). 
There was no significant difference between the apparently longer 
increased kaolin cephalin clotting time at 1°C with the increased 
time at 4°C. No significant differences were observed between 
changes at any temperature after 2 days storage.
6.5 DISCUSSION OF THE INCREASED CLOTTING TIMES DURING BLOOD STORAGE
The change in the blood coagulation times at 4°C compared 
favourably with the results published by Mishler et al., (1978) 
for both the prothrombin time and kaolin cephalin clotting time. The 
results published by Limbird and Silver (1974) were produced as 
percentages of the control times, but demonstrated a sharp increase 
during the first 2 days storage for kaolin cephalin clotting time.
Their results for prothrombin time showed little variation during the 
first 14 days blood storage.
The results showed that the decline in the efficiency of the 
extrinsic blood clotting system is particularly apparent during the 
first 2 days of blood storage, but with no statistical difference
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TABLE 19
KAOLIN/CEPHALIN CLOTTING TIME (seconds)
a)
b)
c)
Storage Time in Days Platelet Count
on Blood Collection
1°C 0_ _2_ 4_ jL 14 (x109.:
41.5 52.5 52.5 53 51 177
43 46.5 50 50 47 179
40 54 56 56.5 57 254
40 63 65 65 61 229
46 56.5 57 57 52 211
47 53.5 52 52 50
mean 43 54 55 55.5 53
+ SEM 1.2 2.2 2.2 2.2 2.1
4°C 43 49.5 53.5 51 51.5
42.5 54.5 55 49.5 52.5
40 45 57 48 51 142
43 50 51 52 47 245
42 47 47 50 55 218
47 55 55 54 50
mean 43 50 53 51 51
+ SEM 1.1 2.0 1.8 1.0 1.3
Room 41.5 42 43 47 , 49
Temperature 39 40 46 43 52 142
45 46.5 47 50 53.5
43 46 47 48 51 245
42 44 43 49 48 218
47 44.5 44 50 51
mean 43 44 45 48 51
+ SEM 1.6 1.3 0.9 1.5 0.9
KCCT
between the three storage temperatures. It is possible that the 
increased prothrombin time was related to activation of the extrinsic 
blood clotting system, rather than to reduced efficiency of the 
coagulated factors. This is because the increase was observed at all 
three temperatures, and occurred during the first 2 days when at least 
factor VII has been found to remain stable, even at 4°C (Limbird 
and Silver, 1974). The activation of the extrinsic system may have 
been due to released tissue thromboplastins at the needle entry site 
during blood collection. Presumably, the lack of calcium ions prev­
ented completion of the pathway as no blood clots were observed, 
and no platelet aggregation occurred at room temperature (which might 
have been expected if thrombin had been generated). Although no 
statistical difference was apparent between the storage temperatures, 
the increase in prothrombin time at room tenperature was generally 
lower during the first 2 days storage. It may be that the increased 
times in the cold were partly due to reduced efficiency of the coag­
ulation factors. As storage continued, the stability of factors VII 
and V would be reduced (Limbird and Silver, 1974), and so any continued 
increase in prothrombin time would most probably be due to decreased 
efficiency of the extrinsic coagulation pathway.
In contrast to the prothrombin time changes, the kaolin cephalin 
clotting times during the first 2 days storage showed a sharp increase 
in the cold, but virtually no change at room temperature. It is not 
known if this increase was due to reduced efficiency of the intrinsic 
coagulation pathway or to activation, as no information is available 
as to the stability of the earlier factors, such as XII and XI, during 
blood storage in the cold. During this time, the platelet count fell 
more dramatically in the cold, but this was associated with an increase
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in platelet aggregation which was very apparent at 1»c (See Chapter 
3). Platelets which are stimulated (as during aggregation), are 
known to become more effective blood clot promoting agents than 
unstimulated ones (Ehrman et al., (978). They also have multiple 
sites of action in coagulation including the enhancement of activation 
of factor IX (Walsh, 1973). factor IX is a zymogen, and its activ­
ation is thought to be its conversion to serine protease ffii Scipio 
et al., 1978). It has teen suggested that the effect of an aggregating 
agent nay be activation of a unique serine protease on the outer 
platelet membrane (toki et al., 1978), and because many coagulation 
factors are associated with the platelet membrane (See Chapter 1), 
it is possible that there is a relationship. - This supports the hypo­
thesis that platelet aggregation and bleed coagulation are interdepen- 
dent (Ardlie and Han, 1974; Akfcar and Ardlie, 1978).
The apparent levelling off of the kaolin cephalin clotting time 
after 2 to 4 days blood storage at 1°C and 4°C suggests that either 
the coagulation factors had become totally unstable during this period 
and that no further increase in time is possible, or that all the 
available factors had beccme activated in the intrinsic coagulation 
pathway. The gradual increase in kaolin cephalin clotting time at 
room temperature at which no measurable platelet aggregation occurred 
suggests a slow decline in coagulation efficiency.
Although it is probable that intrinsic blood coagulation was 
activated by platelet aggregate formation in the cold, and the extri­
nsic pathway by tissue thromboplastins, no blood clots were observed.
This suggests that any coagulation pathway activation was incomplete 
possibly due to the lack of calcium ions, despite their release from 
platelets during aggregation. Also, blood coagulation is a system
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which is delicately balanced and operates most efficient, •
cientiy m  conditions
which suit - the enzyme catalysed sequence (Seegers, 1973). This 
includes temperature which is known to influence blood coagulation 
in-vitro - the colder it is, the longer the coagulation times 
(Dreher and Sutor, 1978). Therefore, blood clot formation in 
blood stored at 1°C or 4°C is likely to be a long process.
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CHAPTER seven
a  GENERAL DISCUSSION OF THE FACTORS INVESTIGATED AND THEIR RELATION­
SHIPS WITH PLATELET AGGREGATION IN STORED BLOOD
A review of Platelets a *  platelet a c t i o n  been
Platelet aggregation occurs during the storage of Mood in the told ' 
and the aggregates have been implicated in ^  of
distress syndrome following massive blood transfusions. ^  sut/  ^
stances have been shown to be able to aggregate blood platelets in-
vitro and in-vivo, but this investigation has examined «  of J ,
factors that were thought nest litely to ln£luence plateJet ^
during blood collection and storage. Although cold per se .
se' *s known to
be a potential platelet aggregate agent, the investigation was begun 
at * . t  « ■  thought to be a storage M a t u r e  of 4»c, because this 
is considered to be the mist suitable temperature for the long tern
storage of blood by the Blood Transfusion Service. .
Platelet aggregation
was measured in blood samples by the SFP technique art ,•*-
^ ' aiKJ ic was sub-
sequently observed that a considerable differen-e in the r i
*-ne rate and extent
of platelet aggregation occurred, which depended upon the storage t 
erature. At rc. platelet aggregation ras observed to te very r a p ^  
whilst at 4«C only a gradual increase in the »  ras generally 
and this varied frcm donor to donor, a  similar difference bet W en 
7»c and 4°C ms  observed in the fall m  platelet counts »
counts. No measurable
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platelet aggregation occurred at ambient room temperature (14°C to 
21°C).
It was thought that a comparison of the concentrations of the 
measured parameters at the three storage temperatures might indicate 
their possible roles in platelet aggregation during blood storage.
For logistical reasons and because several experiments had been carried 
out at 1°C, it was not possible to make all the comparisons between 
the three temperatures in any one experiment. Several experiments 
were performed in which a factor was measured at two of the storage 
temperatures, and several other experiments in which the same factor 
was measured at the remaining temperature. Because of the variation 
in the results between individual donors, it was not possible to 
compare the absolute results and so it was the change between con­
secutive mean results that were compared between the storage tempera­
tures. It was considered that a minimum of six experiments would be 
adequate to permit comparisons on a relative basis between the means of 
the results. The changes at ary one temperature for any one measured 
parameter were analysed for statistical significance using the Students 
paired 't' test.
It should be noted, however, that by using a small sample pop­
ulation, data for only one individual donor needed to show a 
different pattern to data from the other donors to make ary mean inc­
rease or decrease insignificant. For several parameters, there were 
more results at one temperature than another and also, mainly in 
earlier experiments, some measurements were not made as frequently 
as in later ones. As a consequence, the comparison of changes between 
temperatures was made using the Students unpaired 't' test. For both
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types of statistical analysis/ significance was assumed at the 5% 
probability level.
Parametric tests assume that the samples are random and are normally 
distributed. The central limit theorem was applied to test for normal 
distribution in each set of data. In this test, the mean of each 
set of data was subtracted from each result in turn and divided by 
the standard deviation for the set. 95% of the answers should be within 
+ 1.96 if the distribution is normal. Application of the test showed 
that the sets of data were normally distributed.
The parameters examined in this thesis and their relationships 
with platelet aggregation have been discussed in each chapter. The 
following serves as a summary of the more important observations and 
comparison between the parameters.
Plasma adrenaline and noradrenaline concentrations were measured 
in blood sanples taken at the beginning and end of routine collections 
of 450 ml of blood. The concentrations were found to vary considerably 
between individuals, but the noradrenaline concentration was often 
higher at the end of blood donation than at the beginning. The results 
showed that the collection procedure and the blood volume reduction 
had little effect on the concentrations of catecholamines in peripheral 
venous blood, and the absolute values were well below those required 
for the potentiation of platelet aggregation in-vitro by ADP. It is 
possible that a more sensitive method for the measurement of plasma 
catecholamines might have shown greater differences in the concentrations 
of noradrenaline and adrenaline at the beginning and end of blood 
collection. Recently, a kit has been made available in the U.S.A. 
with a sensitivity for plasma adrenaline down to 1 pg.ml-^
(Upjohn), and a gas chromatography/mass spectrometry assay gave a
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sensitivity limit of 2 pg.ml”  ^ for all three catecholamines (Ehrhardt 
and Schwartz, 1978). However, the latter assay gave plasma catechol­
amine concentrations in supine healthy volunteers which were very 
similar to the concentrations recorded at the beginning of blood 
collection in this thesis. The volunteers in this study all had 
normal blood pressures, but a future study could concentrate on 
hypertensive volunteers, who usually have an associated raised 
plasma catecholamine concentrations (Lancet, 1977b), to see if there 
were any increase in the rate of platelet aggregation in stored blood. 
Total plasma catecholamine concentrations were measured at intervals 
during blood storage. An increase in the concentrations was observed 
at all three tenperatures but was most apparent at 1°C and least so 
at roan tenperature. It is not known to what extent the difference 
in concentration between tenperatures was due to catecholamine deg­
radation. Although catecholamines are not thought to be rapidly 
degraded in plasma or taken up into erythrocytes (see Chapter Two), 
it is probable that these would occur more readily at roan tenperature 
than in the cold. It seems unlikely that the difference in catechol­
amine concentration between the tenperatures was entirely due to dif­
ferent degradation rates. It is more probable that the differences 
were due to the extent of platelet release or degradation. However, 
the catecholamine concentrations in plasma during 8 days of blood 
storage were below those that have been shewn to influence platelet 
aggregation in-vitro.
In contrast to the plasma catecholamine concentrations, which 
continued to increase during blood storage, the measurement of plasma 
5-HT shewed an alternating increase and decrease in concentration 
during the first 4 days of blood storage, followed,generally, by a
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gradual decrease. Once again, the change in plasma 5-HT concentration 
was most apparent at 1°C, though there was little apparent difference 
between the changes at 4°C and room temperature. The possible reasons 
for the fluctuating plasma 5-HT concentrations have been discussed 
(Chapter Four). The measured concentrations of plasma 5-HT were 
below those that have been shown to influence platelet aggregation.
It seems that the measurement of plasma 5-HT was not suitable for 
monitoring platelet release and/or degradation, because of the alternate 
increase and decrease in concentration. The measurement of plasma 
catecholamine concentrations appeared to be more suitable for monitoring 
platelet release, but the inclusion of another parameter might have 
been useful. The concentration of a lysosomal enzyme such as acid 
phosphatase has been used as a marker of platelet destruction in stored 
blood (Polasek and Kubisz, 1968), though it may be released from 
other cell types. A platelet specific protein, such as/$-thrcmbo- 
globulin has been suggested as being a suitable marker for the platelet 
release reaction (Ludlam et al., 1975; Pepper, 1977). A radio­
immunoassay kit is now available for the measurement of plasma 
/3-thrcmboglobulin concentrations (Radiochemical Centre, Amersham) and 
could be included in future investigations.
ADP is known to be a potent platelet aggregating agent and like 
catecholamines and 5-HT, is stored in platelets and released during 
the platelet release reaction (see Chapter One). It is also thought 
that ADP released from platelets may be the mediator of platelet 
second phase aggregation by several aggregating agents. A possible 
exception is the aggregating effect of cold (see Chapter Three).
However, because o f  the probable iirportance o f  released  ADP in  p la t e le t
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aggregation, particular attention was paid to its possible role in 
platelet aggregation during blood storage. ADP concentrations were 
measured both in plasma and in whole blood and the cellular concent­
ration calculated from these results. The mean plasma ADP concentration 
showed a decrease after 24 hours storage which was most apparent at 
room temperature and least so at 1°C. This was probably due to the 
rate of degradation in plasma which was found to be rapid, particularly 
at room temperature. This decrease in plasma ADP concentration was 
similar to that of plasma 5-HT. The plasma catecholamine concentration 
was not measured after 24 hours so it is not known how this varied 
during the storage period. The SEP had reached its measurable maximum 
of 600 mmHg after 24 hours blood storage at 1°C, and was often well 
above the normal range at 4°C. Because of the decrease in plasma 5-HT 
and ADP concentrations, this suggests that platelet release is not 
involved in the early stage of platelet aggregation in stored blood, 
an observation supported by Kattlove and Alexander (1971). It was 
possible that, if released, seme of the ADP and 5-HT may have been 
bound to the platelet membranes and would, therefore, not have been 
measured in the plasma fraction. Hcwever, it is unlikely to have 
accounted for all released ADP and 5-HT, and had the release reaction 
occurred conccmitant with the rapid increase in SFP at 1°C after 24 
hours storage, then a nett increase in plasma 5-HT and ADP concen­
trations might have been expected.
Calculation of the mean cellular ATP concentration showed a 
narked decrease after 24 hours blood storage at all three temperatures, 
but particularly at 1°C. Since at this temperature, the SFP increased 
most rapidly, then as proposed in Chapter Five, it seems probable that 
a part of the energy consumed during the first 24 hours blood storage
- 159 -
in the cold was for platelet aggregation. If the energy requiring 
release reaction was not involved during the first 24 hours of blood 
storage, then energy may have been utilised in platelet contractile 
processes during primary aggregation. This occurs before the release 
reaction and secondary aggregation (see Chapter One). Primary platelet 
aggregation is thought to consist of the formation of reversible, 
loosely bound aggregates, and the electron micrographs of 24 hour old 
blood sanples showed these, (Figures 12 and 13, Chapter Four), though 
the reversibility was not obvious from the SFP results. However, some 
preliminary experiments were carried out adding chlorprcmazine in a 
final concentration of 2.8 x 10~^M after 24 hours blood storage. At 
1°C, no reversal in SFP measurements was observed, although because 
600 irniHg was the measurable maximum, it is not known what might 
have occurred if a higher pressure had been measurable. At 4°C 
platelet aggregation was sometimes partly reversed, even after 48 hours 
blood storage (Table 20). Nevertheless, these results do not suggest 
that platelet aggregation in the first 24 hours of blood storage was 
spontaneously reversible. Further evidence for the release reaction 
occurring after the onset of aggregation during blood storage was 
shown with the mean plasma 5-HT, catecholamine and ADP concentations 
being increased after 48 hours storage particularly at 1°C. Since 
5-HT and catecholamines are carried mainly in platelets, it suggests 
that their increased concentration in plasma was due to either the 
platelet release reaction or platelet degradation. However, the contin­
ued increase in plasma catecholamine concentrations up to 4 days blood 
storage and the second increase in plasma 5-HT concentrations at 4 days, 
suggest that the platelet contents were released as a consequence of 
general degradation later than 2 days. Inhibition of ADP using apyrase
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TABLE 20
THE CHANGE IN SEP UPON ADDITION OF CHLORPROMAZINE AT 2.8 
TO BLOOD AFTER 48 HOURS STORAGE AT 4°C
0 1 2 3 4 8 14
26 120 190 90 85 65 40
50 65 112 70 108 205 600
48 140 180 105 145 200 530
42 133 600 600 600 600 600
52 67 345 600 600 600 600
x 10-4 M
(days)
(50 pg.ml- )^ reduced the rate of platelet aggregation in stored blood 
at 1°C, but appeared to have no effect on blood stored at 4°C. This 
suggested that ADP did play a role in platelet aggregation at 1°C.
It had been suggested that ADP released from erythrocytes may be 
important for platelet aggregation in blood in-vivo (Born et al., 1976) 
and this possibility was examined using chlorprcnazine at 2.8 x 10~5M. 
This concentration is thought to diminish or prevent ADP leakage 
from erythrocytes and was found to reduce the rate of platelet 
aggregation at 1°C but not at 4°C. It seems, therefore, that the onset 
of platelet aggregation in blood stored in the cold takes place without 
the mediation of platelet released ADP, 5-HT or catecholamines.
Platelet aggregation at 1°C may occur more rapidly than at 4°C, 
because of ADP released from erythrocytes. The measurement of 
plasma haemoglobin concentrations during blood storage showed a 
marked increase at 1°C compared with blood stored at 4°C. This 
observation added weight to the probable involvement of erythrocytes 
in platelet aggregation at 1°C.
It was observed that particularly with plasma 5-HT concentrations, 
and to a lesser extent plasna catecholamines and plasma ADP concen­
trations, that platelet release at room temperature shewed a similar 
pattern to that in the cold. It might, therefore, have been expected 
that platelet aggregation would have occurred, albeit relatively 
slcwly, in blood stored at ambient room temperature. Although platel­
et aggregation at rocm temperature has been observed by other workers 
(Solis et al., 1975b) no platelet aggregation was measured at rocm 
temperature in this project using the SFP technique (Chapter Three).
It therefore suggests that either the aggregating stimulus was not
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present, or that aggregation was inhibited at rocm temperature. ADP 
is very rapidly degraded at roan tenperature and Born and Cross 
(1963) have shewn that the products of ADP catabolism, adenosine and 
AMP, are potent inhibitors of platelet aggregation. Also, the pH of 
blood stored at roan tenperature decreased rapidly corpared with 
blood stored in the cold. A reduced pH is associated with a reduced 
ability of platelets to aggregate. However, though the products of ADP 
catabolism and the reduced pH would probably have reduced platelet 
aggregation in blood stored at roan tenperature, the apparent lack 
of aggregation early in blood storage suggests that at rocm tenperature, 
the initial aggregation stimulus was not present.
In an ejqoeriment with dog's blood, stored at 4°C, Wright (1975) 
showed that platelet aggregation was less marked in arterial blood 
than in venous blood. In another experiment, Wright (unpublished data) 
compared platelet aggregation in human arterial and venous blood 
sauples. In this study, arterial blood was collected from the ante- 
cubital vein after the arterio-venous shunts in the forearm had been 
opened during submersion of the arm in hot water (45°C). In three 
volunteers, only one showed a marked difference between venous and 
arterial blood samples stored for 7 days at 4°C. The author wished 
to continue these studies but had difficulty in finding volunteers. 
However, two experiments were carried out in which arterial blood 
(450 ml) was collected from the radial artery in the wrist. In both 
experiments, similar SFP results were obtained as had been observed in 
venous blood from other blood donors at all three storage tenperatures 
(Table 21a). It seems that in man, there is no advantage in collecting 
arterial blood so far as platelet aggregation is concerned, though in
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TABLE 21
TOE CHANGE IN SFP AND THE PLASMA CATECHOLAMINE 
CONCENTRATION DURING THE STORAGE OF ARTERIAL BLOOD
a) SFP (mra/Hg) _0_ _2_ _3_ _8_ 14 (days)
1°C 50 600
45 600
4°C 50 35 55 75 110 360 600
45 68 420 600 600 600 600
Rocm Temper- 50 50 62 55 48 42 44
ature
53 55 50 45 46 46“ 45
b) Plasma Catecholamines (pg.ml- )^
0 2 4 8 (days)
1°C 405 357 479 805
395 1133 1133 1776
mean 400 745 806 1291
4°C 405 307 415 641
395 656 854 1277
mean 400 482 635 959
Room Temperature 405 391 429 824
395 363 570 1134
400 377 470 979mean
view of the observations made with dog's blood, this may require 
further evaluation. It is interesting that the plasma catecholamine 
concentrations measured in both packs irrmediately after arterial blood 
collection seemed to be higher than the catecholamine concentrations 
in the majority of venous blood samples. However, there were similar 
increases in the plasma catecholamine concentration during arterial 
blood storage at 1°C, 4°C and room terrperature as in venous blood 
(Table 21b [cf. Table 3, Chapter Two]).
The two basic blood coagulation tests for the intrinsic and 
extrinsic pathways were measured during blood storage. There was no 
apparent difference in the increased prothrombin times (extrinsic) 
between any of the three storage teirperatures. However, the rapid 
increase in the kaolin-cephalin clotting time in the cold, particularly 
at 1°C, suggested a possible involvement of the intrinsic coagulation 
pathway in platelet aggregation during blood storage. It is unlikely, 
though, that during the early stages of blood storage in the cold, that 
the enzyme activated blood coagulation cascade would influence the ext­
ent of platelet aggregation. If the increased clotting time were due 
to factor activation rather than reduced efficiency, it is possible 
that only an early factor (perhaps factor XII) was activated so that 
subsequent measurement showed a longer clotting time. It is thought 
that fibrin may be involved in later stages of platelet aggregation in 
stored blood (Chapter Six). Disintegrating platelets may possibly 
be involved at this stage, by releasing polyunsaturated fatty acids 
which may become peroxidized (Gutteridge and Stocks, 1976). Per- 
oxidized polyunsaturated fatty acids have been shewn to have a marked 
effect on thrombin production in-vitro (Barrcwcliff et al., 1975).
- 163 -
The evidence from the parameters measured in this investigation 
has shown that platelet aggregation during blood storage is induced 
in the cold and that blood storage at room temperature would be more 
suitable to reduce or prevent platelet aggregate formation. Although 
neither the release of catecholamines during blood collection, nor 
the release of catecholamines, 5-HT or ADP frcm platelets during blood 
storage seemed to have influenced the onset of platelet aggregation, 
it is possible that these factors may contribute to platelet 
aggregation later in blood storage. Individually, it would probably 
be only a small contribution, since their measured plasma concentrations 
were often too lew to influence in-vitro aggregation, and the rate of 
platelet aggregation induced by ADP and adrenaline begins to decrease 
about 2 hours after venepuncture (Warlcw et al., 1974). However, as 
discussed in Chapter One, it is thought that very lew concentrations of 
many platelet aggregating agents can act synergistically. The combined 
effect of these agents was not examined in this investigation but 
may be of interest in a future study. Since at roan tenperature, there 
was also an increase in the plasma concentrations of 5-HT, ADP and the 
catecholamines, their synergistic effects might have been expected 
to induce platelet aggregation during blood storage at roan temperature. 
However, it is likely that the catabolic products of ADP and the rapidly 
reduced pH, as mentioned earlier in the chapter, would have inhibited 
any such aggregation. Several other factors may contribute to platelet 
aggregation in stored blood. These include vasopressin, which has 
been considered (see Chapter One) and prostaglandins. It has been 
discussed (Chapter One) that prostaglandins may play an important role 
in the mechanisms of platelet aggregation, and may possibly be the link 
between the aggregating stimulus and platelet aggregation. In a recent
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paper, Moretti and Abraham (1978) reported that various heme contain­
ing corrpounds stimulated the synthesis of PGH2  from PCX^. In the 
presence of aromatic amines (which include catecholamines) these 
compounds produced an even greater stimulation of overall prostaglan­
din synthesis. However, although both plasma haemoglobin and plasma 
catecholamine concentrations have been shown to increase rapidly in 
blood stored in the cold, platelet aggregation at 1°C occurred very 
rapidly. This suggests that the initial aggregating stimulus would have 
had to be present either on blood collection or within the first few 
hours of blood storage. However, an increased concentration of 
prostaglandins in the circulation has only been observed in severe 
circulatory shock.and are mainly of the PGE^ type which have been 
shown to powerfully inhibit platelet aggregation (Bridenbaugh and 
Lefer, 1976). Therefore, it is most unlikely that platelet aggregating 
prostaglandins are released during blood collection, and because cold 
would inhibit or reduce prostaglandin synthesis, it is unlikely that 
prostaglandins play any significant role in platelet aggregation during 
blood storage.
Another factor which may have contributed to platelet aggregation 
in stored blood is platelet aggregating factor (PAF). PAF is a low 
molecular weight phospholipid released frcm IgE sensitized basophils. 
PAF may stimulate platelets to secrete, in a non-cytotoxic manner, 
their granular contents, and also initiate in-vitro platelet aggre­
gation by a mechanism not thought to involve ADP (Henson and Oades, 
1976). Though basophils may degrade quickly during blood storage 
(Lachman, 1977 - personal communication), it is difficult to imagine 
what would stimulate PAF release during blood collection, and, if
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released, why it should not effect platelets at room temperature.
Protein denaturation is another possible cause of platelet 
aggregation. Proteins may be denatured by contact with an interface 
between air and blood. The denaturation occurs when strong electrostatic 
forces exert a polarizing effect that results in the orientation of a 
moncmolecular layer of globular protein molecules on the interface. 
Because of the molecular configuration of the protein molecules, the 
polarizing forces disrupt the sulphydryl and/or hydrogen bonds which 
stabilize the secondary and tertiary structure of the protein molecule 
(Lee et al., 1961). These denatured protein molecules can adsorb 
to the surface of erythrocytes and possibly platelets, and intra­
molecular aggregation may then ensue (Lee and Hairston, 1971).
Although it is possible to visualize these events occurring during 
blood collection and storage, it is unlikely to be extensive and would 
take place at all storage tenperatures.
Platelet aggregation by complement activation may also be con­
sidered, particularly as Clq receptors have been demonstrated on human 
platelets (Wautier et al., 1976). However, platelets are not thought 
to be aggregated by conventional complement activation (Henson, 1969; 
Lachman, 1977 - personal communication), and as with the coagulation 
pathway, complement activation, is thought to be an enzyme dependent 
cascade, which would be reduced at low tenperatures.
CONCLUDING REMARKS
There may be many factors that contribute to platelet aggregation 
during blood storage. Some of these factors have been examined, and 
others have been considered in the introduction and in the previous 
section. None of the examined factors have been found to be the 
initiator of platelet aggregation during blood storage, though ADP 
released from erythrocytes most probably contributed to platelet 
aggregation in blood stored at 1°C. These, and other factors, acting 
synergistically, may have extended platelet aggregation during blood 
storage. Platelet aggregation, as measured by the SFP technique, 
occurred only in the cold, and cold has been shown by other workers 
to initiate platelet aggregation. It is, therefore, possible that the 
blood storage tenperature nay be the basic criterion for platelet 
aggregation. The possible mechanism by which cold induces platelets to 
become sticky and aggregate spontaneously, have been discussed in 
Chapter Three. Kattlove and Alexander (1971) concluded that this 
type of aggregation depended upon the intactness of the platelet 
metabolic pathways, and was not mediated by ADP released from platelets. 
The results in this thesis lend support to these observations by show­
ing that the onset of platelet aggregation in cold stored blood is 
possibly an energy dependent process, and that it may occur in the 
absence of the platelet release reaction. Cold may also have an 
indirect effect by reducing normal platelet metabolism and consequently 
reducing the decrease in pH. This is thought to be an important 
requirement for platelet aggregation; aggregation being gradually 
inhibited as the pH is reduced. It may be the lower pH of ACD
- 167 -
anticoagulated blood, compared with CPD, which accounted for the obser­
ved reduced platelet aggregation in ACD blood at 4°C (Wright and Sand­
erson, 1974; Solis et al., 1974b). Cold may also reduce the rate of 
breakdown of ADP to its platelet aggregation inhibitory products, AMP 
and adenosine.
The great majority of donor blood, however, is stored as whole blood 
in the cold, and in situations were massive blood transfusions are 
needed, the microfiltration of stored blood is widely accepted so that 
the potential risk of transfusing platelet aggregates is reduced.
However, blood filters are expensive, and filter efficiency and filter 
induced haemolysis is seemingly inversely correlated with blood flow 
rates (Kennedy et al., 1977). So in the absence of fresh blood, when 
large amounts of blood are rapidly required, filter selection must 
balance the decisions regarding the risk of microembolization against 
the need for rapid flew properties. Ideally, blood for transfusion 
should contain viable cells and not require filtration. Additives 
such as adenine and inosine have for sane time been known to improve the 
viability of platelets stored at 4°C (Baldini et al., 1960), and in 
Sweden, adenine is regularly added to the anticoagulant to maintain
2,3 DPG, ATP and the post transfusion viability of erythrocytes in cold 
stored blood (Kreuger et al., 1975). Prostaglandin Ej, a potent plate­
let aggregation inhibitor, when added to freshly collected blood per­
mitted 75% of viable platelets to be isolated frcm blood stored for 3 
days at 4°C (Aster et al., 1976), though this degree of success was not 
found in all studies (Valeri et al., 1972). Also, acetyl salicylic 
acid when added to freshly collected blood reduced subsequent platelet 
aggregation by 50% during storage at 4°C (Gervin et al., 1975).
However, the add ition  o f  any a d d itiv es  to  stored  blood i s  probably
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better avoided because of their unknown effects. Continuous agitation 
of blood packs during storage at 4°C reduces platelet aggregation, 
though this nay be a consequence of platelet destruction (Gervin et al., 
1978). The storage of platelet concentrates at roan temperature is 
already widely practised because of better maintained platelet 
viability and the results in this thesis have demonstrated that plate­
let aggregation did not occur in blood stored at roan temperature.
Also, the plasma catecholamine concentrations increased and platelet 
counts decreased more slowly at roan temperature than in the cold, 
suggesting that platelet integrity was better maintained at roan temp­
erature. It would therefore seem that blood stored at roan temperature 
would eliminate the need for filtration, and better maintain platelet 
viability. Considerable work would need to be undertaken to confirm 
that other cells and functions were better maintained in whole blood 
stored at roan temperature. However, from the studies conducted in 
this thesis, it has been shown that the intrinsic blood clotting system 
is probably better maintained at rocm temperature than in the cold.
Also, the measurement of plasma haemoglobin concentrations have shown 
that erythrocyte integrity is better maintained at roan temperature.
It has been shown by McCullough et al., (1978) that granulocyte 
chemotaxis is better preserved at room temperature than in blood stored 
between 1°C and 6°C.
Perhaps the most serious potential disadvantage of blood storage 
at roan temperature is the increased risk of bacterial contamination 
and proliferation (Katz and Tilton, 1970; Murphy and Gardner, 1975). 
Although blood collection and storage is a closed system, the major risk 
of contamination, apart from carelessness and damage, is the skin plug 
that may enter the blood pack during phlebotomy. Bacteria that have
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been found in  blood packs include Escherichia c o l i ,  Staphylococcus
epidermides, Enterobacter cloacae, and Pseudanonas aeruginosa (Kahn 
and Syring, 1975). All these proliferate at room temperature. However, 
a study by Silver et al., (1970), isolated no organisms fran cultures 
from 40 platelet concentrates stored at 30°C, and sanpled at intervals 
for 4 days. This suggests that the risk of bacterial contamination is 
minimal.
Another disadvantage of blood storage at roan temperature is the 
rapid decrease in pH, due to lactic acid production and CC> 2 retention.
A fall in pH is one of the principal causes of gradual damage to 
erythrocytes (Mendonca et al., 1978) and at a pH of 6, platelet 
viability is lost (Murphy and Gardner, 1975). Although the permea­
bility of plastic bags to gases means the blood can be maintained at 
a higher pH by controlling O 2  and CO 2  tensions in the ambient air, 
this presents practical difficulties. However, in this thesis, the 
pH of blood stored at roan temperature for 14 days never decreased to 
a pH at which platelet viability would be lost. Nevertheless, despite 
the lack of platelet aggregation at roan temperature, because of the 
unknown effects of long term roan temperature blood storage, and because 
of the risk of bacterial proliferation, cold storage of blood will prob­
ably continue. An extensive study would be necessary, catparing 
blood cell functions at a variety of storage temperatures to elucidate 
the optimum storage tenperature. However, the results in this thesis 
have demonstrated considerable differences in the behaviour of plate­
lets and erythrocytes in blood stored at 1°C and at 4°C. It would there­
fore seem highly recanmendable not.to maintain a storage tenperature 
below 4°C.
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